<?xml version="1.0" encoding="UTF-8"?><?xml-stylesheet href="https://www.accessdata.fda.gov/spl/stylesheet/spl.xsl" type="text/xsl"?>
<document xmlns="urn:hl7-org:v3" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="urn:hl7-org:v3 https://www.accessdata.fda.gov/spl/schema/spl.xsd">
   <id root="e77efbf4-6a82-42ba-aea3-f833b599dcdc"/>
   <code code="34391-3" codeSystem="2.16.840.1.113883.6.1" displayName="HUMAN PRESCRIPTION DRUG LABEL"/>
   <title>These highlights do not include all the information needed to use PREMPRO/PREMPHASE safely and effectively. See full prescribing information for PREMPRO/PREMPHASE.<br/>
      <br/>PREMPRO<sup>®</sup> (conjugated estrogens/medroxyprogesterone acetate tablets) PREMPHASE<sup>®</sup> (conjugated estrogens plus medroxyprogesterone acetate tablets)<br/>Initial U.S. Approval: 1995</title>
   <effectiveTime value="20250506"/>
   <setId root="fd0c0836-5d23-2183-da81-9dc7f4287052"/>
   <versionNumber value="37"/>
   <author>
      <time/>
      <assignedEntity>
         <representedOrganization>
            <id extension="113008515" root="1.3.6.1.4.1.519.1"/>
            <name>Wyeth Pharmaceuticals LLC, a subsidiary of Pfizer Inc.</name>
            <assignedEntity>
               <assignedOrganization>
                  <assignedEntity>
                     <assignedOrganization>
                        <id extension="458521908" root="1.3.6.1.4.1.519.1"/>
                        <name>Pfizer Italia S.r.l.</name>
                     </assignedOrganization>
                     <performance>
                        <actDefinition>
                           <code code="C84731" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="PACK"/>
                           <product>
                              <manufacturedProduct classCode="MANU">
                                 <manufacturedMaterialKind>
                                    <code code="0046-2575" codeSystem="2.16.840.1.113883.6.69"/>
                                 </manufacturedMaterialKind>
                              </manufacturedProduct>
                           </product>
                        </actDefinition>
                     </performance>
                     <performance>
                        <actDefinition>
                           <code code="C84731" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="PACK"/>
                           <product>
                              <manufacturedProduct classCode="MANU">
                                 <manufacturedMaterialKind>
                                    <code code="0046-1105" codeSystem="2.16.840.1.113883.6.69"/>
                                 </manufacturedMaterialKind>
                              </manufacturedProduct>
                           </product>
                        </actDefinition>
                     </performance>
                     <performance>
                        <actDefinition>
                           <code code="C84731" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="PACK"/>
                           <product>
                              <manufacturedProduct classCode="MANU">
                                 <manufacturedMaterialKind>
                                    <code code="0046-1106" codeSystem="2.16.840.1.113883.6.69"/>
                                 </manufacturedMaterialKind>
                              </manufacturedProduct>
                           </product>
                        </actDefinition>
                     </performance>
                     <performance>
                        <actDefinition>
                           <code code="C84731" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="PACK"/>
                           <product>
                              <manufacturedProduct classCode="MANU">
                                 <manufacturedMaterialKind>
                                    <code code="0046-1107" codeSystem="2.16.840.1.113883.6.69"/>
                                 </manufacturedMaterialKind>
                              </manufacturedProduct>
                           </product>
                        </actDefinition>
                     </performance>
                     <performance>
                        <actDefinition>
                           <code code="C84731" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="PACK"/>
                           <product>
                              <manufacturedProduct classCode="MANU">
                                 <manufacturedMaterialKind>
                                    <code code="0046-1108" codeSystem="2.16.840.1.113883.6.69"/>
                                 </manufacturedMaterialKind>
                              </manufacturedProduct>
                           </product>
                        </actDefinition>
                     </performance>
                     <performance>
                        <actDefinition>
                           <code code="C84732" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="LABEL"/>
                           <product>
                              <manufacturedProduct classCode="MANU">
                                 <manufacturedMaterialKind>
                                    <code code="0046-2575" codeSystem="2.16.840.1.113883.6.69"/>
                                 </manufacturedMaterialKind>
                              </manufacturedProduct>
                           </product>
                        </actDefinition>
                     </performance>
                     <performance>
                        <actDefinition>
                           <code code="C84732" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="LABEL"/>
                           <product>
                              <manufacturedProduct classCode="MANU">
                                 <manufacturedMaterialKind>
                                    <code code="0046-1105" codeSystem="2.16.840.1.113883.6.69"/>
                                 </manufacturedMaterialKind>
                              </manufacturedProduct>
                           </product>
                        </actDefinition>
                     </performance>
                     <performance>
                        <actDefinition>
                           <code code="C84732" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="LABEL"/>
                           <product>
                              <manufacturedProduct classCode="MANU">
                                 <manufacturedMaterialKind>
                                    <code code="0046-1106" codeSystem="2.16.840.1.113883.6.69"/>
                                 </manufacturedMaterialKind>
                              </manufacturedProduct>
                           </product>
                        </actDefinition>
                     </performance>
                     <performance>
                        <actDefinition>
                           <code code="C84732" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="LABEL"/>
                           <product>
                              <manufacturedProduct classCode="MANU">
                                 <manufacturedMaterialKind>
                                    <code code="0046-1107" codeSystem="2.16.840.1.113883.6.69"/>
                                 </manufacturedMaterialKind>
                              </manufacturedProduct>
                           </product>
                        </actDefinition>
                     </performance>
                     <performance>
                        <actDefinition>
                           <code code="C84732" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="LABEL"/>
                           <product>
                              <manufacturedProduct classCode="MANU">
                                 <manufacturedMaterialKind>
                                    <code code="0046-1108" codeSystem="2.16.840.1.113883.6.69"/>
                                 </manufacturedMaterialKind>
                              </manufacturedProduct>
                           </product>
                        </actDefinition>
                     </performance>
                  </assignedEntity>
                  <assignedEntity>
                     <assignedOrganization>
                        <id extension="986019327" root="1.3.6.1.4.1.519.1"/>
                        <name>Pfizer Ireland Pharmaceuticals Unlimited Company</name>
                     </assignedOrganization>
                     <performance>
                        <actDefinition>
                           <code code="C25391" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="ANALYSIS"/>
                           <product>
                              <manufacturedProduct classCode="MANU">
                                 <manufacturedMaterialKind>
                                    <code code="0046-1105" codeSystem="2.16.840.1.113883.6.69"/>
                                 </manufacturedMaterialKind>
                              </manufacturedProduct>
                           </product>
                        </actDefinition>
                     </performance>
                     <performance>
                        <actDefinition>
                           <code code="C25391" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="ANALYSIS"/>
                           <product>
                              <manufacturedProduct classCode="MANU">
                                 <manufacturedMaterialKind>
                                    <code code="0046-1106" codeSystem="2.16.840.1.113883.6.69"/>
                                 </manufacturedMaterialKind>
                              </manufacturedProduct>
                           </product>
                        </actDefinition>
                     </performance>
                     <performance>
                        <actDefinition>
                           <code code="C25391" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="ANALYSIS"/>
                           <product>
                              <manufacturedProduct classCode="MANU">
                                 <manufacturedMaterialKind>
                                    <code code="0046-1107" codeSystem="2.16.840.1.113883.6.69"/>
                                 </manufacturedMaterialKind>
                              </manufacturedProduct>
                           </product>
                        </actDefinition>
                     </performance>
                     <performance>
                        <actDefinition>
                           <code code="C25391" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="ANALYSIS"/>
                           <product>
                              <manufacturedProduct classCode="MANU">
                                 <manufacturedMaterialKind>
                                    <code code="0046-1108" codeSystem="2.16.840.1.113883.6.69"/>
                                 </manufacturedMaterialKind>
                              </manufacturedProduct>
                           </product>
                        </actDefinition>
                     </performance>
                     <performance>
                        <actDefinition>
                           <code code="C25391" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="ANALYSIS"/>
                           <product>
                              <manufacturedProduct classCode="MANU">
                                 <manufacturedMaterialKind>
                                    <code code="0046-2575" codeSystem="2.16.840.1.113883.6.69"/>
                                 </manufacturedMaterialKind>
                              </manufacturedProduct>
                           </product>
                        </actDefinition>
                     </performance>
                     <performance>
                        <actDefinition>
                           <code code="C43360" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="MANUFACTURE"/>
                           <product>
                              <manufacturedProduct classCode="MANU">
                                 <manufacturedMaterialKind>
                                    <code code="0046-1105" codeSystem="2.16.840.1.113883.6.69"/>
                                 </manufacturedMaterialKind>
                              </manufacturedProduct>
                           </product>
                        </actDefinition>
                     </performance>
                     <performance>
                        <actDefinition>
                           <code code="C43360" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="MANUFACTURE"/>
                           <product>
                              <manufacturedProduct classCode="MANU">
                                 <manufacturedMaterialKind>
                                    <code code="0046-1106" codeSystem="2.16.840.1.113883.6.69"/>
                                 </manufacturedMaterialKind>
                              </manufacturedProduct>
                           </product>
                        </actDefinition>
                     </performance>
                     <performance>
                        <actDefinition>
                           <code code="C43360" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="MANUFACTURE"/>
                           <product>
                              <manufacturedProduct classCode="MANU">
                                 <manufacturedMaterialKind>
                                    <code code="0046-1107" codeSystem="2.16.840.1.113883.6.69"/>
                                 </manufacturedMaterialKind>
                              </manufacturedProduct>
                           </product>
                        </actDefinition>
                     </performance>
                     <performance>
                        <actDefinition>
                           <code code="C43360" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="MANUFACTURE"/>
                           <product>
                              <manufacturedProduct classCode="MANU">
                                 <manufacturedMaterialKind>
                                    <code code="0046-1108" codeSystem="2.16.840.1.113883.6.69"/>
                                 </manufacturedMaterialKind>
                              </manufacturedProduct>
                           </product>
                        </actDefinition>
                     </performance>
                     <performance>
                        <actDefinition>
                           <code code="C43360" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="MANUFACTURE"/>
                           <product>
                              <manufacturedProduct classCode="MANU">
                                 <manufacturedMaterialKind>
                                    <code code="0046-2575" codeSystem="2.16.840.1.113883.6.69"/>
                                 </manufacturedMaterialKind>
                              </manufacturedProduct>
                           </product>
                        </actDefinition>
                     </performance>
                  </assignedEntity>
                  <assignedEntity>
                     <assignedOrganization>
                        <id extension="943955690" root="1.3.6.1.4.1.519.1"/>
                        <name>Pfizer Inc</name>
                     </assignedOrganization>
                     <performance>
                        <actDefinition>
                           <code code="C25391" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="ANALYSIS"/>
                           <product>
                              <manufacturedProduct classCode="MANU">
                                 <manufacturedMaterialKind>
                                    <code code="0046-2575" codeSystem="2.16.840.1.113883.6.69"/>
                                 </manufacturedMaterialKind>
                              </manufacturedProduct>
                           </product>
                        </actDefinition>
                     </performance>
                     <performance>
                        <actDefinition>
                           <code code="C25391" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="ANALYSIS"/>
                           <product>
                              <manufacturedProduct classCode="MANU">
                                 <manufacturedMaterialKind>
                                    <code code="0046-1105" codeSystem="2.16.840.1.113883.6.69"/>
                                 </manufacturedMaterialKind>
                              </manufacturedProduct>
                           </product>
                        </actDefinition>
                     </performance>
                     <performance>
                        <actDefinition>
                           <code code="C25391" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="ANALYSIS"/>
                           <product>
                              <manufacturedProduct classCode="MANU">
                                 <manufacturedMaterialKind>
                                    <code code="0046-1106" codeSystem="2.16.840.1.113883.6.69"/>
                                 </manufacturedMaterialKind>
                              </manufacturedProduct>
                           </product>
                        </actDefinition>
                     </performance>
                     <performance>
                        <actDefinition>
                           <code code="C25391" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="ANALYSIS"/>
                           <product>
                              <manufacturedProduct classCode="MANU">
                                 <manufacturedMaterialKind>
                                    <code code="0046-1107" codeSystem="2.16.840.1.113883.6.69"/>
                                 </manufacturedMaterialKind>
                              </manufacturedProduct>
                           </product>
                        </actDefinition>
                     </performance>
                     <performance>
                        <actDefinition>
                           <code code="C25391" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="ANALYSIS"/>
                           <product>
                              <manufacturedProduct classCode="MANU">
                                 <manufacturedMaterialKind>
                                    <code code="0046-1108" codeSystem="2.16.840.1.113883.6.69"/>
                                 </manufacturedMaterialKind>
                              </manufacturedProduct>
                           </product>
                        </actDefinition>
                     </performance>
                  </assignedEntity>
                  <assignedEntity>
                     <assignedOrganization>
                        <id extension="203382973" root="1.3.6.1.4.1.519.1"/>
                        <name>Pfizer Canada ULC</name>
                     </assignedOrganization>
                     <performance>
                        <actDefinition>
                           <code code="C25391" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="ANALYSIS"/>
                           <product>
                              <manufacturedProduct classCode="MANU">
                                 <manufacturedMaterialKind>
                                    <code code="0046-2575" codeSystem="2.16.840.1.113883.6.69"/>
                                 </manufacturedMaterialKind>
                              </manufacturedProduct>
                           </product>
                        </actDefinition>
                     </performance>
                     <performance>
                        <actDefinition>
                           <code code="C25391" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="ANALYSIS"/>
                           <product>
                              <manufacturedProduct classCode="MANU">
                                 <manufacturedMaterialKind>
                                    <code code="0046-1105" codeSystem="2.16.840.1.113883.6.69"/>
                                 </manufacturedMaterialKind>
                              </manufacturedProduct>
                           </product>
                        </actDefinition>
                     </performance>
                     <performance>
                        <actDefinition>
                           <code code="C25391" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="ANALYSIS"/>
                           <product>
                              <manufacturedProduct classCode="MANU">
                                 <manufacturedMaterialKind>
                                    <code code="0046-1106" codeSystem="2.16.840.1.113883.6.69"/>
                                 </manufacturedMaterialKind>
                              </manufacturedProduct>
                           </product>
                        </actDefinition>
                     </performance>
                     <performance>
                        <actDefinition>
                           <code code="C25391" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="ANALYSIS"/>
                           <product>
                              <manufacturedProduct classCode="MANU">
                                 <manufacturedMaterialKind>
                                    <code code="0046-1107" codeSystem="2.16.840.1.113883.6.69"/>
                                 </manufacturedMaterialKind>
                              </manufacturedProduct>
                           </product>
                        </actDefinition>
                     </performance>
                     <performance>
                        <actDefinition>
                           <code code="C25391" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="ANALYSIS"/>
                           <product>
                              <manufacturedProduct classCode="MANU">
                                 <manufacturedMaterialKind>
                                    <code code="0046-1108" codeSystem="2.16.840.1.113883.6.69"/>
                                 </manufacturedMaterialKind>
                              </manufacturedProduct>
                           </product>
                        </actDefinition>
                     </performance>
                     <performance>
                        <actDefinition>
                           <code code="C82401" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="API MANUFACTURE"/>
                           <product>
                              <manufacturedProduct classCode="MANU">
                                 <manufacturedMaterialKind>
                                    <code code="0046-2575" codeSystem="2.16.840.1.113883.6.69"/>
                                 </manufacturedMaterialKind>
                              </manufacturedProduct>
                           </product>
                        </actDefinition>
                     </performance>
                     <performance>
                        <actDefinition>
                           <code code="C82401" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="API MANUFACTURE"/>
                           <product>
                              <manufacturedProduct classCode="MANU">
                                 <manufacturedMaterialKind>
                                    <code code="0046-1105" codeSystem="2.16.840.1.113883.6.69"/>
                                 </manufacturedMaterialKind>
                              </manufacturedProduct>
                           </product>
                        </actDefinition>
                     </performance>
                     <performance>
                        <actDefinition>
                           <code code="C82401" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="API MANUFACTURE"/>
                           <product>
                              <manufacturedProduct classCode="MANU">
                                 <manufacturedMaterialKind>
                                    <code code="0046-1106" codeSystem="2.16.840.1.113883.6.69"/>
                                 </manufacturedMaterialKind>
                              </manufacturedProduct>
                           </product>
                        </actDefinition>
                     </performance>
                     <performance>
                        <actDefinition>
                           <code code="C82401" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="API MANUFACTURE"/>
                           <product>
                              <manufacturedProduct classCode="MANU">
                                 <manufacturedMaterialKind>
                                    <code code="0046-1107" codeSystem="2.16.840.1.113883.6.69"/>
                                 </manufacturedMaterialKind>
                              </manufacturedProduct>
                           </product>
                        </actDefinition>
                     </performance>
                     <performance>
                        <actDefinition>
                           <code code="C82401" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="API MANUFACTURE"/>
                           <product>
                              <manufacturedProduct classCode="MANU">
                                 <manufacturedMaterialKind>
                                    <code code="0046-1108" codeSystem="2.16.840.1.113883.6.69"/>
                                 </manufacturedMaterialKind>
                              </manufacturedProduct>
                           </product>
                        </actDefinition>
                     </performance>
                  </assignedEntity>
               </assignedOrganization>
            </assignedEntity>
         </representedOrganization>
      </assignedEntity>
   </author>
   <component>
      <structuredBody>
         <component>
            <section>
               <id root="1813fb92-4c1d-4180-a80e-eeb50bc79dce"/>
               <code code="48780-1" codeSystem="2.16.840.1.113883.6.1" displayName="SPL product data elements section"/>
               <effectiveTime value="20221129"/>
               <subject>
                  <manufacturedProduct>
                     <manufacturedProduct>
                        <code code="0046-2575" codeSystem="2.16.840.1.113883.6.69"/>
                        <name>Premphase</name>
                        <formCode code="C47916" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="KIT"/>
                        <asEntityWithGeneric>
                           <genericMedicine>
                              <name>conjugated estrogens and medroxyprogesterone acetate</name>
                           </genericMedicine>
                        </asEntityWithGeneric>
                        <asContent>
                           <quantity>
                              <numerator unit="1" value="1"/>
                              <denominator value="1"/>
                           </quantity>
                           <containerPackagedProduct>
                              <code/>
                              <formCode code="C43168" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="BLISTER PACK"/>
                              <asContent>
                                 <quantity>
                                    <numerator unit="1" value="1"/>
                                    <denominator value="1"/>
                                 </quantity>
                                 <containerPackagedProduct>
                                    <code code="0046-2575-12" codeSystem="2.16.840.1.113883.6.69"/>
                                    <formCode code="C43182" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="CARTON"/>
                                 </containerPackagedProduct>
                                 <subjectOf>
                                    <marketingAct>
                                       <code code="C53292" codeSystem="2.16.840.1.113883.3.26.1.1"/>
                                       <statusCode code="active"/>
                                       <effectiveTime>
                                          <low value="20120301"/>
                                       </effectiveTime>
                                    </marketingAct>
                                 </subjectOf>
                              </asContent>
                           </containerPackagedProduct>
                           <subjectOf>
                              <characteristic classCode="OBS">
                                 <code code="SPLCMBPRDTP" codeSystem="2.16.840.1.113883.1.11.19255"/>
                                 <value code="C112160" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="Type 0: Not a Combination Product" xsi:type="CE"/>
                              </characteristic>
                           </subjectOf>
                        </asContent>
                        <part>
                           <quantity>
                              <numerator unit="1" value="14"/>
                              <denominator value="1"/>
                           </quantity>
                           <partProduct>
                              <name>Prempro</name>
                              <formCode code="C42998" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="TABLET"/>
                              <asEntityWithGeneric>
                                 <genericMedicine>
                                    <name>conjugated estrogens and medroxyprogesterone acetate</name>
                                 </genericMedicine>
                              </asEntityWithGeneric>
                              <ingredient classCode="ACTIB">
                                 <quantity>
                                    <numerator unit="mg" value="0.625"/>
                                    <denominator unit="1" value="1"/>
                                 </quantity>
                                 <ingredientSubstance>
                                    <code code="IU5QR144QX" codeSystem="2.16.840.1.113883.4.9"/>
                                    <name>ESTROGENS, CONJUGATED</name>
                                    <activeMoiety>
                                       <activeMoiety>
                                          <code code="IU5QR144QX" codeSystem="2.16.840.1.113883.4.9"/>
                                          <name>ESTROGENS, CONJUGATED</name>
                                       </activeMoiety>
                                    </activeMoiety>
                                 </ingredientSubstance>
                              </ingredient>
                              <ingredient classCode="ACTIB">
                                 <quantity>
                                    <numerator unit="mg" value="5"/>
                                    <denominator unit="1" value="1"/>
                                 </quantity>
                                 <ingredientSubstance>
                                    <code code="C2QI4IOI2G" codeSystem="2.16.840.1.113883.4.9"/>
                                    <name>MEDROXYPROGESTERONE ACETATE</name>
                                    <activeMoiety>
                                       <activeMoiety>
                                          <code code="HSU1C9YRES" codeSystem="2.16.840.1.113883.4.9"/>
                                          <name>MEDROXYPROGESTERONE</name>
                                       </activeMoiety>
                                    </activeMoiety>
                                 </ingredientSubstance>
                              </ingredient>
                              <ingredient classCode="IACT">
                                 <ingredientSubstance>
                                    <code code="RFW2ET671P" codeSystem="2.16.840.1.113883.4.9"/>
                                    <name>HYDROXYPROPYL CELLULOSE (1600000 WAMW)</name>
                                 </ingredientSubstance>
                              </ingredient>
                              <ingredient classCode="IACT">
                                 <ingredientSubstance>
                                    <code code="OP1R32D61U" codeSystem="2.16.840.1.113883.4.9"/>
                                    <name>MICROCRYSTALLINE CELLULOSE</name>
                                 </ingredientSubstance>
                              </ingredient>
                              <ingredient classCode="IACT">
                                 <ingredientSubstance>
                                    <code code="EWQ57Q8I5X" codeSystem="2.16.840.1.113883.4.9"/>
                                    <name>LACTOSE MONOHYDRATE</name>
                                 </ingredientSubstance>
                              </ingredient>
                              <ingredient classCode="IACT">
                                 <ingredientSubstance>
                                    <code code="70097M6I30" codeSystem="2.16.840.1.113883.4.9"/>
                                    <name>MAGNESIUM STEARATE</name>
                                 </ingredientSubstance>
                              </ingredient>
                              <ingredient classCode="IACT">
                                 <ingredientSubstance>
                                    <code code="B697894SGQ" codeSystem="2.16.840.1.113883.4.9"/>
                                    <name>POLYETHYLENE GLYCOL 400</name>
                                 </ingredientSubstance>
                              </ingredient>
                              <ingredient classCode="IACT">
                                 <ingredientSubstance>
                                    <code code="C151H8M554" codeSystem="2.16.840.1.113883.4.9"/>
                                    <name>SUCROSE</name>
                                 </ingredientSubstance>
                              </ingredient>
                              <ingredient classCode="IACT">
                                 <ingredientSubstance>
                                    <code code="15FIX9V2JP" codeSystem="2.16.840.1.113883.4.9"/>
                                    <name>TITANIUM DIOXIDE</name>
                                 </ingredientSubstance>
                              </ingredient>
                              <ingredient classCode="IACT">
                                 <ingredientSubstance>
                                    <code code="L06K8R7DQK" codeSystem="2.16.840.1.113883.4.9"/>
                                    <name>FD&amp;C BLUE NO. 2</name>
                                 </ingredientSubstance>
                              </ingredient>
                              <ingredient classCode="IACT">
                                 <ingredientSubstance>
                                    <code code="R12CBM0EIZ" codeSystem="2.16.840.1.113883.4.9"/>
                                    <name>CARNAUBA WAX</name>
                                 </ingredientSubstance>
                              </ingredient>
                              <ingredient classCode="IACT">
                                 <ingredientSubstance>
                                    <code code="91D9GV0Z28" codeSystem="2.16.840.1.113883.4.9"/>
                                    <name>TRIBASIC CALCIUM PHOSPHATE</name>
                                 </ingredientSubstance>
                              </ingredient>
                              <ingredient classCode="IACT">
                                 <ingredientSubstance>
                                    <code code="XM0M87F357" codeSystem="2.16.840.1.113883.4.9"/>
                                    <name>FERROSOFERRIC OXIDE</name>
                                 </ingredientSubstance>
                              </ingredient>
                              <ingredient classCode="IACT">
                                 <ingredientSubstance>
                                    <code code="Z78RG6M2N2" codeSystem="2.16.840.1.113883.4.9"/>
                                    <name>HYPROMELLOSE 2208 (15000 MPA.S)</name>
                                 </ingredientSubstance>
                              </ingredient>
                              <ingredient classCode="IACT">
                                 <ingredientSubstance>
                                    <code code="36SFW2JZ0W" codeSystem="2.16.840.1.113883.4.9"/>
                                    <name>HYPROMELLOSE 2910 (15 MPA.S)</name>
                                 </ingredientSubstance>
                              </ingredient>
                              <ingredient classCode="IACT">
                                 <ingredientSubstance>
                                    <code code="0WZ8WG20P6" codeSystem="2.16.840.1.113883.4.9"/>
                                    <name>HYPROMELLOSE 2910 (6 MPA.S)</name>
                                 </ingredientSubstance>
                              </ingredient>
                              <ingredient classCode="IACT">
                                 <ingredientSubstance>
                                    <code code="NX76LV5T8J" codeSystem="2.16.840.1.113883.4.9"/>
                                    <name>METHACRYLIC ACID AND ETHYL ACRYLATE COPOLYMER</name>
                                 </ingredientSubstance>
                              </ingredient>
                              <ingredient classCode="IACT">
                                 <ingredientSubstance>
                                    <code code="8Z96QXD6UM" codeSystem="2.16.840.1.113883.4.9"/>
                                    <name>TRIETHYL CITRATE</name>
                                 </ingredientSubstance>
                              </ingredient>
                              <ingredient classCode="IACT">
                                 <ingredientSubstance>
                                    <code code="6DC9Q167V3" codeSystem="2.16.840.1.113883.4.9"/>
                                    <name>PROPYLENE GLYCOL</name>
                                 </ingredientSubstance>
                              </ingredient>
                           </partProduct>
                           <subjectOf>
                              <approval>
                                 <id extension="NDA020527" root="2.16.840.1.113883.3.150"/>
                                 <code code="C73594" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="NDA"/>
                                 <author>
                                    <territorialAuthority>
                                       <territory>
                                          <code code="USA" codeSystem="2.16.840.1.113883.5.28"/>
                                       </territory>
                                    </territorialAuthority>
                                 </author>
                              </approval>
                           </subjectOf>
                           <subjectOf>
                              <marketingAct>
                                 <code code="C53292" codeSystem="2.16.840.1.113883.3.26.1.1"/>
                                 <statusCode code="active"/>
                                 <effectiveTime>
                                    <low value="20120301"/>
                                 </effectiveTime>
                              </marketingAct>
                           </subjectOf>
                           <subjectOf>
                              <characteristic classCode="OBS">
                                 <code code="SPLCOLOR" codeSystem="2.16.840.1.113883.1.11.19255"/>
                                 <value code="C48333" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="BLUE" xsi:type="CE">
                                    <originalText>LIGHT BLUE</originalText>
                                 </value>
                              </characteristic>
                           </subjectOf>
                           <subjectOf>
                              <characteristic classCode="OBS">
                                 <code code="SPLSIZE" codeSystem="2.16.840.1.113883.1.11.19255"/>
                                 <value unit="mm" value="10" xsi:type="PQ"/>
                              </characteristic>
                           </subjectOf>
                           <subjectOf>
                              <characteristic classCode="OBS">
                                 <code code="SPLSHAPE" codeSystem="2.16.840.1.113883.1.11.19255"/>
                                 <value code="C48345" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="OVAL" xsi:type="CE">
                                    <originalText>OVAL</originalText>
                                 </value>
                              </characteristic>
                           </subjectOf>
                           <subjectOf>
                              <characteristic classCode="OBS">
                                 <code code="SPLSCORE" codeSystem="2.16.840.1.113883.1.11.19255"/>
                                 <value value="1" xsi:type="INT"/>
                              </characteristic>
                           </subjectOf>
                           <subjectOf>
                              <characteristic classCode="OBS">
                                 <code code="SPLIMPRINT" codeSystem="2.16.840.1.113883.1.11.19255"/>
                                 <value xsi:type="ST">PREMPRO;0625;5</value>
                              </characteristic>
                           </subjectOf>
                           <consumedIn>
                              <substanceAdministration>
                                 <routeCode code="C38288" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="ORAL"/>
                              </substanceAdministration>
                           </consumedIn>
                        </part>
                        <part>
                           <quantity>
                              <numerator unit="1" value="14"/>
                              <denominator value="1"/>
                           </quantity>
                           <partProduct>
                              <name>Premarin</name>
                              <formCode code="C42992" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="TABLET, SUGAR COATED"/>
                              <asEntityWithGeneric>
                                 <genericMedicine>
                                    <name>conjugated estrogens</name>
                                 </genericMedicine>
                              </asEntityWithGeneric>
                              <ingredient classCode="ACTIB">
                                 <quantity>
                                    <numerator unit="mg" value="0.625"/>
                                    <denominator unit="1" value="1"/>
                                 </quantity>
                                 <ingredientSubstance>
                                    <code code="IU5QR144QX" codeSystem="2.16.840.1.113883.4.9"/>
                                    <name>ESTROGENS, CONJUGATED</name>
                                    <activeMoiety>
                                       <activeMoiety>
                                          <code code="IU5QR144QX" codeSystem="2.16.840.1.113883.4.9"/>
                                          <name>ESTROGENS, CONJUGATED</name>
                                       </activeMoiety>
                                    </activeMoiety>
                                 </ingredientSubstance>
                              </ingredient>
                              <ingredient classCode="IACT">
                                 <ingredientSubstance>
                                    <code code="RFW2ET671P" codeSystem="2.16.840.1.113883.4.9"/>
                                    <name>HYDROXYPROPYL CELLULOSE (1600000 WAMW)</name>
                                 </ingredientSubstance>
                              </ingredient>
                              <ingredient classCode="IACT">
                                 <ingredientSubstance>
                                    <code code="OP1R32D61U" codeSystem="2.16.840.1.113883.4.9"/>
                                    <name>MICROCRYSTALLINE CELLULOSE</name>
                                 </ingredientSubstance>
                              </ingredient>
                              <ingredient classCode="IACT">
                                 <ingredientSubstance>
                                    <code code="EWQ57Q8I5X" codeSystem="2.16.840.1.113883.4.9"/>
                                    <name>LACTOSE MONOHYDRATE</name>
                                 </ingredientSubstance>
                              </ingredient>
                              <ingredient classCode="IACT">
                                 <ingredientSubstance>
                                    <code code="70097M6I30" codeSystem="2.16.840.1.113883.4.9"/>
                                    <name>MAGNESIUM STEARATE</name>
                                 </ingredientSubstance>
                              </ingredient>
                              <ingredient classCode="IACT">
                                 <ingredientSubstance>
                                    <code code="B697894SGQ" codeSystem="2.16.840.1.113883.4.9"/>
                                    <name>POLYETHYLENE GLYCOL 400</name>
                                 </ingredientSubstance>
                              </ingredient>
                              <ingredient classCode="IACT">
                                 <ingredientSubstance>
                                    <code code="C151H8M554" codeSystem="2.16.840.1.113883.4.9"/>
                                    <name>SUCROSE</name>
                                 </ingredientSubstance>
                              </ingredient>
                              <ingredient classCode="IACT">
                                 <ingredientSubstance>
                                    <code code="15FIX9V2JP" codeSystem="2.16.840.1.113883.4.9"/>
                                    <name>TITANIUM DIOXIDE</name>
                                 </ingredientSubstance>
                              </ingredient>
                              <ingredient classCode="IACT">
                                 <ingredientSubstance>
                                    <code code="L06K8R7DQK" codeSystem="2.16.840.1.113883.4.9"/>
                                    <name>FD&amp;C BLUE NO. 2</name>
                                 </ingredientSubstance>
                              </ingredient>
                              <ingredient classCode="IACT">
                                 <ingredientSubstance>
                                    <code code="WZB9127XOA" codeSystem="2.16.840.1.113883.4.9"/>
                                    <name>FD&amp;C RED NO. 40</name>
                                 </ingredientSubstance>
                              </ingredient>
                              <ingredient classCode="IACT">
                                 <ingredientSubstance>
                                    <code code="91D9GV0Z28" codeSystem="2.16.840.1.113883.4.9"/>
                                    <name>TRIBASIC CALCIUM PHOSPHATE</name>
                                 </ingredientSubstance>
                              </ingredient>
                              <ingredient classCode="IACT">
                                 <ingredientSubstance>
                                    <code code="SMD1X3XO9M" codeSystem="2.16.840.1.113883.4.9"/>
                                    <name>POWDERED CELLULOSE</name>
                                 </ingredientSubstance>
                              </ingredient>
                              <ingredient classCode="IACT">
                                 <ingredientSubstance>
                                    <code code="Z78RG6M2N2" codeSystem="2.16.840.1.113883.4.9"/>
                                    <name>HYPROMELLOSE 2208 (15000 MPA.S)</name>
                                 </ingredientSubstance>
                              </ingredient>
                              <ingredient classCode="IACT">
                                 <ingredientSubstance>
                                    <code code="36SFW2JZ0W" codeSystem="2.16.840.1.113883.4.9"/>
                                    <name>HYPROMELLOSE 2910 (15 MPA.S)</name>
                                 </ingredientSubstance>
                              </ingredient>
                              <ingredient classCode="IACT">
                                 <ingredientSubstance>
                                    <code code="0WZ8WG20P6" codeSystem="2.16.840.1.113883.4.9"/>
                                    <name>HYPROMELLOSE 2910 (6 MPA.S)</name>
                                 </ingredientSubstance>
                              </ingredient>
                              <ingredient classCode="IACT">
                                 <ingredientSubstance>
                                    <code code="R12CBM0EIZ" codeSystem="2.16.840.1.113883.4.9"/>
                                    <name>CARNAUBA WAX</name>
                                 </ingredientSubstance>
                              </ingredient>
                              <ingredient classCode="IACT">
                                 <ingredientSubstance>
                                    <code code="6DC9Q167V3" codeSystem="2.16.840.1.113883.4.9"/>
                                    <name>PROPYLENE GLYCOL</name>
                                 </ingredientSubstance>
                              </ingredient>
                           </partProduct>
                           <subjectOf>
                              <approval>
                                 <id extension="NDA020527" root="2.16.840.1.113883.3.150"/>
                                 <code code="C73594" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="NDA"/>
                                 <author>
                                    <territorialAuthority>
                                       <territory>
                                          <code code="USA" codeSystem="2.16.840.1.113883.5.28"/>
                                       </territory>
                                    </territorialAuthority>
                                 </author>
                              </approval>
                           </subjectOf>
                           <subjectOf>
                              <marketingAct>
                                 <code code="C53292" codeSystem="2.16.840.1.113883.3.26.1.1"/>
                                 <statusCode code="active"/>
                                 <effectiveTime>
                                    <low value="20120301"/>
                                 </effectiveTime>
                              </marketingAct>
                           </subjectOf>
                           <subjectOf>
                              <characteristic classCode="OBS">
                                 <code code="SPLCOLOR" codeSystem="2.16.840.1.113883.1.11.19255"/>
                                 <value code="C48332" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="BROWN" xsi:type="CE">
                                    <originalText>MAROON</originalText>
                                 </value>
                              </characteristic>
                           </subjectOf>
                           <subjectOf>
                              <characteristic classCode="OBS">
                                 <code code="SPLSIZE" codeSystem="2.16.840.1.113883.1.11.19255"/>
                                 <value unit="mm" value="10" xsi:type="PQ"/>
                              </characteristic>
                           </subjectOf>
                           <subjectOf>
                              <characteristic classCode="OBS">
                                 <code code="SPLSHAPE" codeSystem="2.16.840.1.113883.1.11.19255"/>
                                 <value code="C48345" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="OVAL" xsi:type="CE">
                                    <originalText>OVAL</originalText>
                                 </value>
                              </characteristic>
                           </subjectOf>
                           <subjectOf>
                              <characteristic classCode="OBS">
                                 <code code="SPLSCORE" codeSystem="2.16.840.1.113883.1.11.19255"/>
                                 <value value="1" xsi:type="INT"/>
                              </characteristic>
                           </subjectOf>
                           <subjectOf>
                              <characteristic classCode="OBS">
                                 <code code="SPLIMPRINT" codeSystem="2.16.840.1.113883.1.11.19255"/>
                                 <value xsi:type="ST">PREMARIN;0625</value>
                              </characteristic>
                           </subjectOf>
                           <consumedIn>
                              <substanceAdministration>
                                 <routeCode code="C38288" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="ORAL"/>
                              </substanceAdministration>
                           </consumedIn>
                        </part>
                     </manufacturedProduct>
                     <subjectOf>
                        <approval>
                           <id extension="NDA020527" root="2.16.840.1.113883.3.150"/>
                           <code code="C73594" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="NDA"/>
                           <author>
                              <territorialAuthority>
                                 <territory>
                                    <code code="USA" codeSystem="2.16.840.1.113883.5.28"/>
                                 </territory>
                              </territorialAuthority>
                           </author>
                        </approval>
                     </subjectOf>
                     <subjectOf>
                        <marketingAct>
                           <code code="C53292" codeSystem="2.16.840.1.113883.3.26.1.1"/>
                           <statusCode code="active"/>
                           <effectiveTime>
                              <low value="20120301"/>
                           </effectiveTime>
                        </marketingAct>
                     </subjectOf>
                  </manufacturedProduct>
               </subject>
               <subject>
                  <manufacturedProduct>
                     <manufacturedProduct>
                        <code code="0046-1105" codeSystem="2.16.840.1.113883.6.69"/>
                        <name>Prempro</name>
                        <formCode code="C42992" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="TABLET, SUGAR COATED"/>
                        <asEntityWithGeneric>
                           <genericMedicine>
                              <name>conjugated estrogens and medroxyprogesterone acetate</name>
                           </genericMedicine>
                        </asEntityWithGeneric>
                        <ingredient classCode="ACTIB">
                           <quantity>
                              <numerator unit="mg" value="0.3"/>
                              <denominator unit="1" value="1"/>
                           </quantity>
                           <ingredientSubstance>
                              <code code="IU5QR144QX" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>ESTROGENS, CONJUGATED</name>
                              <activeMoiety>
                                 <activeMoiety>
                                    <code code="IU5QR144QX" codeSystem="2.16.840.1.113883.4.9"/>
                                    <name>ESTROGENS, CONJUGATED</name>
                                 </activeMoiety>
                              </activeMoiety>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="ACTIB">
                           <quantity>
                              <numerator unit="mg" value="1.5"/>
                              <denominator unit="1" value="1"/>
                           </quantity>
                           <ingredientSubstance>
                              <code code="C2QI4IOI2G" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>MEDROXYPROGESTERONE ACETATE</name>
                              <activeMoiety>
                                 <activeMoiety>
                                    <code code="HSU1C9YRES" codeSystem="2.16.840.1.113883.4.9"/>
                                    <name>MEDROXYPROGESTERONE</name>
                                 </activeMoiety>
                              </activeMoiety>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <ingredientSubstance>
                              <code code="OP1R32D61U" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>MICROCRYSTALLINE CELLULOSE</name>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <ingredientSubstance>
                              <code code="RFW2ET671P" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>HYDROXYPROPYL CELLULOSE (1600000 WAMW)</name>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <ingredientSubstance>
                              <code code="C151H8M554" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>SUCROSE</name>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <ingredientSubstance>
                              <code code="EWQ57Q8I5X" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>LACTOSE MONOHYDRATE</name>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <ingredientSubstance>
                              <code code="70097M6I30" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>MAGNESIUM STEARATE</name>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <ingredientSubstance>
                              <code code="B697894SGQ" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>POLYETHYLENE GLYCOL 400</name>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <ingredientSubstance>
                              <code code="15FIX9V2JP" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>TITANIUM DIOXIDE</name>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <ingredientSubstance>
                              <code code="EX438O2MRT" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>FERRIC OXIDE YELLOW</name>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <ingredientSubstance>
                              <code code="XM0M87F357" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>FERROSOFERRIC OXIDE</name>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <ingredientSubstance>
                              <code code="91D9GV0Z28" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>TRIBASIC CALCIUM PHOSPHATE</name>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <ingredientSubstance>
                              <code code="NX76LV5T8J" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>METHACRYLIC ACID AND ETHYL ACRYLATE COPOLYMER</name>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <ingredientSubstance>
                              <code code="Z78RG6M2N2" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>HYPROMELLOSE 2208 (15000 MPA.S)</name>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <ingredientSubstance>
                              <code code="36SFW2JZ0W" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>HYPROMELLOSE 2910 (15 MPA.S)</name>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <ingredientSubstance>
                              <code code="0WZ8WG20P6" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>HYPROMELLOSE 2910 (6 MPA.S)</name>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <ingredientSubstance>
                              <code code="R12CBM0EIZ" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>CARNAUBA WAX</name>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <ingredientSubstance>
                              <code code="6DC9Q167V3" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>PROPYLENE GLYCOL</name>
                           </ingredientSubstance>
                        </ingredient>
                        <asContent>
                           <quantity>
                              <numerator unit="1" value="28"/>
                              <denominator value="1"/>
                           </quantity>
                           <containerPackagedProduct>
                              <code/>
                              <formCode code="C43168" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="BLISTER PACK"/>
                              <asContent>
                                 <quantity>
                                    <numerator unit="1" value="1"/>
                                    <denominator value="1"/>
                                 </quantity>
                                 <containerPackagedProduct>
                                    <code code="0046-1105-11" codeSystem="2.16.840.1.113883.6.69"/>
                                    <formCode code="C43182" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="CARTON"/>
                                 </containerPackagedProduct>
                                 <subjectOf>
                                    <marketingAct>
                                       <code code="C53292" codeSystem="2.16.840.1.113883.3.26.1.1"/>
                                       <statusCode code="active"/>
                                       <effectiveTime>
                                          <low value="20090921"/>
                                       </effectiveTime>
                                    </marketingAct>
                                 </subjectOf>
                              </asContent>
                           </containerPackagedProduct>
                           <subjectOf>
                              <characteristic classCode="OBS">
                                 <code code="SPLCMBPRDTP" codeSystem="2.16.840.1.113883.1.11.19255"/>
                                 <value code="C112160" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="Type 0: Not a Combination Product" xsi:type="CE"/>
                              </characteristic>
                           </subjectOf>
                        </asContent>
                     </manufacturedProduct>
                     <subjectOf>
                        <approval>
                           <id extension="NDA020527" root="2.16.840.1.113883.3.150"/>
                           <code code="C73594" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="NDA"/>
                           <author>
                              <territorialAuthority>
                                 <territory>
                                    <code code="USA" codeSystem="2.16.840.1.113883.5.28"/>
                                 </territory>
                              </territorialAuthority>
                           </author>
                        </approval>
                     </subjectOf>
                     <subjectOf>
                        <marketingAct>
                           <code code="C53292" codeSystem="2.16.840.1.113883.3.26.1.1"/>
                           <statusCode code="active"/>
                           <effectiveTime>
                              <low value="20090921"/>
                           </effectiveTime>
                        </marketingAct>
                     </subjectOf>
                     <subjectOf>
                        <characteristic classCode="OBS">
                           <code code="SPLCOLOR" codeSystem="2.16.840.1.113883.1.11.19255"/>
                           <value code="C48330" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="YELLOW" xsi:type="CE">
                              <originalText>CREAM</originalText>
                           </value>
                        </characteristic>
                     </subjectOf>
                     <subjectOf>
                        <characteristic classCode="OBS">
                           <code code="SPLSIZE" codeSystem="2.16.840.1.113883.1.11.19255"/>
                           <value unit="mm" value="10" xsi:type="PQ"/>
                        </characteristic>
                     </subjectOf>
                     <subjectOf>
                        <characteristic classCode="OBS">
                           <code code="SPLSHAPE" codeSystem="2.16.840.1.113883.1.11.19255"/>
                           <value code="C48345" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="OVAL" xsi:type="CE">
                              <originalText>OVAL</originalText>
                           </value>
                        </characteristic>
                     </subjectOf>
                     <subjectOf>
                        <characteristic classCode="OBS">
                           <code code="SPLSCORE" codeSystem="2.16.840.1.113883.1.11.19255"/>
                           <value value="1" xsi:type="INT"/>
                        </characteristic>
                     </subjectOf>
                     <subjectOf>
                        <characteristic classCode="OBS">
                           <code code="SPLIMPRINT" codeSystem="2.16.840.1.113883.1.11.19255"/>
                           <value xsi:type="ST">PREMPRO;03;15</value>
                        </characteristic>
                     </subjectOf>
                     <consumedIn>
                        <substanceAdministration>
                           <routeCode code="C38288" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="ORAL"/>
                        </substanceAdministration>
                     </consumedIn>
                  </manufacturedProduct>
               </subject>
               <subject>
                  <manufacturedProduct>
                     <manufacturedProduct>
                        <code code="0046-1106" codeSystem="2.16.840.1.113883.6.69"/>
                        <name>Prempro</name>
                        <formCode code="C42992" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="TABLET, SUGAR COATED"/>
                        <asEntityWithGeneric>
                           <genericMedicine>
                              <name>conjugated estrogens and medroxyprogesterone acetate</name>
                           </genericMedicine>
                        </asEntityWithGeneric>
                        <ingredient classCode="ACTIB">
                           <quantity>
                              <numerator unit="mg" value="0.45"/>
                              <denominator unit="1" value="1"/>
                           </quantity>
                           <ingredientSubstance>
                              <code code="IU5QR144QX" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>ESTROGENS, CONJUGATED</name>
                              <activeMoiety>
                                 <activeMoiety>
                                    <code code="IU5QR144QX" codeSystem="2.16.840.1.113883.4.9"/>
                                    <name>ESTROGENS, CONJUGATED</name>
                                 </activeMoiety>
                              </activeMoiety>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="ACTIB">
                           <quantity>
                              <numerator unit="mg" value="1.5"/>
                              <denominator unit="1" value="1"/>
                           </quantity>
                           <ingredientSubstance>
                              <code code="C2QI4IOI2G" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>MEDROXYPROGESTERONE ACETATE</name>
                              <activeMoiety>
                                 <activeMoiety>
                                    <code code="HSU1C9YRES" codeSystem="2.16.840.1.113883.4.9"/>
                                    <name>MEDROXYPROGESTERONE</name>
                                 </activeMoiety>
                              </activeMoiety>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <ingredientSubstance>
                              <code code="OP1R32D61U" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>MICROCRYSTALLINE CELLULOSE</name>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <ingredientSubstance>
                              <code code="RFW2ET671P" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>HYDROXYPROPYL CELLULOSE (1600000 WAMW)</name>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <ingredientSubstance>
                              <code code="C151H8M554" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>SUCROSE</name>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <ingredientSubstance>
                              <code code="EWQ57Q8I5X" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>LACTOSE MONOHYDRATE</name>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <ingredientSubstance>
                              <code code="70097M6I30" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>MAGNESIUM STEARATE</name>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <ingredientSubstance>
                              <code code="B697894SGQ" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>POLYETHYLENE GLYCOL 400</name>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <ingredientSubstance>
                              <code code="15FIX9V2JP" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>TITANIUM DIOXIDE</name>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <ingredientSubstance>
                              <code code="EX438O2MRT" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>FERRIC OXIDE YELLOW</name>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <ingredientSubstance>
                              <code code="XM0M87F357" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>FERROSOFERRIC OXIDE</name>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <ingredientSubstance>
                              <code code="NX76LV5T8J" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>METHACRYLIC ACID AND ETHYL ACRYLATE COPOLYMER</name>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <ingredientSubstance>
                              <code code="91D9GV0Z28" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>TRIBASIC CALCIUM PHOSPHATE</name>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <ingredientSubstance>
                              <code code="Z78RG6M2N2" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>HYPROMELLOSE 2208 (15000 MPA.S)</name>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <ingredientSubstance>
                              <code code="36SFW2JZ0W" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>HYPROMELLOSE 2910 (15 MPA.S)</name>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <ingredientSubstance>
                              <code code="0WZ8WG20P6" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>HYPROMELLOSE 2910 (6 MPA.S)</name>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <ingredientSubstance>
                              <code code="R12CBM0EIZ" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>CARNAUBA WAX</name>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <ingredientSubstance>
                              <code code="6DC9Q167V3" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>PROPYLENE GLYCOL</name>
                           </ingredientSubstance>
                        </ingredient>
                        <asContent>
                           <quantity>
                              <numerator unit="1" value="28"/>
                              <denominator value="1"/>
                           </quantity>
                           <containerPackagedProduct>
                              <code/>
                              <formCode code="C43168" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="BLISTER PACK"/>
                              <asContent>
                                 <quantity>
                                    <numerator unit="1" value="1"/>
                                    <denominator value="1"/>
                                 </quantity>
                                 <containerPackagedProduct>
                                    <code code="0046-1106-11" codeSystem="2.16.840.1.113883.6.69"/>
                                    <formCode code="C43182" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="CARTON"/>
                                 </containerPackagedProduct>
                                 <subjectOf>
                                    <marketingAct>
                                       <code code="C53292" codeSystem="2.16.840.1.113883.3.26.1.1"/>
                                       <statusCode code="active"/>
                                       <effectiveTime>
                                          <low value="20090921"/>
                                       </effectiveTime>
                                    </marketingAct>
                                 </subjectOf>
                              </asContent>
                           </containerPackagedProduct>
                           <subjectOf>
                              <characteristic classCode="OBS">
                                 <code code="SPLCMBPRDTP" codeSystem="2.16.840.1.113883.1.11.19255"/>
                                 <value code="C112160" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="Type 0: Not a Combination Product" xsi:type="CE"/>
                              </characteristic>
                           </subjectOf>
                        </asContent>
                     </manufacturedProduct>
                     <subjectOf>
                        <approval>
                           <id extension="NDA020527" root="2.16.840.1.113883.3.150"/>
                           <code code="C73594" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="NDA"/>
                           <author>
                              <territorialAuthority>
                                 <territory>
                                    <code code="USA" codeSystem="2.16.840.1.113883.5.28"/>
                                 </territory>
                              </territorialAuthority>
                           </author>
                        </approval>
                     </subjectOf>
                     <subjectOf>
                        <marketingAct>
                           <code code="C53292" codeSystem="2.16.840.1.113883.3.26.1.1"/>
                           <statusCode code="active"/>
                           <effectiveTime>
                              <low value="20090921"/>
                           </effectiveTime>
                        </marketingAct>
                     </subjectOf>
                     <subjectOf>
                        <characteristic classCode="OBS">
                           <code code="SPLCOLOR" codeSystem="2.16.840.1.113883.1.11.19255"/>
                           <value code="C48330" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="YELLOW" xsi:type="CE">
                              <originalText>GOLD</originalText>
                           </value>
                        </characteristic>
                     </subjectOf>
                     <subjectOf>
                        <characteristic classCode="OBS">
                           <code code="SPLSIZE" codeSystem="2.16.840.1.113883.1.11.19255"/>
                           <value unit="mm" value="10" xsi:type="PQ"/>
                        </characteristic>
                     </subjectOf>
                     <subjectOf>
                        <characteristic classCode="OBS">
                           <code code="SPLSHAPE" codeSystem="2.16.840.1.113883.1.11.19255"/>
                           <value code="C48345" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="OVAL" xsi:type="CE">
                              <originalText>OVAL</originalText>
                           </value>
                        </characteristic>
                     </subjectOf>
                     <subjectOf>
                        <characteristic classCode="OBS">
                           <code code="SPLSCORE" codeSystem="2.16.840.1.113883.1.11.19255"/>
                           <value value="1" xsi:type="INT"/>
                        </characteristic>
                     </subjectOf>
                     <subjectOf>
                        <characteristic classCode="OBS">
                           <code code="SPLIMPRINT" codeSystem="2.16.840.1.113883.1.11.19255"/>
                           <value xsi:type="ST">PREMPRO;045;15</value>
                        </characteristic>
                     </subjectOf>
                     <consumedIn>
                        <substanceAdministration>
                           <routeCode code="C38288" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="ORAL"/>
                        </substanceAdministration>
                     </consumedIn>
                  </manufacturedProduct>
               </subject>
               <subject>
                  <manufacturedProduct>
                     <manufacturedProduct>
                        <code code="0046-1107" codeSystem="2.16.840.1.113883.6.69"/>
                        <name>Prempro</name>
                        <formCode code="C42992" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="TABLET, SUGAR COATED"/>
                        <asEntityWithGeneric>
                           <genericMedicine>
                              <name>conjugated estrogens and medroxyprogesterone acetate</name>
                           </genericMedicine>
                        </asEntityWithGeneric>
                        <ingredient classCode="ACTIB">
                           <quantity>
                              <numerator unit="mg" value="0.625"/>
                              <denominator unit="1" value="1"/>
                           </quantity>
                           <ingredientSubstance>
                              <code code="IU5QR144QX" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>ESTROGENS, CONJUGATED</name>
                              <activeMoiety>
                                 <activeMoiety>
                                    <code code="IU5QR144QX" codeSystem="2.16.840.1.113883.4.9"/>
                                    <name>ESTROGENS, CONJUGATED</name>
                                 </activeMoiety>
                              </activeMoiety>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="ACTIB">
                           <quantity>
                              <numerator unit="mg" value="2.5"/>
                              <denominator unit="1" value="1"/>
                           </quantity>
                           <ingredientSubstance>
                              <code code="C2QI4IOI2G" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>MEDROXYPROGESTERONE ACETATE</name>
                              <activeMoiety>
                                 <activeMoiety>
                                    <code code="HSU1C9YRES" codeSystem="2.16.840.1.113883.4.9"/>
                                    <name>MEDROXYPROGESTERONE</name>
                                 </activeMoiety>
                              </activeMoiety>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <ingredientSubstance>
                              <code code="OP1R32D61U" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>MICROCRYSTALLINE CELLULOSE</name>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <ingredientSubstance>
                              <code code="RFW2ET671P" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>HYDROXYPROPYL CELLULOSE (1600000 WAMW)</name>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <ingredientSubstance>
                              <code code="C151H8M554" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>SUCROSE</name>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <ingredientSubstance>
                              <code code="EWQ57Q8I5X" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>LACTOSE MONOHYDRATE</name>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <ingredientSubstance>
                              <code code="70097M6I30" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>MAGNESIUM STEARATE</name>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <ingredientSubstance>
                              <code code="B697894SGQ" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>POLYETHYLENE GLYCOL 400</name>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <ingredientSubstance>
                              <code code="15FIX9V2JP" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>TITANIUM DIOXIDE</name>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <ingredientSubstance>
                              <code code="EX438O2MRT" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>FERRIC OXIDE YELLOW</name>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <ingredientSubstance>
                              <code code="XM0M87F357" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>FERROSOFERRIC OXIDE</name>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <ingredientSubstance>
                              <code code="NX76LV5T8J" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>METHACRYLIC ACID AND ETHYL ACRYLATE COPOLYMER</name>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <ingredientSubstance>
                              <code code="91D9GV0Z28" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>TRIBASIC CALCIUM PHOSPHATE</name>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <ingredientSubstance>
                              <code code="Z78RG6M2N2" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>HYPROMELLOSE 2208 (15000 MPA.S)</name>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <ingredientSubstance>
                              <code code="36SFW2JZ0W" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>HYPROMELLOSE 2910 (15 MPA.S)</name>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <ingredientSubstance>
                              <code code="0WZ8WG20P6" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>HYPROMELLOSE 2910 (6 MPA.S)</name>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <ingredientSubstance>
                              <code code="R12CBM0EIZ" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>CARNAUBA WAX</name>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <ingredientSubstance>
                              <code code="6DC9Q167V3" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>PROPYLENE GLYCOL</name>
                           </ingredientSubstance>
                        </ingredient>
                        <asContent>
                           <quantity>
                              <numerator unit="1" value="28"/>
                              <denominator value="1"/>
                           </quantity>
                           <containerPackagedProduct>
                              <code/>
                              <formCode code="C43168" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="BLISTER PACK"/>
                              <asContent>
                                 <quantity>
                                    <numerator unit="1" value="1"/>
                                    <denominator value="1"/>
                                 </quantity>
                                 <containerPackagedProduct>
                                    <code code="0046-1107-11" codeSystem="2.16.840.1.113883.6.69"/>
                                    <formCode code="C43182" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="CARTON"/>
                                 </containerPackagedProduct>
                                 <subjectOf>
                                    <marketingAct>
                                       <code code="C53292" codeSystem="2.16.840.1.113883.3.26.1.1"/>
                                       <statusCode code="active"/>
                                       <effectiveTime>
                                          <low value="20090921"/>
                                       </effectiveTime>
                                    </marketingAct>
                                 </subjectOf>
                              </asContent>
                           </containerPackagedProduct>
                           <subjectOf>
                              <characteristic classCode="OBS">
                                 <code code="SPLCMBPRDTP" codeSystem="2.16.840.1.113883.1.11.19255"/>
                                 <value code="C112160" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="Type 0: Not a Combination Product" xsi:type="CE"/>
                              </characteristic>
                           </subjectOf>
                        </asContent>
                     </manufacturedProduct>
                     <subjectOf>
                        <approval>
                           <id extension="NDA020527" root="2.16.840.1.113883.3.150"/>
                           <code code="C73594" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="NDA"/>
                           <author>
                              <territorialAuthority>
                                 <territory>
                                    <code code="USA" codeSystem="2.16.840.1.113883.5.28"/>
                                 </territory>
                              </territorialAuthority>
                           </author>
                        </approval>
                     </subjectOf>
                     <subjectOf>
                        <marketingAct>
                           <code code="C53292" codeSystem="2.16.840.1.113883.3.26.1.1"/>
                           <statusCode code="active"/>
                           <effectiveTime>
                              <low value="20090921"/>
                           </effectiveTime>
                        </marketingAct>
                     </subjectOf>
                     <subjectOf>
                        <characteristic classCode="OBS">
                           <code code="SPLCOLOR" codeSystem="2.16.840.1.113883.1.11.19255"/>
                           <value code="C48331" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="ORANGE" xsi:type="CE">
                              <originalText>PEACH</originalText>
                           </value>
                        </characteristic>
                     </subjectOf>
                     <subjectOf>
                        <characteristic classCode="OBS">
                           <code code="SPLSIZE" codeSystem="2.16.840.1.113883.1.11.19255"/>
                           <value unit="mm" value="10" xsi:type="PQ"/>
                        </characteristic>
                     </subjectOf>
                     <subjectOf>
                        <characteristic classCode="OBS">
                           <code code="SPLSHAPE" codeSystem="2.16.840.1.113883.1.11.19255"/>
                           <value code="C48345" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="OVAL" xsi:type="CE">
                              <originalText>OVAL</originalText>
                           </value>
                        </characteristic>
                     </subjectOf>
                     <subjectOf>
                        <characteristic classCode="OBS">
                           <code code="SPLSCORE" codeSystem="2.16.840.1.113883.1.11.19255"/>
                           <value value="1" xsi:type="INT"/>
                        </characteristic>
                     </subjectOf>
                     <subjectOf>
                        <characteristic classCode="OBS">
                           <code code="SPLIMPRINT" codeSystem="2.16.840.1.113883.1.11.19255"/>
                           <value xsi:type="ST">PREMPRO;0625;25</value>
                        </characteristic>
                     </subjectOf>
                     <consumedIn>
                        <substanceAdministration>
                           <routeCode code="C38288" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="ORAL"/>
                        </substanceAdministration>
                     </consumedIn>
                  </manufacturedProduct>
               </subject>
               <subject>
                  <manufacturedProduct>
                     <manufacturedProduct>
                        <code code="0046-1108" codeSystem="2.16.840.1.113883.6.69"/>
                        <name>Prempro</name>
                        <formCode code="C42992" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="TABLET, SUGAR COATED"/>
                        <asEntityWithGeneric>
                           <genericMedicine>
                              <name>conjugated estrogens and medroxyprogesterone acetate</name>
                           </genericMedicine>
                        </asEntityWithGeneric>
                        <ingredient classCode="ACTIB">
                           <quantity>
                              <numerator unit="mg" value="0.625"/>
                              <denominator unit="1" value="1"/>
                           </quantity>
                           <ingredientSubstance>
                              <code code="IU5QR144QX" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>ESTROGENS, CONJUGATED</name>
                              <activeMoiety>
                                 <activeMoiety>
                                    <code code="IU5QR144QX" codeSystem="2.16.840.1.113883.4.9"/>
                                    <name>ESTROGENS, CONJUGATED</name>
                                 </activeMoiety>
                              </activeMoiety>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="ACTIB">
                           <quantity>
                              <numerator unit="mg" value="5"/>
                              <denominator unit="1" value="1"/>
                           </quantity>
                           <ingredientSubstance>
                              <code code="C2QI4IOI2G" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>MEDROXYPROGESTERONE ACETATE</name>
                              <activeMoiety>
                                 <activeMoiety>
                                    <code code="HSU1C9YRES" codeSystem="2.16.840.1.113883.4.9"/>
                                    <name>MEDROXYPROGESTERONE</name>
                                 </activeMoiety>
                              </activeMoiety>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <ingredientSubstance>
                              <code code="OP1R32D61U" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>MICROCRYSTALLINE CELLULOSE</name>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <ingredientSubstance>
                              <code code="RFW2ET671P" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>HYDROXYPROPYL CELLULOSE (1600000 WAMW)</name>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <ingredientSubstance>
                              <code code="C151H8M554" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>SUCROSE</name>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <ingredientSubstance>
                              <code code="EWQ57Q8I5X" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>LACTOSE MONOHYDRATE</name>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <ingredientSubstance>
                              <code code="70097M6I30" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>MAGNESIUM STEARATE</name>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <ingredientSubstance>
                              <code code="B697894SGQ" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>POLYETHYLENE GLYCOL 400</name>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <ingredientSubstance>
                              <code code="R12CBM0EIZ" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>CARNAUBA WAX</name>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <ingredientSubstance>
                              <code code="15FIX9V2JP" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>TITANIUM DIOXIDE</name>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <ingredientSubstance>
                              <code code="L06K8R7DQK" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>FD&amp;C BLUE NO. 2</name>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <ingredientSubstance>
                              <code code="XM0M87F357" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>FERROSOFERRIC OXIDE</name>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <ingredientSubstance>
                              <code code="NX76LV5T8J" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>METHACRYLIC ACID AND ETHYL ACRYLATE COPOLYMER</name>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <ingredientSubstance>
                              <code code="91D9GV0Z28" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>TRIBASIC CALCIUM PHOSPHATE</name>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <ingredientSubstance>
                              <code code="Z78RG6M2N2" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>HYPROMELLOSE 2208 (15000 MPA.S)</name>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <ingredientSubstance>
                              <code code="36SFW2JZ0W" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>HYPROMELLOSE 2910 (15 MPA.S)</name>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <ingredientSubstance>
                              <code code="0WZ8WG20P6" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>HYPROMELLOSE 2910 (6 MPA.S)</name>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <ingredientSubstance>
                              <code code="6DC9Q167V3" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>PROPYLENE GLYCOL</name>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <ingredientSubstance>
                              <code code="8Z96QXD6UM" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>TRIETHYL CITRATE</name>
                           </ingredientSubstance>
                        </ingredient>
                        <asContent>
                           <quantity>
                              <numerator unit="1" value="28"/>
                              <denominator value="1"/>
                           </quantity>
                           <containerPackagedProduct>
                              <code/>
                              <formCode code="C43168" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="BLISTER PACK"/>
                              <asContent>
                                 <quantity>
                                    <numerator unit="1" value="1"/>
                                    <denominator value="1"/>
                                 </quantity>
                                 <containerPackagedProduct>
                                    <code code="0046-1108-11" codeSystem="2.16.840.1.113883.6.69"/>
                                    <formCode code="C43182" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="CARTON"/>
                                 </containerPackagedProduct>
                                 <subjectOf>
                                    <marketingAct>
                                       <code code="C53292" codeSystem="2.16.840.1.113883.3.26.1.1"/>
                                       <statusCode code="active"/>
                                       <effectiveTime>
                                          <low value="20121203"/>
                                       </effectiveTime>
                                    </marketingAct>
                                 </subjectOf>
                              </asContent>
                           </containerPackagedProduct>
                           <subjectOf>
                              <characteristic classCode="OBS">
                                 <code code="SPLCMBPRDTP" codeSystem="2.16.840.1.113883.1.11.19255"/>
                                 <value code="C112160" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="Type 0: Not a Combination Product" xsi:type="CE"/>
                              </characteristic>
                           </subjectOf>
                        </asContent>
                     </manufacturedProduct>
                     <subjectOf>
                        <approval>
                           <id extension="NDA020527" root="2.16.840.1.113883.3.150"/>
                           <code code="C73594" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="NDA"/>
                           <author>
                              <territorialAuthority>
                                 <territory>
                                    <code code="USA" codeSystem="2.16.840.1.113883.5.28"/>
                                 </territory>
                              </territorialAuthority>
                           </author>
                        </approval>
                     </subjectOf>
                     <subjectOf>
                        <marketingAct>
                           <code code="C53292" codeSystem="2.16.840.1.113883.3.26.1.1"/>
                           <statusCode code="active"/>
                           <effectiveTime>
                              <low value="20121203"/>
                           </effectiveTime>
                        </marketingAct>
                     </subjectOf>
                     <subjectOf>
                        <characteristic classCode="OBS">
                           <code code="SPLCOLOR" codeSystem="2.16.840.1.113883.1.11.19255"/>
                           <value code="C48333" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="BLUE" xsi:type="CE">
                              <originalText>LIGHT BLUE</originalText>
                           </value>
                        </characteristic>
                     </subjectOf>
                     <subjectOf>
                        <characteristic classCode="OBS">
                           <code code="SPLSIZE" codeSystem="2.16.840.1.113883.1.11.19255"/>
                           <value unit="mm" value="10" xsi:type="PQ"/>
                        </characteristic>
                     </subjectOf>
                     <subjectOf>
                        <characteristic classCode="OBS">
                           <code code="SPLSHAPE" codeSystem="2.16.840.1.113883.1.11.19255"/>
                           <value code="C48345" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="OVAL" xsi:type="CE">
                              <originalText>OVAL</originalText>
                           </value>
                        </characteristic>
                     </subjectOf>
                     <subjectOf>
                        <characteristic classCode="OBS">
                           <code code="SPLSCORE" codeSystem="2.16.840.1.113883.1.11.19255"/>
                           <value value="1" xsi:type="INT"/>
                        </characteristic>
                     </subjectOf>
                     <subjectOf>
                        <characteristic classCode="OBS">
                           <code code="SPLIMPRINT" codeSystem="2.16.840.1.113883.1.11.19255"/>
                           <value xsi:type="ST">PREMPRO;0625;5</value>
                        </characteristic>
                     </subjectOf>
                     <consumedIn>
                        <substanceAdministration>
                           <routeCode code="C38288" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="ORAL"/>
                        </substanceAdministration>
                     </consumedIn>
                  </manufacturedProduct>
               </subject>
            </section>
         </component>
         <component>
            <section ID="BOX">
               <id root="2b9b398f-fa4f-4c34-a834-a9a4a4696a49"/>
               <code code="34066-1" codeSystem="2.16.840.1.113883.6.1" displayName="Boxed Warning section"/>
               <title>WARNING: CARDIOVASCULAR DISORDERS, BREAST CANCER, ENDOMETRIAL CANCER and PROBABLE DEMENTIA</title>
               <text>
                  <paragraph>
                     <content styleCode="bold">
                        <content styleCode="underline">Estrogen Plus Progestin Therapy</content>
                     </content>
                  </paragraph>
                  <paragraph>
                     <content styleCode="bold">Cardiovascular Disorders and Probable Dementia</content>
                  </paragraph>
                  <paragraph>
                     <content styleCode="bold">Estrogen plus progestin therapy should not be used for the prevention of cardiovascular disease or dementia <content styleCode="italics">[see <linkHtml href="#S5.1">Warnings and Precautions (5.1</linkHtml>, <linkHtml href="#S5.3">5.3)</linkHtml>, and <linkHtml href="#S14.6">Clinical Studies (14.6</linkHtml>, <linkHtml href="#S14.7">14.7)</linkHtml>]</content>.</content>
                  </paragraph>
                  <paragraph>
                     <content styleCode="bold">The Women's Health Initiative (WHI) estrogen plus progestin substudy reported an increased risk of deep vein thrombosis (DVT), pulmonary embolism (PE), stroke and myocardial infarction (MI) in postmenopausal women (50 to 79 years of age) during 5.6 years of treatment with daily oral conjugated estrogen (CE) (0.625 mg) combined with medroxyprogesterone acetate (MPA) (2.5 mg), relative to placebo <content styleCode="italics">[see <linkHtml href="#S5.1">Warnings and Precautions (5.1)</linkHtml>, and <linkHtml href="#S14.6">Clinical Studies (14.6)</linkHtml>]</content>.</content>
                  </paragraph>
                  <paragraph>
                     <content styleCode="bold">The WHI Memory Study (WHIMS) estrogen plus progestin ancillary study of the WHI reported an increased risk of developing probable dementia in postmenopausal women 65 years of age or older during 4 years of treatment with daily CE (0.625 mg) combined with MPA (2.5 mg), relative to placebo. It is unknown whether this finding applies to younger postmenopausal women <content styleCode="italics">[see <linkHtml href="#S5.3">Warnings and Precautions (5.3)</linkHtml>, <linkHtml href="#S8.5">Use in Specific Populations (8.5)</linkHtml>, and <linkHtml href="#S14.7">Clinical Studies (14.7)</linkHtml>]</content>.</content>
                  </paragraph>
                  <paragraph>
                     <content styleCode="bold">Breast Cancer</content>
                  </paragraph>
                  <paragraph>
                     <content styleCode="bold">The WHI estrogen plus progestin substudy also demonstrated an increased risk of invasive breast cancer <content styleCode="italics">[see <linkHtml href="#S5.2">Warnings and Precautions (5.2)</linkHtml>, and <linkHtml href="#S14.6">Clinical Studies (14.6)</linkHtml>]</content>.</content>
                  </paragraph>
                  <paragraph>
                     <content styleCode="bold">In the absence of comparable data, these risks should be assumed to be similar for other doses of CE and MPA and other combinations and dosage forms of estrogens and progestins.</content>
                  </paragraph>
                  <paragraph>
                     <content styleCode="bold">Estrogens with or without progestins should be prescribed at the lowest effective doses and for the shortest duration consistent with treatment goals and risks for the individual woman. </content>
                  </paragraph>
                  <paragraph>
                     <content styleCode="bold">
                        <content styleCode="underline">Estrogen-Alone Therapy</content>
                     </content>
                  </paragraph>
                  <paragraph>
                     <content styleCode="bold">Endometrial Cancer</content>
                  </paragraph>
                  <paragraph>
                     <content styleCode="bold">There is an increased risk of endometrial cancer in a woman with a uterus who uses unopposed estrogens. Adding a progestin to estrogen therapy has been shown to reduce the risk of endometrial hyperplasia, which may be a precursor to endometrial cancer. Adequate diagnostic measures, including directed or random endometrial sampling when indicated, should be undertaken to rule out malignancy in postmenopausal women with undiagnosed persistent or recurring abnormal genital bleeding <content styleCode="italics">[see <linkHtml href="#S5.2">Warnings and Precautions (5.2)</linkHtml>]</content>.</content>
                  </paragraph>
                  <paragraph>
                     <content styleCode="bold">Cardiovascular Disorders and Probable Dementia</content>
                  </paragraph>
                  <paragraph>
                     <content styleCode="bold">Estrogen-alone therapy should not be used for the prevention of cardiovascular disease or dementia <content styleCode="italics">[see <linkHtml href="#S5.1">Warnings and Precautions (5.1</linkHtml>, <linkHtml href="#S5.3">5.3)</linkHtml>, and <linkHtml href="#S14.6">Clinical Studies (14.6</linkHtml>, <linkHtml href="#S14.7">14.7)</linkHtml>]</content>.</content>
                  </paragraph>
                  <paragraph>
                     <content styleCode="bold">The WHI estrogen-alone substudy reported increased risks of stroke and DVT in postmenopausal women (50 to 79 years of age) during 7.1 years of treatment with daily oral CE (0.625 mg)-alone, relative to placebo <content styleCode="italics">[see <linkHtml href="#S5.1">Warnings and Precautions (5.1)</linkHtml>, and <linkHtml href="#S14.6">Clinical Studies (14.6)</linkHtml>]</content>.</content>
                  </paragraph>
                  <paragraph>
                     <content styleCode="bold">The WHIMS estrogen-alone ancillary study of WHI reported an increased risk of developing probable dementia in postmenopausal women 65 years of age or older during 5.2 years of treatment with daily CE (0.625 mg)-alone, relative to placebo. It is unknown whether this finding applies to younger postmenopausal women <content styleCode="italics">[see <linkHtml href="#S5.3">Warnings and Precautions (5.3)</linkHtml>, <linkHtml href="#S8.5">Use in Specific Populations (8.5)</linkHtml>, and <linkHtml href="#S14.7">Clinical Studies (14.7)</linkHtml>]</content>.</content>
                  </paragraph>
                  <paragraph>
                     <content styleCode="bold">In the absence of comparable data, these risks should be assumed to be similar for other doses of CE and other dosage forms of estrogens.</content>
                  </paragraph>
                  <paragraph>
                     <content styleCode="bold">Estrogens with or without progestins should be prescribed at the lowest effective doses and for the shortest duration consistent with treatment goals and risks for the individual woman.</content>
                  </paragraph>
               </text>
               <effectiveTime value="20250429"/>
               <excerpt>
                  <highlight>
                     <text>
                        <paragraph>WARNING: CARDIOVASCULAR DISORDERS, BREAST CANCER, ENDOMETRIAL CANCER and PROBABLE DEMENTIA</paragraph>
                        <paragraph>
                           <content styleCode="bold">
                              <content styleCode="italics">See full prescribing information for complete boxed warning.</content>
                           </content>
                        </paragraph>
                        <paragraph>
                           <content styleCode="bold">
                              <content styleCode="underline">Estrogen Plus Progestin Therapy</content>
                           </content>
                        </paragraph>
                        <list listType="unordered">
                           <item>
                              <caption>•</caption>
                              <content styleCode="bold">Estrogen plus progestin therapy should not be used for the prevention of cardiovascular disease or dementia (<linkHtml href="#S5.1">5.1</linkHtml>, <linkHtml href="#S5.3">5.3</linkHtml>)</content>
                           </item>
                           <item>
                              <caption>•</caption>
                              <content styleCode="bold">The Women's Health Initiative (WHI) estrogen plus progestin substudy reported increased risks of stroke, deep vein thrombosis (DVT), pulmonary embolism (PE), and myocardial infarction (MI) (<linkHtml href="#S5.1">5.1</linkHtml>)</content>
                           </item>
                           <item>
                              <caption>•</caption>
                              <content styleCode="bold">The WHI estrogen plus progestin substudy reported increased risks of invasive breast cancer (<linkHtml href="#S5.2">5.2</linkHtml>)</content>
                           </item>
                           <item>
                              <caption>•</caption>
                              <content styleCode="bold">The WHI Memory Study (WHIMS) estrogen plus progestin ancillary study of WHI reported an increased risk of probable dementia in postmenopausal women 65 years of age and older (<linkHtml href="#S5.3">5.3</linkHtml>)</content>
                           </item>
                        </list>
                        <paragraph>
                           <content styleCode="bold">
                              <content styleCode="underline">Estrogen-Alone Therapy</content>
                           </content>
                        </paragraph>
                        <list listType="unordered">
                           <item>
                              <caption>•</caption>
                              <content styleCode="bold">There is an increased risk of endometrial cancer in a woman with a uterus who uses unopposed estrogens (<linkHtml href="#S5.2">5.2</linkHtml>)</content>
                           </item>
                           <item>
                              <caption>•</caption>
                              <content styleCode="bold">Estrogen-alone therapy should not be used for the prevention of cardiovascular disease or dementia (<linkHtml href="#S5.1">5.1</linkHtml>, <linkHtml href="#S5.3">5.3</linkHtml>)</content>
                           </item>
                           <item>
                              <caption>•</caption>
                              <content styleCode="bold">The WHI estrogen-alone substudy reported increased risks of stroke and DVT (<linkHtml href="#S5.1">5.1</linkHtml>)</content>
                           </item>
                           <item>
                              <caption>•</caption>
                              <content styleCode="bold">The WHIMS estrogen-alone ancillary study of WHI reported an increased risk of probable dementia in postmenopausal women 65 years of age and older (<linkHtml href="#S5.3">5.3</linkHtml>)</content>
                           </item>
                        </list>
                     </text>
                  </highlight>
               </excerpt>
            </section>
         </component>
         <component>
            <section ID="S1">
               <id root="ad46ff21-c676-4f49-8933-c4a8a7efc90b"/>
               <code code="34067-9" codeSystem="2.16.840.1.113883.6.1" displayName="INDICATIONS &amp; USAGE SECTION"/>
               <title>1 INDICATIONS AND USAGE</title>
               <text>
                  <paragraph>   </paragraph>
               </text>
               <effectiveTime value="20240215"/>
               <excerpt>
                  <highlight>
                     <text>
                        <paragraph>PREMPRO/PREMPHASE is an estrogen plus progestin indicated in a woman with a uterus for:</paragraph>
                        <list listType="unordered">
                           <item>
                              <caption>•</caption>Treatment of Moderate to Severe Vasomotor Symptoms due to Menopause (<linkHtml href="#S1.1">1.1</linkHtml>)</item>
                           <item>
                              <caption>•</caption>Treatment of Moderate to Severe Vulvar and Vaginal Atrophy due to Menopause (<linkHtml href="#S1.2">1.2</linkHtml>)</item>
                           <item>
                              <caption>•</caption>Prevention of Postmenopausal Osteoporosis (<linkHtml href="#S1.3">1.3</linkHtml>)</item>
                        </list>
                     </text>
                  </highlight>
               </excerpt>
               <component>
                  <section ID="S1.1">
                     <id root="54fd3f96-4081-4927-a773-ca3bbc04b07d"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title>1.1 Treatment of Moderate to Severe Vasomotor Symptoms due to Menopause</title>
                     <text>
                        <paragraph>   </paragraph>
                     </text>
                     <effectiveTime value="20240215"/>
                  </section>
               </component>
               <component>
                  <section ID="S1.2">
                     <id root="537b28c0-91cb-4378-9e27-30140e17061e"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title>1.2 Treatment of Moderate to Severe Vulvar and Vaginal Atrophy due to Menopause</title>
                     <text>
                        <paragraph>   </paragraph>
                     </text>
                     <effectiveTime value="20240215"/>
                  </section>
               </component>
               <component>
                  <section ID="S1.3">
                     <id root="db14eeae-d39d-46c2-a8bb-07325871fe95"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title>1.3 Prevention of Postmenopausal Osteoporosis</title>
                     <text>
                        <paragraph>   </paragraph>
                     </text>
                     <effectiveTime value="20240215"/>
                  </section>
               </component>
            </section>
         </component>
         <component>
            <section ID="S2">
               <id root="a8b0625f-9ace-4e18-abe7-b1aae28cd159"/>
               <code code="34068-7" codeSystem="2.16.840.1.113883.6.1" displayName="DOSAGE &amp; ADMINISTRATION SECTION"/>
               <title>2 DOSAGE AND ADMINISTRATION</title>
               <text>
                  <paragraph>Use of estrogen-alone, or in combination with a progestin, should be with the lowest effective dose and for the shortest duration consistent with treatment goals and risks for the individual woman. Postmenopausal women should be re-evaluated periodically as clinically appropriate to determine if treatment is still necessary.</paragraph>
               </text>
               <effectiveTime value="20190531"/>
               <excerpt>
                  <highlight>
                     <text>
                        <paragraph>PREMPRO: one tablet containing conjugated estrogens (CE) plus medroxyprogesterone acetate (MPA) taken orally once daily. (<linkHtml href="#S2">2</linkHtml>)<br/>
                           <br/>PREMPHASE: one maroon tablet containing 0.625 mg CE taken orally on days 1 through 14, and one light-blue tablet containing 0.625 mg CE plus 5.0 mg MPA taken orally on days 15 through 28. (<linkHtml href="#S2">2</linkHtml>)</paragraph>
                     </text>
                  </highlight>
               </excerpt>
               <component>
                  <section ID="S2.1">
                     <id root="83674869-809e-48d7-9caa-7793c77bc6e4"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title>2.1 Treatment of Moderate to Severe Vasomotor Symptoms due to Menopause</title>
                     <text>
                        <paragraph>PREMPRO therapy consists of a single tablet to be taken orally once daily.</paragraph>
                        <paragraph>PREMPHASE therapy consists of two separate tablets: one maroon 0.625 mg Premarin [conjugated estrogens (CE)] tablet taken daily on days 1 through 14 and one light-blue tablet containing 0.625 mg CE and 5 mg of medroxyprogesterone acetate (MPA) taken on days 15 through 28.</paragraph>
                     </text>
                     <effectiveTime value="20190531"/>
                  </section>
               </component>
               <component>
                  <section ID="S2.2">
                     <id root="8248d303-c500-4106-96c2-951580015428"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title>2.2 Treatment of Moderate to Severe Vulvar and Vaginal Atrophy due to Menopause</title>
                     <text>
                        <paragraph>PREMPRO therapy consists of a single tablet to be taken orally once daily.</paragraph>
                        <paragraph>PREMPHASE therapy consists of two separate tablets: one maroon 0.625 mg CE tablet taken daily on days 1 through 14 and one light-blue tablet containing 0.625 mg CE and 5 mg MPA taken on days 15 through 28.</paragraph>
                        <paragraph>When prescribing solely for the treatment of moderate to severe vulvar and vaginal atrophy, topical vaginal products should be considered.</paragraph>
                     </text>
                     <effectiveTime value="20190531"/>
                  </section>
               </component>
               <component>
                  <section ID="S2.3">
                     <id root="08337650-17b5-45f9-803a-1bbd5982e292"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title>2.3 Prevention of Postmenopausal Osteoporosis</title>
                     <text>
                        <paragraph>PREMPRO therapy consists of a single tablet to be taken orally once daily.</paragraph>
                        <paragraph>PREMPHASE therapy consists of two separate tablets: one maroon 0.625 mg CE tablet taken daily on days 1 through 14 and one light-blue tablet containing 0.625 mg CE and 5 mg of MPA taken on days 15 through 28.</paragraph>
                        <paragraph>When prescribing solely for the prevention of postmenopausal osteoporosis, therapy should only be considered for women at significant risk of osteoporosis and non-estrogen medications should be carefully considered.</paragraph>
                     </text>
                     <effectiveTime value="20190531"/>
                  </section>
               </component>
            </section>
         </component>
         <component>
            <section ID="S3">
               <id root="850f4661-8f9e-4a54-8bb0-9e8be1314b69"/>
               <code code="43678-2" codeSystem="2.16.840.1.113883.6.1" displayName="DOSAGE FORMS &amp; STRENGTHS SECTION"/>
               <title>3 DOSAGE FORMS AND STRENGTHS</title>
               <text>
                  <table width="100%">
                     <col width="40%"/>
                     <col width="40%"/>
                     <col width="20%"/>
                     <tbody>
                        <tr>
                           <td align="center" colspan="3" styleCode="Rrule Botrule Lrule Toprule " valign="top">
                              <paragraph>PREMPRO (conjugated estrogens/medroxyprogesterone acetate tablets)</paragraph>
                           </td>
                        </tr>
                        <tr>
                           <td align="center" styleCode="Rrule Lrule Toprule Botrule " valign="top">
                              <paragraph>Tablet Strength</paragraph>
                           </td>
                           <td align="center" styleCode="Rrule Toprule Botrule " valign="top">
                              <paragraph>Tablet Shape/Color</paragraph>
                           </td>
                           <td align="center" styleCode="Rrule Toprule Botrule " valign="top">
                              <paragraph>Imprint</paragraph>
                           </td>
                        </tr>
                        <tr>
                           <td align="center" styleCode="Rrule Lrule Botrule " valign="top">
                              <paragraph>0.3 mg CE plus 1.5 mg MPA</paragraph>
                           </td>
                           <td align="center" styleCode="Rrule Botrule " valign="top">
                              <paragraph>oval/cream</paragraph>
                           </td>
                           <td align="center" styleCode="Rrule Botrule " valign="top">
                              <paragraph>PREMPRO<br/>0.3/1.5 </paragraph>
                           </td>
                        </tr>
                        <tr>
                           <td align="center" styleCode="Rrule Lrule Botrule " valign="top">
                              <paragraph>0.45 mg CE plus 1.5 mg MPA</paragraph>
                           </td>
                           <td align="center" styleCode="Rrule Botrule " valign="top">
                              <paragraph>oval/gold</paragraph>
                           </td>
                           <td align="center" styleCode="Rrule Botrule " valign="top">
                              <paragraph>PREMPRO<br/>0.45/1.5 </paragraph>
                           </td>
                        </tr>
                        <tr>
                           <td align="center" styleCode="Rrule Lrule Botrule " valign="top">
                              <paragraph>0.625 mg CE plus 2.5 mg MPA</paragraph>
                           </td>
                           <td align="center" styleCode="Rrule Botrule " valign="top">
                              <paragraph>oval/peach</paragraph>
                           </td>
                           <td align="center" styleCode="Rrule Botrule " valign="top">
                              <paragraph>PREMPRO<br/>0.625/2.5</paragraph>
                           </td>
                        </tr>
                        <tr>
                           <td align="center" styleCode="Rrule Lrule Botrule " valign="top">
                              <paragraph>0.625 mg CE plus 5 mg MPA</paragraph>
                           </td>
                           <td align="center" styleCode="Rrule Botrule " valign="top">
                              <paragraph>oval/light blue</paragraph>
                           </td>
                           <td align="center" styleCode="Rrule Botrule " valign="top">
                              <paragraph>PREMPRO<br/>0.625/5</paragraph>
                           </td>
                        </tr>
                        <tr>
                           <td align="center" colspan="3" styleCode="Rrule Lrule Botrule " valign="top">
                              <paragraph>PREMPHASE (conjugated estrogens/medroxyprogesterone acetate tablets)</paragraph>
                           </td>
                        </tr>
                        <tr>
                           <td align="center" styleCode="Rrule Lrule Botrule " valign="top">
                              <paragraph>Tablet Strength</paragraph>
                           </td>
                           <td align="center" styleCode="Rrule Botrule " valign="top">
                              <paragraph>Tablet Shape/Color</paragraph>
                           </td>
                           <td align="center" styleCode="Rrule Botrule " valign="top">
                              <paragraph>Imprint</paragraph>
                           </td>
                        </tr>
                        <tr>
                           <td align="center" styleCode="Rrule Lrule Botrule " valign="top">
                              <paragraph>0.625 mg CE</paragraph>
                           </td>
                           <td align="center" styleCode="Rrule Botrule " valign="top">
                              <paragraph>oval/maroon (14 tablets)</paragraph>
                           </td>
                           <td align="center" styleCode="Rrule Botrule " valign="top">
                              <paragraph>PREMARIN<br/>0.625</paragraph>
                           </td>
                        </tr>
                        <tr>
                           <td align="center" styleCode="Rrule Botrule Lrule " valign="top">
                              <paragraph>0.625 mg CE plus 5 mg MPA</paragraph>
                           </td>
                           <td align="center" styleCode="Rrule Botrule " valign="top">
                              <paragraph>oval/light-blue (14 tablets)</paragraph>
                           </td>
                           <td align="center" styleCode="Rrule Botrule " valign="top">
                              <paragraph>PREMPRO<br/>0.625/5 </paragraph>
                           </td>
                        </tr>
                     </tbody>
                  </table>
               </text>
               <effectiveTime value="20250429"/>
               <excerpt>
                  <highlight>
                     <text>
                        <paragraph>PREMPRO Tablets: 0.3 mg CE plus 1.5 mg MPA, 0.45 mg CE plus 1.5 mg MPA, 0.625 mg CE plus 2.5 mg MPA, 0.625 mg CE plus 5 mg MPA.<br/>
                           <br/>PREMPHASE Tablets: 0.625 mg CE, 0.625 mg CE plus 5 mg MPA.</paragraph>
                     </text>
                  </highlight>
               </excerpt>
            </section>
         </component>
         <component>
            <section ID="S4">
               <id root="257c4714-5b55-4f60-8299-83d50c810cd6"/>
               <code code="34070-3" codeSystem="2.16.840.1.113883.6.1" displayName="CONTRAINDICATIONS SECTION"/>
               <title>4 CONTRAINDICATIONS</title>
               <text>
                  <paragraph>PREMPRO and PREMPHASE are contraindicated in women with any of the following conditions:</paragraph>
                  <list listType="unordered">
                     <item>
                        <caption>•</caption>Undiagnosed abnormal genital bleeding <content styleCode="italics">[see <linkHtml href="#S5.2">Warnings and Precautions (5.2)</linkHtml>]</content>
                     </item>
                     <item>
                        <caption>•</caption>Breast cancer or a history of breast cancer <content styleCode="italics">[see <linkHtml href="#S5.2">Warnings and Precautions (5.2)</linkHtml>]</content>
                     </item>
                     <item>
                        <caption>•</caption>Estrogen-dependent neoplasia <content styleCode="italics">[see <linkHtml href="#S5.2">Warnings and Precautions (5.2)</linkHtml>]</content>
                     </item>
                     <item>
                        <caption>•</caption>Active DVT, PE, or a history of these conditions <content styleCode="italics">[see <linkHtml href="#S5.1">Warnings and Precautions (5.1)</linkHtml>]</content>
                     </item>
                     <item>
                        <caption>•</caption>Active arterial thromboembolic disease (for example, stroke and MI), or a history of these conditions <content styleCode="italics">[see <linkHtml href="#S5.1">Warnings and Precautions (5.1)</linkHtml>]</content>
                     </item>
                     <item>
                        <caption>•</caption>Known anaphylactic reaction or angioedema with PREMPRO/PREMPHASE <content styleCode="italics">[see <linkHtml href="#S5.15">Warnings and Precautions (5.15</linkHtml>, <linkHtml href="#S5.16">5.16</linkHtml>)]</content>
                     </item>
                     <item>
                        <caption>•</caption>Hepatic impairment or disease <content styleCode="italics">[see <linkHtml href="#S5.10">Warnings and Precautions (5.10)</linkHtml>]</content>
                     </item>
                     <item>
                        <caption>•</caption>Protein C, protein S, or antithrombin deficiency, or other known thrombophilic disorders </item>
                  </list>
               </text>
               <effectiveTime value="20250429"/>
               <excerpt>
                  <highlight>
                     <text>
                        <list listType="unordered">
                           <item>
                              <caption>•</caption>Undiagnosed abnormal genital bleeding (<linkHtml href="#S4">4</linkHtml>)</item>
                           <item>
                              <caption>•</caption>Breast cancer or history of breast cancer (<linkHtml href="#S4">4</linkHtml>, <linkHtml href="#S5.2">5.2</linkHtml>)</item>
                           <item>
                              <caption>•</caption>Estrogen-dependent neoplasia (<linkHtml href="#S4">4</linkHtml>, <linkHtml href="#S5.2">5.2</linkHtml>)</item>
                           <item>
                              <caption>•</caption>Active DVT, PE, or a history of these conditions (<linkHtml href="#S4">4</linkHtml>, <linkHtml href="#S5.1">5.1</linkHtml>)</item>
                           <item>
                              <caption>•</caption>Active arterial thromboembolic disease (for example, stroke and MI), or a history of these conditions (<linkHtml href="#S4">4</linkHtml>, <linkHtml href="#S5.1">5.1</linkHtml>)</item>
                           <item>
                              <caption>•</caption>Known anaphylactic reaction or angioedema to PREMPRO/PREMPHASE (<linkHtml href="#S5.15">5.15</linkHtml>, <linkHtml href="#S5.16">5.16</linkHtml>)</item>
                           <item>
                              <caption>•</caption>Hepatic impairment or disease (<linkHtml href="#S4">4</linkHtml>, <linkHtml href="#S5.10">5.10</linkHtml>)</item>
                           <item>
                              <caption>•</caption>Protein C, protein S, or antithrombin deficiency, or other known thrombophilic disorders (<linkHtml href="#S4">4</linkHtml>)</item>
                        </list>
                     </text>
                  </highlight>
               </excerpt>
            </section>
         </component>
         <component>
            <section ID="S5">
               <id root="de0fcb3b-051d-4115-9fd8-7836ff6dc2d3"/>
               <code code="43685-7" codeSystem="2.16.840.1.113883.6.1" displayName="WARNINGS AND PRECAUTIONS SECTION"/>
               <title>5 WARNINGS AND PRECAUTIONS</title>
               <effectiveTime value="20250429"/>
               <excerpt>
                  <highlight>
                     <text>
                        <list listType="unordered">
                           <item>
                              <caption>•</caption>Estrogens increase the risk of gallbladder disease (<linkHtml href="#S5.4">5.4</linkHtml>)</item>
                           <item>
                              <caption>•</caption>Discontinue estrogen if severe hypercalcemia, loss of vision, severe hypertriglyceridemia or cholestatic jaundice occurs (<linkHtml href="#S5.5">5.5</linkHtml>, <linkHtml href="#S5.6">5.6</linkHtml>, <linkHtml href="#S5.9">5.9</linkHtml>, <linkHtml href="#S5.10">5.10</linkHtml>)</item>
                           <item>
                              <caption>•</caption>Monitor thyroid function in women on thyroid replacement therapy (<linkHtml href="#S5.11">5.11</linkHtml>, <linkHtml href="#S5.19">5.19</linkHtml>)</item>
                        </list>
                     </text>
                  </highlight>
               </excerpt>
               <component>
                  <section ID="S5.1">
                     <id root="df91a11b-4894-4171-9ea1-329850aa0926"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title>5.1 Cardiovascular Disorders</title>
                     <text>
                        <paragraph>An increased risk of PE, DVT, stroke and MI has been reported with estrogen plus progestin therapy. An increased risk of stroke and DVT has been reported with estrogen-alone therapy. Should any of these occur or be suspected, estrogen with or without progestin therapy should be discontinued immediately.</paragraph>
                        <paragraph>Risk factors for arterial vascular disease (for example, hypertension, diabetes mellitus, tobacco use, hypercholesterolemia, and obesity) and/or venous thromboembolism (VTE) (for example, personal history or family history of VTE, obesity, and systemic lupus erythematosus) should be managed appropriately.</paragraph>
                     </text>
                     <effectiveTime value="20250429"/>
                     <component>
                        <section ID="stroke">
                           <id root="27f5e611-ca96-4288-8dfb-6516bea9a3e5"/>
                           <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                           <text>
                              <paragraph>
                                 <content styleCode="italics">Stroke</content>
                              </paragraph>
                              <paragraph>In the WHI estrogen plus progestin substudy, a statistically significant increased risk of stroke was reported in women 50 to 79 years of age receiving daily CE (0.625 mg) plus MPA (2.5 mg) compared to women in the same age group receiving placebo (33 versus 25 per 10,000 women-years) <content styleCode="italics">[see <linkHtml href="#S14.6">Clinical Studies (14.6)</linkHtml>]</content>. The increase in risk was demonstrated after the first year and persisted.<sup>1</sup> Should a stroke occur or be suspected, estrogen plus progestin therapy should be discontinued immediately.</paragraph>
                              <paragraph>In the WHI estrogen-alone substudy, a statistically significant increased risk of stroke was reported in women 50 to 79 years of age receiving daily CE (0.625 mg)-alone compared to women in the same age group receiving placebo (45 versus 33 per 10,000 women-years). The increase in risk was demonstrated in Year 1 and persisted <content styleCode="italics">[see <linkHtml href="#S14.6">Clinical Studies (14.6)</linkHtml>]</content>. Should a stroke occur or be suspected, estrogen-alone therapy should be discontinued immediately.</paragraph>
                              <paragraph>Subgroup analyses of women 50 to 59 years of age suggest no increased risk of stroke for those women receiving CE (0.625 mg)-alone versus those receiving placebo (18 versus 21 per 10,000 women-years).<sup>1</sup>
                              </paragraph>
                           </text>
                           <effectiveTime value="20250429"/>
                        </section>
                     </component>
                     <component>
                        <section ID="G784cbfae-86ad-4b8d-8bb9-3e44b7f2512d">
                           <id root="92791c52-5bae-42a7-834d-b0aa00b8e2fb"/>
                           <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                           <text>
                              <paragraph>
                                 <content styleCode="italics">Coronary Heart Disease</content>
                              </paragraph>
                              <paragraph>In the WHI estrogen plus progestin substudy, there was a statistically non-significant increased risk of coronary heart disease (CHD) events (defined as nonfatal MI, silent MI, or CHD death) reported in women receiving daily CE (0.625 mg) plus MPA (2.5 mg) compared to women receiving placebo (41 versus 34 per 10,000 women-years).<sup>1</sup> An increase in relative risk was demonstrated in year 1, and a trend toward decreasing relative risk was reported in years 2 through 5 <content styleCode="italics">[see <linkHtml href="#S14.6">Clinical Studies (14.6)</linkHtml>]</content>.</paragraph>
                              <paragraph>In the WHI estrogen-alone substudy, no overall effect on CHD events was reported in women receiving estrogen-alone compared to placebo<sup>2</sup>
                                 <content styleCode="italics"> [see <linkHtml href="#S14.6">Clinical Studies (14.6)</linkHtml>]</content>.</paragraph>
                              <paragraph>Subgroup analyses of women 50 to 59 years of age suggest a statistically non-significant reduction in CHD events (CE [0.625 mg]-alone compared to placebo) in women with less than 10 years since menopause (8 versus 16 per 10,000 women-years).<sup>1</sup>
                              </paragraph>
                              <paragraph>In postmenopausal women with documented heart disease (n = 2,763), average 66.7 years of age, in a controlled clinical trial of secondary prevention of cardiovascular disease (Heart and Estrogen/Progestin Replacement Study [HERS]), treatment with daily CE (0.625 mg) plus MPA (2.5 mg) demonstrated no cardiovascular benefit. During an average follow-up of 4.1 years, treatment with CE plus MPA did not reduce the overall rate of CHD events in postmenopausal women with established coronary heart disease. There were more CHD events in the CE plus MPA-treated group than in the placebo group in Year 1, but not during subsequent years. Two thousand, three hundred and twenty-one (2,321) women from the original HERS trial agreed to participate in an open label extension of HERS, HERS II. Average follow-up in HERS II was an additional 2.7 years, for a total of 6.8 years overall. Rates of CHD events were comparable among women in the CE plus MPA group and the placebo group in HERS, HERS II, and overall.</paragraph>
                           </text>
                           <effectiveTime value="20250429"/>
                        </section>
                     </component>
                     <component>
                        <section ID="venous">
                           <id root="4e0e3337-53e7-4299-9804-19f5e223b434"/>
                           <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                           <text>
                              <paragraph>
                                 <content styleCode="italics">Venous Thromboembolism (VTE)</content>
                              </paragraph>
                              <paragraph>In the WHI estrogen plus progestin substudy, a statistically significant 2-fold greater rate of VTE (DVT and PE) was reported in women receiving daily CE (0.625 mg) plus MPA (2.5 mg) compared to women receiving placebo (35 versus 17 per 10,000 women-years). Statistically significant increases in risk for both DVT (26 versus 13 per 10,000 women-years) and PE (18 versus 8 per 10,000 women-years) were also demonstrated. The increase in VTE risk was demonstrated during the first year and persisted<sup>3</sup>
                                 <content styleCode="italics"> [see <linkHtml href="#S14.6">Clinical Studies (14.6)</linkHtml>]</content>. Should a VTE occur or be suspected, estrogen plus progestin therapy should be discontinued immediately.</paragraph>
                              <paragraph>In the WHI estrogen-alone substudy, the risk of VTE was increased for women receiving daily CE (0.625 mg)-alone compared to placebo (30 versus 22 per 10,000 women-years), although only the increased risk of DVT reached statistical significance (23 versus 15 per 10,000 women-years). The increase in VTE risk was demonstrated during the first 2 years<sup>4</sup>
                                 <content styleCode="italics"> [see <linkHtml href="#S14.6">Clinical Studies (14.6)</linkHtml>]</content>. Should a VTE occur or be suspected, estrogen-alone therapy should be discontinued immediately.</paragraph>
                              <paragraph>If feasible, estrogens should be discontinued at least 4 to 6 weeks before surgery of the type associated with an increased risk of thromboembolism, or during periods of prolonged immobilization.</paragraph>
                           </text>
                           <effectiveTime value="20250429"/>
                        </section>
                     </component>
                  </section>
               </component>
               <component>
                  <section ID="S5.2">
                     <id root="f8034974-c727-4d9b-8363-a4e3bac7dd42"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title>5.2 Malignant Neoplasms</title>
                     <effectiveTime value="20250429"/>
                     <component>
                        <section ID="G05bbef7d-47f2-461c-9b6b-3808b59b9658">
                           <id root="2f225569-ca0d-4038-82bc-c436f5164c1e"/>
                           <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                           <text>
                              <paragraph>
                                 <content styleCode="bold">
                                    <content styleCode="italics">Breast Cancer</content>
                                 </content>
                              </paragraph>
                              <paragraph>The WHI substudy of daily CE (0.625 mg)-alone provided information about breast cancer in estrogen-alone users. In the WHI estrogen-alone substudy, after an average follow-up of 7.1 years, daily CE (0.625 mg)-alone was not associated with an increased risk of invasive breast cancer [relative risk (RR) 0.80]<sup>5</sup>
                                 <content styleCode="italics">[see <linkHtml href="#S14.6">Clinical Studies (14.6)]</linkHtml>
                                 </content>.</paragraph>
                              <paragraph>After a mean follow-up of 5.6 years, the estrogen plus progestin substudy reported an increased risk of invasive breast cancer in women who took daily CE plus MPA. In this substudy, prior use of estrogen-alone or estrogen plus progestin therapy was reported by 26% of the women. The relative risk of invasive breast cancer was 1.24, and the absolute risk was 41 versus 33 cases per 10,000 women-years, for CE plus MPA compared with placebo. Among women who reported prior use of hormone therapy, the relative risk of invasive breast cancer was 1.86, and the absolute risk was 46 versus 25 cases per 10,000 women-years, for CE plus MPA compared with placebo. Among women who reported no prior use of hormone therapy, the relative risk of invasive breast cancer was 1.09, and the absolute risk was 40 versus 36 cases per 10,000 women-years, for CE plus MPA compared with placebo. In the same substudy, invasive breast cancers were larger, were more likely to be node positive, and were diagnosed at a more advanced stage in the CE (0.625 mg) plus MPA (2.5 mg) group compared with the placebo group. Metastatic disease was rare, with no apparent difference between the two groups. Other prognostic factors, such as histologic subtype, grade and hormone receptor status did not differ between the groups<sup>6</sup>
                                 <content styleCode="italics"> [see <linkHtml href="#S14.6">Clinical Studies (14.6)</linkHtml>]</content>.</paragraph>
                              <paragraph>Consistent with the WHI clinical trials, observational studies have also reported an increased risk of breast cancer for estrogen plus progestin therapy and a smaller increased risk for estrogen-alone therapy, after several years of use. One large meta-analysis of prospective cohort studies reported increased risks that were dependent upon duration of use and could last up to &gt; 10 years after discontinuation of estrogen plus progestin therapy and estrogen-alone therapy. Extension of the WHI trials also demonstrated increased breast cancer risk associated with estrogen plus progestin therapy. Observational studies also suggest that the risk of breast cancer was greater, and became apparent earlier, with estrogen plus progestin therapy as compared to the risk with estrogen-alone therapy. However, these studies have not found significant variation in the risk of breast cancer among different estrogen plus progestin combinations, doses, or routes of administration.</paragraph>
                              <paragraph>The use of estrogen-alone and estrogen plus progestin has been reported to result in an increase in abnormal mammograms requiring further evaluation.</paragraph>
                              <paragraph>All women should receive yearly breast examinations by a healthcare provider and perform monthly breast self-examinations. In addition, mammography examinations should be scheduled based on patient age, risk factors, and prior mammogram results.</paragraph>
                           </text>
                           <effectiveTime value="20250429"/>
                        </section>
                     </component>
                     <component>
                        <section ID="G286c9e5d-af66-48d5-bb84-502d2bd64f45">
                           <id root="fe0bc85a-e8bb-41b6-9675-6e7b31222926"/>
                           <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                           <text>
                              <paragraph>
                                 <content styleCode="bold">
                                    <content styleCode="italics">Endometrial Cancer</content>
                                 </content>
                              </paragraph>
                              <paragraph>Endometrial hyperplasia (a possible precursor of endometrial cancer) has been reported to occur at a rate of approximately 1% or less with PREMPRO or PREMPHASE.</paragraph>
                              <paragraph>An increased risk of endometrial cancer has been reported with the use of unopposed estrogen therapy in a woman with a uterus. The reported endometrial cancer risk among unopposed estrogen users is about 2 to 12 times greater than in non-users, and appears dependent on duration of treatment and on estrogen dose. Most studies show no significant increased risk associated with use of estrogens for less than 1 year. The greatest risk appears to be associated with prolonged use, with increased risks of 15- to 24-fold for 5 to 10 years or more, and this risk has been shown to persist for at least 8 to 15 years after estrogen therapy is discontinued.</paragraph>
                              <paragraph>Clinical surveillance of all women using estrogen-alone or estrogen plus progestin therapy is important. Adequate diagnostic measures, including directed or random endometrial sampling when indicated, should be undertaken to rule out malignancy in postmenopausal women with undiagnosed persistent or recurring abnormal genital bleeding.</paragraph>
                              <paragraph>There is no evidence that the use of natural estrogens results in a different endometrial risk profile than synthetic estrogens of equivalent estrogen dose. Adding a progestin to estrogen therapy in postmenopausal women has been shown to reduce the risk of endometrial hyperplasia, which may be a precursor to endometrial cancer.</paragraph>
                           </text>
                           <effectiveTime value="20250429"/>
                        </section>
                     </component>
                     <component>
                        <section ID="Ga7b94c4f-051d-489d-8e34-d37d91ac076a">
                           <id root="16681ca7-b015-4abc-b5c7-e97b9dbdfa90"/>
                           <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                           <text>
                              <paragraph>
                                 <content styleCode="bold">
                                    <content styleCode="italics">Ovarian Cancer</content>
                                 </content>
                              </paragraph>
                              <paragraph>The WHI estrogen plus progestin substudy reported a statistically non-significant increased risk of ovarian cancer. After an average follow-up of 5.6 years, the relative risk for ovarian cancer for CE plus MPA versus placebo was 1.58 (95% confidence interval (CI), 0.77–3.24). The absolute risk for CE plus MPA versus placebo was 4 versus 3 cases per 10,000 women-years.<sup>7</sup>
                              </paragraph>
                              <paragraph>A meta-analysis of 17 prospective and 35 retrospective epidemiology studies found that women who used hormonal therapy for menopausal symptoms had an increased risk for ovarian cancer. The primary analysis, using case-control comparisons, included 12,110 cancer cases from the 17 prospective studies. The relative risks associated with current use of hormonal therapy was 1.41 (95% CI 1.32 to 1.50); there was no difference in the risk estimates by duration of the exposure (less than 5 years [median of 3 years] vs. greater than 5 years [median of 10 years] of use before the cancer diagnosis). The relative risk associated with combined current and recent use (discontinued use within 5 years before cancer diagnosis) was 1.37 (95% CI 1.27–1.48), and the elevated risk was significant for both estrogen-alone and estrogen plus progestin products. The exact duration of hormone therapy use associated with an increased risk of ovarian cancer, however, is unknown.</paragraph>
                           </text>
                           <effectiveTime value="20250429"/>
                        </section>
                     </component>
                  </section>
               </component>
               <component>
                  <section ID="S5.3">
                     <id root="d8cf25a4-70b1-4cf6-a84d-1923939c7e51"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title>5.3 Probable Dementia</title>
                     <text>
                        <paragraph>In the WHIMS estrogen plus progestin ancillary study of WHI, a population of 4,532 postmenopausal women 65 to 79 years of age was randomized to daily CE (0.625 mg) plus MPA (2.5 mg) or placebo.</paragraph>
                        <paragraph>After an average follow-up of 4 years, 40 women in the CE plus MPA group and 21 women in the placebo group were diagnosed with probable dementia. The relative risk of probable dementia for CE plus MPA versus placebo was 2.05 (95% CI, 1.21–3.48). The absolute risk of probable dementia for CE plus MPA versus placebo was 45 versus 22 cases per 10,000 women-years<sup>8 </sup>
                           <content styleCode="italics">[see <linkHtml href="#S8.5">Use in Specific Populations (8.5)</linkHtml>, and <linkHtml href="#S14.7">Clinical Studies (14.7)</linkHtml>]</content>.</paragraph>
                        <paragraph>In the WHIMS estrogen-alone ancillary study of WHI, a population of 2,947 hysterectomized women 65 to 79 years of age was randomized to daily CE (0.625 mg)-alone or placebo. After an average follow-up of 5.2 years, 28 women in the estrogen-alone group and 19 women in the placebo group were diagnosed with probable dementia. The relative risk of probable dementia for CE-alone versus placebo was 1.49 (95% CI, 0.83–2.66). The absolute risk of probable dementia for CE-alone versus placebo was 37 versus 25 cases per 10,000 women-years<sup>8 </sup>
                           <content styleCode="italics">[see <linkHtml href="#S8.5">Use in Specific Populations (8.5)</linkHtml>, and <linkHtml href="#S14.7">Clinical Studies (14.7)</linkHtml>]</content>.</paragraph>
                        <paragraph>When data from the two populations in the WHIMS estrogen-alone and estrogen plus progestin ancillary studies were pooled as planned in the WHIMS protocol, the reported overall relative risk for probable dementia was 1.76 (95% CI, 1.19–2.60). Since both substudies were conducted in women 65 to 79 years of age, it is unknown whether these findings apply to younger postmenopausal women<sup>8 </sup>
                           <content styleCode="italics">[see <linkHtml href="#S8.5">Use in Specific Populations (8.5)</linkHtml>, and <linkHtml href="#S14.7">Clinical Studies (14.7)</linkHtml>]</content>.</paragraph>
                     </text>
                     <effectiveTime value="20250429"/>
                  </section>
               </component>
               <component>
                  <section ID="S5.4">
                     <id root="24eca889-89d3-477d-89c4-ef532036c86a"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title>5.4 Gallbladder Disease</title>
                     <text>
                        <paragraph>A 2- to 4-fold increase in the risk of gallbladder disease requiring surgery in postmenopausal women receiving estrogens has been reported.</paragraph>
                     </text>
                     <effectiveTime value="20190531"/>
                  </section>
               </component>
               <component>
                  <section ID="S5.5">
                     <id root="157761c7-22f7-4657-9276-7598072c0b48"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title>5.5 Hypercalcemia</title>
                     <text>
                        <paragraph>Estrogen administration may lead to severe hypercalcemia in women with breast cancer and bone metastases. If hypercalcemia occurs, use of the drug should be stopped and appropriate measures taken to reduce the serum calcium level.</paragraph>
                     </text>
                     <effectiveTime value="20190531"/>
                  </section>
               </component>
               <component>
                  <section ID="S5.6">
                     <id root="ab10a344-c1a9-4e0e-8cee-b9ce163f4c47"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title>5.6 Visual Abnormalities</title>
                     <text>
                        <paragraph>Retinal vascular thrombosis has been reported in women receiving estrogens. Discontinue medication pending examination if there is sudden partial or complete loss of vision, or a sudden onset of proptosis, diplopia, or migraine. If examination reveals papilledema or retinal vascular lesions, estrogens should be permanently discontinued.</paragraph>
                     </text>
                     <effectiveTime value="20190531"/>
                  </section>
               </component>
               <component>
                  <section ID="S5.7">
                     <id root="f7bad74a-548e-4e45-917d-78771fa0e0f1"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title>5.7 Addition of a Progestin When a Woman Has Not Had a Hysterectomy</title>
                     <text>
                        <paragraph>Studies of the addition of a progestin for 10 or more days of a cycle of estrogen administration or daily with estrogen in a continuous regimen, have reported a lowered incidence of endometrial hyperplasia than would be induced by estrogen treatment alone. Endometrial hyperplasia may be a precursor to endometrial cancer.</paragraph>
                        <paragraph>There are, however, possible risks that may be associated with the use of progestins with estrogens compared to estrogen-alone regimens. These include an increased risk of breast cancer.</paragraph>
                     </text>
                     <effectiveTime value="20190531"/>
                  </section>
               </component>
               <component>
                  <section ID="S5.8">
                     <id root="1a0867e7-d4fb-4a54-9e84-cb1985f97825"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title>5.8 Elevated Blood Pressure</title>
                     <text>
                        <paragraph>In a small number of case reports, substantial increases in blood pressure have been attributed to idiosyncratic reactions to estrogens. In a large, randomized, placebo-controlled clinical trial, a generalized effect of estrogen therapy on blood pressure was not seen.</paragraph>
                     </text>
                     <effectiveTime value="20190531"/>
                  </section>
               </component>
               <component>
                  <section ID="S5.9">
                     <id root="821f9570-c7e9-4e97-b7c2-3a653e324978"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title>5.9 Exacerbation of Hypertriglyceridemia</title>
                     <text>
                        <paragraph>In women with pre-existing hypertriglyceridemia, estrogen therapy may be associated with elevations of plasma triglycerides leading to pancreatitis. Consider discontinuation of treatment if pancreatitis occurs.</paragraph>
                     </text>
                     <effectiveTime value="20250429"/>
                  </section>
               </component>
               <component>
                  <section ID="S5.10">
                     <id root="b5803c70-0102-4ffb-a617-cf046f372884"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title>5.10 Hepatic Impairment and/or Past History of Cholestatic Jaundice</title>
                     <text>
                        <paragraph>Estrogens may be poorly metabolized in women with impaired liver function. For women with a history of cholestatic jaundice associated with past estrogen use or with pregnancy, caution should be exercised, and in the case of recurrence, medication should be discontinued.</paragraph>
                     </text>
                     <effectiveTime value="20190531"/>
                  </section>
               </component>
               <component>
                  <section ID="S5.11">
                     <id root="81d05794-fd51-4e61-a4c7-96d71402f4e7"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title>5.11 Exacerbation of Hypothyroidism</title>
                     <text>
                        <paragraph>Estrogen administration leads to increased thyroid-binding globulin (TBG) levels. Women with normal thyroid function can compensate for the increased TBG by making more thyroid hormone, thus maintaining free T<sub>4</sub> and T<sub>3</sub> serum concentrations in the normal range. Women dependent on thyroid hormone replacement therapy who are also receiving estrogens may require increased doses of their thyroid replacement therapy. These women should have their thyroid function monitored in order to maintain their free thyroid hormone levels in an acceptable range.</paragraph>
                     </text>
                     <effectiveTime value="20250429"/>
                  </section>
               </component>
               <component>
                  <section ID="S5.12">
                     <id root="f264b709-e0b5-4a0a-8265-95b1bd5dac4b"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title>5.12 Fluid Retention</title>
                     <text>
                        <paragraph>Estrogens plus progestins may cause some degree of fluid retention. Women with conditions that might be influenced by this factor, such as a cardiac or renal dysfunction, warrant careful observation when estrogens plus progestins are prescribed.</paragraph>
                     </text>
                     <effectiveTime value="20250429"/>
                  </section>
               </component>
               <component>
                  <section ID="S5.13">
                     <id root="08d0cb34-d1db-46a2-aa84-17672332df7d"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title>5.13 Hypocalcemia</title>
                     <text>
                        <paragraph>Estrogen therapy should be used with caution in women with hypoparathyroidism as estrogen-induced hypocalcemia may occur.</paragraph>
                     </text>
                     <effectiveTime value="20190531"/>
                  </section>
               </component>
               <component>
                  <section ID="S5.14">
                     <id root="65ffa946-c34e-4703-a428-ff9f6334f3fd"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title>5.14 Exacerbation of Endometriosis</title>
                     <text>
                        <paragraph>A few cases of malignant transformation of residual endometrial implants have been reported in women treated post-hysterectomy with estrogen-alone therapy. For women known to have residual endometriosis post-hysterectomy, the addition of progestin should be considered.</paragraph>
                     </text>
                     <effectiveTime value="20190531"/>
                  </section>
               </component>
               <component>
                  <section ID="S5.15">
                     <id root="ad4bff5c-f86d-4344-810b-64e0ec3e7b86"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title>5.15 Anaphylactic Reaction and Angioedema</title>
                     <text>
                        <paragraph>Cases of anaphylaxis, which developed within minutes to hours after taking PREMPRO or PREMPHASE and require emergency medical management, have been reported in the postmarketing setting. Skin (hives, pruritis, swollen lips-tongue-face) and either respiratory tract (respiratory compromise) or gastrointestinal tract (abdominal pain, vomiting) involvement has been noted.</paragraph>
                        <paragraph>Angioedema involving the tongue, larynx, face, hands, and feet requiring medical intervention has occurred postmarketing in patients taking PREMPRO or PREMPHASE. If angioedema involves the tongue, glottis, or larynx, airway obstruction may occur. Patients who develop an anaphylactic reaction with or without angioedema after treatment with PREMPRO or PREMPHASE should not receive PREMPRO or PREMPHASE again.</paragraph>
                     </text>
                     <effectiveTime value="20190531"/>
                  </section>
               </component>
               <component>
                  <section ID="S5.16">
                     <id root="dbffbc03-ea7d-4907-ab3c-6e05f2d34ab1"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title>5.16 Hereditary Angioedema</title>
                     <text>
                        <paragraph>Exogenous estrogens may exacerbate symptoms of angioedema in women with hereditary angioedema.</paragraph>
                     </text>
                     <effectiveTime value="20190531"/>
                  </section>
               </component>
               <component>
                  <section ID="S5.17">
                     <id root="26fe3d12-c93e-48de-9deb-e9cace7838d6"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title>5.17 Exacerbation of Other Conditions</title>
                     <text>
                        <paragraph>Estrogen therapy may cause an exacerbation of asthma, diabetes mellitus, epilepsy, migraine, porphyria, systemic lupus erythematosus, and hepatic hemangiomas and should be used with caution in women with these conditions.</paragraph>
                     </text>
                     <effectiveTime value="20190531"/>
                  </section>
               </component>
               <component>
                  <section ID="S5.18">
                     <id root="86af2620-bde0-4f1f-ad55-c99294425b00"/>
                     <code code="34075-2" codeSystem="2.16.840.1.113883.6.1" displayName="LABORATORY TESTS SECTION"/>
                     <title>5.18 Laboratory Tests </title>
                     <text>
                        <paragraph>Serum follicle stimulating hormone (FSH) and estradiol levels have not been shown to be useful in the management of moderate to severe vasomotor symptoms and moderate to severe symptoms of vulvar and vaginal atrophy.</paragraph>
                     </text>
                     <effectiveTime value="20190531"/>
                  </section>
               </component>
               <component>
                  <section ID="S5.19">
                     <id root="09d383f0-a1d5-47a9-88cd-2ae3bf0c4acf"/>
                     <code code="34074-5" codeSystem="2.16.840.1.113883.6.1" displayName="DRUG &amp; OR LABORATORY TEST INTERACTIONS SECTION"/>
                     <title>5.19 Drug-Laboratory Test Interactions </title>
                     <text>
                        <list listType="unordered">
                           <item>
                              <caption>•</caption>Accelerated prothrombin time, partial thromboplastin time, and platelet aggregation time; increased platelet count; increased factors II, VII antigen, VIII antigen, VIII coagulant activity, IX, X, XII, VII-X complex, II-VII-X complex, and beta-thromboglobulin; decreased levels of anti-factor Xa and antithrombin III, decreased antithrombin III activity; increased levels of fibrinogen and fibrinogen activity; increased plasminogen antigen and activity.</item>
                           <item>
                              <caption>•</caption>Increased thyroid-binding globulin (TBG) leading to increased circulating total thyroid hormone, as measured by protein-bound iodine (PBI), T<sub>4</sub> levels (by column or by radioimmunoassay), or T<sub>3</sub> levels by radioimmunoassay. T<sub>3</sub> resin uptake is decreased, reflecting the elevated TBG. Free T<sub>4</sub> and free T<sub>3</sub> concentrations are unaltered. Women on thyroid replacement therapy may require higher doses of thyroid hormone.</item>
                           <item>
                              <caption>•</caption>Other binding proteins may be elevated in serum, for example, corticosteroid binding globulin (CBG), sex hormone-binding globulin (SHBG), leading to increased total circulating corticosteroids and sex steroids, respectively. Free hormone concentrations, such as testosterone and estradiol, may be decreased. Other plasma proteins may be increased (angiotensinogen/renin substrate, alpha-1-antitrypsin, ceruloplasmin).</item>
                           <item>
                              <caption>•</caption>Increased plasma high-density lipoprotein (HDL) and HDL<sub>2</sub> cholesterol subfraction, reduced low-density lipoprotein (LDL) cholesterol, increased triglyceride levels.</item>
                           <item>
                              <caption>•</caption>Impaired glucose tolerance.</item>
                        </list>
                     </text>
                     <effectiveTime value="20250429"/>
                  </section>
               </component>
            </section>
         </component>
         <component>
            <section ID="S6">
               <id root="a0abf1ea-5366-422c-a0e0-42750a7e7c09"/>
               <code code="34084-4" codeSystem="2.16.840.1.113883.6.1" displayName="ADVERSE REACTIONS SECTION"/>
               <title>6 ADVERSE REACTIONS</title>
               <text>
                  <paragraph>The following serious adverse reactions are discussed elsewhere in the labeling:</paragraph>
                  <list listType="unordered">
                     <item>
                        <caption>•</caption>Cardiovascular Disorders <content styleCode="italics">[see <linkHtml href="#BOX">Boxed Warning</linkHtml>, <linkHtml href="#S5.1">Warnings and Precautions (5.1)</linkHtml>]</content>
                     </item>
                     <item>
                        <caption>•</caption>Malignant Neoplasms <content styleCode="italics">[see <linkHtml href="#BOX">Boxed Warning</linkHtml>, <linkHtml href="#S5.2">Warnings and Precautions (5.2)</linkHtml>]</content>
                     </item>
                  </list>
               </text>
               <effectiveTime value="20250429"/>
               <excerpt>
                  <highlight>
                     <text>
                        <paragraph>In two prospective, randomized clinical studies, the most common adverse reactions &gt;5% are abdominal pain, asthenia, back pain, headache, flatulence, nausea, depression, pruritus, breast pain, dysmenorrhea, and leukorrhea. (<linkHtml href="#S6.1">6.1</linkHtml>)<br/>
                           <br/>
                           <content styleCode="bold">To report SUSPECTED ADVERSE REACTIONS, contact Pfizer Inc. at 1-800-438-1985 or FDA at 1-800-FDA-1088 or <content styleCode="italics">
                                 <linkHtml href="http://www.fda.gov/medwatch">www.fda.gov/medwatch</linkHtml>
                              </content>
                           </content>.</paragraph>
                     </text>
                  </highlight>
               </excerpt>
               <component>
                  <section ID="S6.1">
                     <id root="8aa5e420-cfde-4765-bb72-421bfae3100f"/>
                     <code code="90374-0" codeSystem="2.16.840.1.113883.6.1" displayName="CLINICAL TRIALS EXPERIENCE SECTION"/>
                     <title>6.1 Clinical Trials Experience</title>
                     <text>
                        <paragraph>Because clinical trials are conducted under widely varying conditions, adverse reaction rates observed in the clinical trial of a drug cannot be directly compared to rates in the clinical trials of another drug and may not reflect the rates observed in practice.</paragraph>
                        <paragraph>In a 1-year clinical trial that included 678 postmenopausal women treated with PREMPRO and 351 postmenopausal women treated with PREMPHASE, the following adverse reactions occurred at a rate ≥ 1%, see <linkHtml href="#_Reftable1">Table 1</linkHtml>.</paragraph>
                        <table ID="_Reftable1" width="100%">
                           <caption>Table 1: Treatment-Related Adverse Reactions at a Frequency ≥1%</caption>
                           <col width="25%"/>
                           <col width="25%"/>
                           <col width="25%"/>
                           <col width="25%"/>
                           <tbody>
                              <tr>
                                 <td styleCode="Toprule " valign="bottom">
                                    <paragraph>
                                       <content styleCode="bold">Body System</content>
                                    </paragraph>
                                 </td>
                                 <td align="center" styleCode="Toprule " valign="bottom">
                                    <paragraph>
                                       <content styleCode="bold">PREMPRO</content>
                                       <br/>0.625 mg/2.5 mg<br/>continuous</paragraph>
                                 </td>
                                 <td align="center" styleCode="Toprule " valign="bottom">
                                    <paragraph>
                                       <content styleCode="bold">PREMPRO</content>
                                       <br/>0.625 mg/5 mg<br/>continuous</paragraph>
                                 </td>
                                 <td align="center" styleCode="Toprule " valign="bottom">
                                    <paragraph>
                                       <content styleCode="bold">PREMPHASE</content>
                                       <br/>0.625 mg/5 mg <br/>sequential</paragraph>
                                 </td>
                              </tr>
                              <tr>
                                 <td styleCode="Botrule " valign="top">
                                    <paragraph>  Adverse event </paragraph>
                                 </td>
                                 <td align="center" styleCode="Botrule " valign="top">
                                    <paragraph>(n = 340)</paragraph>
                                 </td>
                                 <td align="center" styleCode="Botrule " valign="top">
                                    <paragraph>(n = 338)</paragraph>
                                 </td>
                                 <td align="center" styleCode="Botrule " valign="top">
                                    <paragraph>(n = 351)</paragraph>
                                 </td>
                              </tr>
                              <tr>
                                 <td styleCode="Toprule " valign="top">
                                    <paragraph>
                                       <content styleCode="bold">Body As A Whole</content>
                                    </paragraph>
                                 </td>
                                 <td colspan="3" styleCode="Toprule " valign="top"/>
                              </tr>
                              <tr>
                                 <td valign="top">
                                    <paragraph>  Abdominal pain </paragraph>
                                 </td>
                                 <td align="center" valign="top">
                                    <paragraph>35 (10%)</paragraph>
                                 </td>
                                 <td align="center" valign="top">
                                    <paragraph>51 (15%)</paragraph>
                                 </td>
                                 <td align="center" valign="top">
                                    <paragraph>58 (17%)</paragraph>
                                 </td>
                              </tr>
                              <tr>
                                 <td valign="top">
                                    <paragraph>  Asthenia </paragraph>
                                 </td>
                                 <td align="center" valign="top">
                                    <paragraph>13 (4%)</paragraph>
                                 </td>
                                 <td align="center" valign="top">
                                    <paragraph>18 (5%)</paragraph>
                                 </td>
                                 <td align="center" valign="top">
                                    <paragraph>21 (6%)</paragraph>
                                 </td>
                              </tr>
                              <tr>
                                 <td valign="top">
                                    <paragraph>  Back pain </paragraph>
                                 </td>
                                 <td align="center" valign="top">
                                    <paragraph>19 (6%)</paragraph>
                                 </td>
                                 <td align="center" valign="top">
                                    <paragraph>16 (5%)</paragraph>
                                 </td>
                                 <td align="center" valign="top">
                                    <paragraph>23 (7%)</paragraph>
                                 </td>
                              </tr>
                              <tr>
                                 <td valign="top">
                                    <paragraph>  Chest pain </paragraph>
                                 </td>
                                 <td align="center" valign="top">
                                    <paragraph>5 (1%)</paragraph>
                                 </td>
                                 <td align="center" valign="top">
                                    <paragraph>4 (1%)</paragraph>
                                 </td>
                                 <td align="center" valign="top">
                                    <paragraph>4 (1%)</paragraph>
                                 </td>
                              </tr>
                              <tr>
                                 <td valign="top">
                                    <paragraph>  Flu syndrome </paragraph>
                                 </td>
                                 <td align="center" valign="top">
                                    <paragraph>1 (&lt;1%) </paragraph>
                                 </td>
                                 <td align="center" valign="top">
                                    <paragraph>1 (&lt;1%) </paragraph>
                                 </td>
                                 <td align="center" valign="top">
                                    <paragraph>4 (1%) </paragraph>
                                 </td>
                              </tr>
                              <tr>
                                 <td valign="top">
                                    <paragraph>  Generalized edema</paragraph>
                                 </td>
                                 <td align="center" valign="top">
                                    <paragraph>12 (4%) </paragraph>
                                 </td>
                                 <td align="center" valign="top">
                                    <paragraph>12 (4%)</paragraph>
                                 </td>
                                 <td align="center" valign="top">
                                    <paragraph>8 (2%)</paragraph>
                                 </td>
                              </tr>
                              <tr>
                                 <td valign="top">
                                    <paragraph>  Headache</paragraph>
                                 </td>
                                 <td align="center" valign="top">
                                    <paragraph>64 (19%)</paragraph>
                                 </td>
                                 <td align="center" valign="top">
                                    <paragraph>52 (15%) </paragraph>
                                 </td>
                                 <td align="center" valign="top">
                                    <paragraph>66 (19%) </paragraph>
                                 </td>
                              </tr>
                              <tr>
                                 <td valign="top">
                                    <paragraph>  Infection</paragraph>
                                 </td>
                                 <td align="center" valign="top">
                                    <paragraph>2 (&lt;1%) </paragraph>
                                 </td>
                                 <td align="center" valign="top">
                                    <paragraph>4 (1)%</paragraph>
                                 </td>
                                 <td align="center" valign="top">
                                    <paragraph>0</paragraph>
                                 </td>
                              </tr>
                              <tr>
                                 <td valign="top">
                                    <paragraph>  Moniliasis</paragraph>
                                 </td>
                                 <td align="center" valign="top">
                                    <paragraph>4 (1%) </paragraph>
                                 </td>
                                 <td align="center" valign="top">
                                    <paragraph>3 (&lt;1%)</paragraph>
                                 </td>
                                 <td align="center" valign="top">
                                    <paragraph>4 (1%)</paragraph>
                                 </td>
                              </tr>
                              <tr>
                                 <td valign="top">
                                    <paragraph>  Pain</paragraph>
                                 </td>
                                 <td align="center" valign="top">
                                    <paragraph>12 (4%) </paragraph>
                                 </td>
                                 <td align="center" valign="top">
                                    <paragraph>14 (4%)</paragraph>
                                 </td>
                                 <td align="center" valign="top">
                                    <paragraph>15 (4%)</paragraph>
                                 </td>
                              </tr>
                              <tr>
                                 <td valign="top">
                                    <paragraph>  Pelvic pain</paragraph>
                                 </td>
                                 <td align="center" valign="top">
                                    <paragraph>11 (3%) </paragraph>
                                 </td>
                                 <td align="center" valign="top">
                                    <paragraph>13 (4%)</paragraph>
                                 </td>
                                 <td align="center" valign="top">
                                    <paragraph>16 (5%)</paragraph>
                                 </td>
                              </tr>
                              <tr>
                                 <td valign="top">
                                    <paragraph>
                                       <content styleCode="bold">Cardiovascular System</content>
                                    </paragraph>
                                 </td>
                                 <td valign="top"/>
                                 <td valign="top"/>
                                 <td valign="top"/>
                              </tr>
                              <tr>
                                 <td valign="top">
                                    <paragraph>  Hypertension</paragraph>
                                 </td>
                                 <td align="center" valign="top">
                                    <paragraph>7 (2%) </paragraph>
                                 </td>
                                 <td align="center" valign="top">
                                    <paragraph>7 (2%)</paragraph>
                                 </td>
                                 <td align="center" valign="top">
                                    <paragraph>6 (2%)</paragraph>
                                 </td>
                              </tr>
                              <tr>
                                 <td valign="top">
                                    <paragraph>  Migraine </paragraph>
                                 </td>
                                 <td align="center" valign="top">
                                    <paragraph>6 (2%) </paragraph>
                                 </td>
                                 <td align="center" valign="top">
                                    <paragraph>8 (2%) </paragraph>
                                 </td>
                                 <td align="center" valign="top">
                                    <paragraph>7 (2%) </paragraph>
                                 </td>
                              </tr>
                              <tr>
                                 <td valign="top">
                                    <paragraph>  Palpitation</paragraph>
                                 </td>
                                 <td align="center" valign="top">
                                    <paragraph>2 (&lt;1%)</paragraph>
                                 </td>
                                 <td align="center" valign="top">
                                    <paragraph>3 (&lt;1%)</paragraph>
                                 </td>
                                 <td align="center" valign="top">
                                    <paragraph>4 (1%)</paragraph>
                                 </td>
                              </tr>
                              <tr>
                                 <td valign="top">
                                    <paragraph>  Vasodilatation</paragraph>
                                 </td>
                                 <td align="center" valign="top">
                                    <paragraph>2 (&lt;1%)</paragraph>
                                 </td>
                                 <td align="center" valign="top">
                                    <paragraph>7 (2%)</paragraph>
                                 </td>
                                 <td align="center" valign="top">
                                    <paragraph>2 (&lt;1%)</paragraph>
                                 </td>
                              </tr>
                              <tr>
                                 <td valign="top">
                                    <paragraph>
                                       <content styleCode="bold">Digestive System</content>
                                    </paragraph>
                                 </td>
                                 <td valign="top"/>
                                 <td valign="top"/>
                                 <td valign="top"/>
                              </tr>
                              <tr>
                                 <td valign="top">
                                    <paragraph>  Diarrhea</paragraph>
                                 </td>
                                 <td align="center" valign="top">
                                    <paragraph>4 (1%) </paragraph>
                                 </td>
                                 <td align="center" valign="top">
                                    <paragraph>3 (&lt;1%) </paragraph>
                                 </td>
                                 <td align="center" valign="top">
                                    <paragraph>7 (2%)</paragraph>
                                 </td>
                              </tr>
                              <tr>
                                 <td valign="top">
                                    <paragraph>  Dyspepsia</paragraph>
                                 </td>
                                 <td align="center" valign="top">
                                    <paragraph>5 (1%)</paragraph>
                                 </td>
                                 <td align="center" valign="top">
                                    <paragraph>5 (1%)</paragraph>
                                 </td>
                                 <td align="center" valign="top">
                                    <paragraph>7 (2%)</paragraph>
                                 </td>
                              </tr>
                              <tr>
                                 <td valign="top">
                                    <paragraph>  Eructation</paragraph>
                                 </td>
                                 <td align="center" valign="top">
                                    <paragraph>0</paragraph>
                                 </td>
                                 <td align="center" valign="top">
                                    <paragraph>2 (&lt;1%)</paragraph>
                                 </td>
                                 <td align="center" valign="top">
                                    <paragraph>4 (1%)</paragraph>
                                 </td>
                              </tr>
                              <tr>
                                 <td valign="top">
                                    <paragraph>  Flatulence</paragraph>
                                 </td>
                                 <td align="center" valign="top">
                                    <paragraph>25 (7%)</paragraph>
                                 </td>
                                 <td align="center" valign="top">
                                    <paragraph>27 (8%)</paragraph>
                                 </td>
                                 <td align="center" valign="top">
                                    <paragraph>24 (7%)</paragraph>
                                 </td>
                              </tr>
                              <tr>
                                 <td valign="top">
                                    <paragraph>  Increased appetite</paragraph>
                                 </td>
                                 <td align="center" valign="top">
                                    <paragraph>1 (&lt;1%)</paragraph>
                                 </td>
                                 <td align="center" valign="top">
                                    <paragraph>5 (1%)</paragraph>
                                 </td>
                                 <td align="center" valign="top">
                                    <paragraph>5 (1%)</paragraph>
                                 </td>
                              </tr>
                              <tr>
                                 <td valign="top">
                                    <paragraph>  Nausea</paragraph>
                                 </td>
                                 <td align="center" valign="top">
                                    <paragraph>26 (8%)</paragraph>
                                 </td>
                                 <td align="center" valign="top">
                                    <paragraph>19 (6%)</paragraph>
                                 </td>
                                 <td align="center" valign="top">
                                    <paragraph>26 (7%)</paragraph>
                                 </td>
                              </tr>
                              <tr>
                                 <td valign="top">
                                    <paragraph>
                                       <content styleCode="bold">Metabolic and Nutritional</content>
                                    </paragraph>
                                 </td>
                                 <td valign="top"/>
                                 <td valign="top"/>
                                 <td valign="top"/>
                              </tr>
                              <tr>
                                 <td valign="top">
                                    <paragraph>  Edema</paragraph>
                                 </td>
                                 <td align="center" valign="top">
                                    <paragraph>5 (1%) </paragraph>
                                 </td>
                                 <td align="center" valign="top">
                                    <paragraph>6 (2%)</paragraph>
                                 </td>
                                 <td align="center" valign="top">
                                    <paragraph>3 (&lt;1%) </paragraph>
                                 </td>
                              </tr>
                              <tr>
                                 <td valign="top">
                                    <paragraph>  Glucose tolerance<br/>  decreased</paragraph>
                                 </td>
                                 <td align="center" valign="top">
                                    <paragraph>2 (&lt;1%)</paragraph>
                                 </td>
                                 <td align="center" valign="top">
                                    <paragraph>5 (1%)</paragraph>
                                 </td>
                                 <td align="center" valign="top">
                                    <paragraph>4 (1%)</paragraph>
                                 </td>
                              </tr>
                              <tr>
                                 <td valign="top">
                                    <paragraph>  Peripheral edema </paragraph>
                                 </td>
                                 <td align="center" valign="top">
                                    <paragraph>11 (3%)</paragraph>
                                 </td>
                                 <td align="center" valign="top">
                                    <paragraph>10 (3%) </paragraph>
                                 </td>
                                 <td align="center" valign="top">
                                    <paragraph>11 (3%)</paragraph>
                                 </td>
                              </tr>
                              <tr>
                                 <td valign="top">
                                    <paragraph>    Weight gain</paragraph>
                                 </td>
                                 <td align="center" valign="top">
                                    <paragraph>9 (3%)</paragraph>
                                 </td>
                                 <td align="center" valign="top">
                                    <paragraph>10 (3%)</paragraph>
                                 </td>
                                 <td align="center" valign="top">
                                    <paragraph>11 (3%)</paragraph>
                                 </td>
                              </tr>
                              <tr>
                                 <td valign="top">
                                    <paragraph>
                                       <content styleCode="bold">Musculoskeletal System</content>
                                    </paragraph>
                                 </td>
                                 <td valign="top"/>
                                 <td valign="top"/>
                                 <td valign="top"/>
                              </tr>
                              <tr>
                                 <td valign="top">
                                    <paragraph>  Arthralgia </paragraph>
                                 </td>
                                 <td align="center" valign="top">
                                    <paragraph>6 (2%)</paragraph>
                                 </td>
                                 <td align="center" valign="top">
                                    <paragraph>2 (&lt;1%)</paragraph>
                                 </td>
                                 <td align="center" valign="top">
                                    <paragraph>7 (2%)</paragraph>
                                 </td>
                              </tr>
                              <tr>
                                 <td valign="top">
                                    <paragraph>  Leg cramps </paragraph>
                                 </td>
                                 <td align="center" valign="top">
                                    <paragraph>8 (2%)</paragraph>
                                 </td>
                                 <td align="center" valign="top">
                                    <paragraph>11 (3%)</paragraph>
                                 </td>
                                 <td align="center" valign="top">
                                    <paragraph>12 (3%)</paragraph>
                                 </td>
                              </tr>
                              <tr>
                                 <td valign="top">
                                    <paragraph>
                                       <content styleCode="bold">Nervous System</content>
                                    </paragraph>
                                 </td>
                                 <td valign="top"/>
                                 <td valign="top"/>
                                 <td valign="top"/>
                              </tr>
                              <tr>
                                 <td valign="top">
                                    <paragraph>  Depression </paragraph>
                                 </td>
                                 <td align="center" valign="top">
                                    <paragraph>14 (4%)</paragraph>
                                 </td>
                                 <td align="center" valign="top">
                                    <paragraph>26 (8%)</paragraph>
                                 </td>
                                 <td align="center" valign="top">
                                    <paragraph>29 (8%)</paragraph>
                                 </td>
                              </tr>
                              <tr>
                                 <td valign="top">
                                    <paragraph>  Dizziness </paragraph>
                                 </td>
                                 <td align="center" valign="top">
                                    <paragraph>9 (3%)</paragraph>
                                 </td>
                                 <td align="center" valign="top">
                                    <paragraph>8 (2%)</paragraph>
                                 </td>
                                 <td align="center" valign="top">
                                    <paragraph>7 (2%)</paragraph>
                                 </td>
                              </tr>
                              <tr>
                                 <td valign="top">
                                    <paragraph>  Emotional lability </paragraph>
                                 </td>
                                 <td align="center" valign="top">
                                    <paragraph>5 (1%) </paragraph>
                                 </td>
                                 <td align="center" valign="top">
                                    <paragraph>5 (1%) </paragraph>
                                 </td>
                                 <td align="center" valign="top">
                                    <paragraph>6 (2%) </paragraph>
                                 </td>
                              </tr>
                              <tr>
                                 <td valign="top">
                                    <paragraph>  Hypertonia</paragraph>
                                 </td>
                                 <td align="center" valign="top">
                                    <paragraph>4 (1%)</paragraph>
                                 </td>
                                 <td align="center" valign="top">
                                    <paragraph>4 (1%)</paragraph>
                                 </td>
                                 <td align="center" valign="top">
                                    <paragraph>7 (2%)</paragraph>
                                 </td>
                              </tr>
                              <tr>
                                 <td valign="top">
                                    <paragraph>  Insomnia</paragraph>
                                 </td>
                                 <td align="center" valign="top">
                                    <paragraph>7 (2%)</paragraph>
                                 </td>
                                 <td align="center" valign="top">
                                    <paragraph>6 (2%)</paragraph>
                                 </td>
                                 <td align="center" valign="top">
                                    <paragraph>4 (1%)</paragraph>
                                 </td>
                              </tr>
                              <tr>
                                 <td valign="top">
                                    <paragraph>  Nervousness</paragraph>
                                 </td>
                                 <td align="center" valign="top">
                                    <paragraph>4 (1%) </paragraph>
                                 </td>
                                 <td align="center" valign="top">
                                    <paragraph>9 (3%) </paragraph>
                                 </td>
                                 <td align="center" valign="top">
                                    <paragraph>6 (2%) </paragraph>
                                 </td>
                              </tr>
                              <tr>
                                 <td valign="top">
                                    <paragraph>
                                       <content styleCode="bold">Skin and Appendages</content>
                                    </paragraph>
                                 </td>
                                 <td valign="top"/>
                                 <td valign="top"/>
                                 <td valign="top"/>
                              </tr>
                              <tr>
                                 <td valign="top">
                                    <paragraph>  Acne</paragraph>
                                 </td>
                                 <td align="center" valign="top">
                                    <paragraph>1 (&lt;1%) </paragraph>
                                 </td>
                                 <td align="center" valign="top">
                                    <paragraph>5 (1%)</paragraph>
                                 </td>
                                 <td align="center" valign="top">
                                    <paragraph>4 (1%) </paragraph>
                                 </td>
                              </tr>
                              <tr>
                                 <td valign="top">
                                    <paragraph>  Alopecia</paragraph>
                                 </td>
                                 <td align="center" valign="top">
                                    <paragraph>3 (&lt;1%)</paragraph>
                                 </td>
                                 <td align="center" valign="top">
                                    <paragraph>4 (1%)</paragraph>
                                 </td>
                                 <td align="center" valign="top">
                                    <paragraph>0</paragraph>
                                 </td>
                              </tr>
                              <tr>
                                 <td valign="top">
                                    <paragraph>  Dry skin</paragraph>
                                 </td>
                                 <td align="center" valign="top">
                                    <paragraph>2 (&lt;1%)</paragraph>
                                 </td>
                                 <td align="center" valign="top">
                                    <paragraph>3 (&lt;1%)</paragraph>
                                 </td>
                                 <td align="center" valign="top">
                                    <paragraph>4 (1%)</paragraph>
                                 </td>
                              </tr>
                              <tr>
                                 <td valign="top">
                                    <paragraph>  Pruritus</paragraph>
                                 </td>
                                 <td align="center" valign="top">
                                    <paragraph>20 (6%)</paragraph>
                                 </td>
                                 <td align="center" valign="top">
                                    <paragraph>18 (5%)</paragraph>
                                 </td>
                                 <td align="center" valign="top">
                                    <paragraph>13 (4%)</paragraph>
                                 </td>
                              </tr>
                              <tr>
                                 <td valign="top">
                                    <paragraph>  Rash</paragraph>
                                 </td>
                                 <td align="center" valign="top">
                                    <paragraph>8 (2%)</paragraph>
                                 </td>
                                 <td align="center" valign="top">
                                    <paragraph>6 (2%)</paragraph>
                                 </td>
                                 <td align="center" valign="top">
                                    <paragraph>7 (2%)</paragraph>
                                 </td>
                              </tr>
                              <tr>
                                 <td valign="top">
                                    <paragraph>  Sweating </paragraph>
                                 </td>
                                 <td align="center" valign="top">
                                    <paragraph>2 (&lt;1%)</paragraph>
                                 </td>
                                 <td align="center" valign="top">
                                    <paragraph>4 (1%)</paragraph>
                                 </td>
                                 <td align="center" valign="top">
                                    <paragraph>2 (&lt;1%)</paragraph>
                                 </td>
                              </tr>
                              <tr>
                                 <td valign="top">
                                    <paragraph>
                                       <content styleCode="bold">Urogenital System</content>
                                    </paragraph>
                                 </td>
                                 <td valign="top"/>
                                 <td valign="top"/>
                                 <td valign="top"/>
                              </tr>
                              <tr>
                                 <td valign="top">
                                    <paragraph>  Breast engorgement</paragraph>
                                 </td>
                                 <td align="center" valign="top">
                                    <paragraph>5 (1%)</paragraph>
                                 </td>
                                 <td align="center" valign="top">
                                    <paragraph>5 (1%)</paragraph>
                                 </td>
                                 <td align="center" valign="top">
                                    <paragraph>0</paragraph>
                                 </td>
                              </tr>
                              <tr>
                                 <td valign="top">
                                    <paragraph>  Breast enlargement</paragraph>
                                 </td>
                                 <td align="center" valign="top">
                                    <paragraph>14 (4%) </paragraph>
                                 </td>
                                 <td align="center" valign="top">
                                    <paragraph>14 (4%) </paragraph>
                                 </td>
                                 <td align="center" valign="top">
                                    <paragraph>14 (4%) </paragraph>
                                 </td>
                              </tr>
                              <tr>
                                 <td valign="top">
                                    <paragraph>  Breast neoplasm</paragraph>
                                 </td>
                                 <td align="center" valign="top">
                                    <paragraph>2 (&lt;1%)</paragraph>
                                 </td>
                                 <td align="center" valign="top">
                                    <paragraph>2 (&lt;1%)</paragraph>
                                 </td>
                                 <td align="center" valign="top">
                                    <paragraph>4 (1%)</paragraph>
                                 </td>
                              </tr>
                              <tr>
                                 <td valign="top">
                                    <paragraph>  Breast pain</paragraph>
                                 </td>
                                 <td align="center" valign="top">
                                    <paragraph>110 (32%)</paragraph>
                                 </td>
                                 <td align="center" valign="top">
                                    <paragraph>123 (36%)</paragraph>
                                 </td>
                                 <td align="center" valign="top">
                                    <paragraph>109 (31%)</paragraph>
                                 </td>
                              </tr>
                              <tr>
                                 <td valign="top">
                                    <paragraph>  Cervix disorder</paragraph>
                                 </td>
                                 <td align="center" valign="top">
                                    <paragraph>10 (3%)</paragraph>
                                 </td>
                                 <td align="center" valign="top">
                                    <paragraph>6 (2%)</paragraph>
                                 </td>
                                 <td align="center" valign="top">
                                    <paragraph>10 (3%) </paragraph>
                                 </td>
                              </tr>
                              <tr>
                                 <td valign="top">
                                    <paragraph>  Dysmenorrhea </paragraph>
                                 </td>
                                 <td align="center" valign="top">
                                    <paragraph>26 (8%)</paragraph>
                                 </td>
                                 <td align="center" valign="top">
                                    <paragraph>18 (5%)</paragraph>
                                 </td>
                                 <td align="center" valign="top">
                                    <paragraph>44 (13%) </paragraph>
                                 </td>
                              </tr>
                              <tr>
                                 <td valign="top">
                                    <paragraph>  Leukorrhea </paragraph>
                                 </td>
                                 <td align="center" valign="top">
                                    <paragraph>19 (6%)</paragraph>
                                 </td>
                                 <td align="center" valign="top">
                                    <paragraph>13 (4%)</paragraph>
                                 </td>
                                 <td align="center" valign="top">
                                    <paragraph>29 (8%) </paragraph>
                                 </td>
                              </tr>
                              <tr>
                                 <td valign="top">
                                    <paragraph>  Menstrual disorder </paragraph>
                                 </td>
                                 <td align="center" valign="top">
                                    <paragraph>7 (2%) </paragraph>
                                 </td>
                                 <td align="center" valign="top">
                                    <paragraph>1 (&lt;1%)</paragraph>
                                 </td>
                                 <td align="center" valign="top">
                                    <paragraph>5 (1%) </paragraph>
                                 </td>
                              </tr>
                              <tr>
                                 <td valign="top">
                                    <paragraph>  Menorrhagia</paragraph>
                                 </td>
                                 <td align="center" valign="top">
                                    <paragraph>0</paragraph>
                                 </td>
                                 <td align="center" valign="top">
                                    <paragraph>1 (&lt;1%)</paragraph>
                                 </td>
                                 <td align="center" valign="top">
                                    <paragraph>5 (1%) </paragraph>
                                 </td>
                              </tr>
                              <tr>
                                 <td valign="top">
                                    <paragraph>  Metrorrhagia </paragraph>
                                 </td>
                                 <td align="center" valign="top">
                                    <paragraph>13 (4%)</paragraph>
                                 </td>
                                 <td align="center" valign="top">
                                    <paragraph>5 (1%)</paragraph>
                                 </td>
                                 <td align="center" valign="top">
                                    <paragraph>7 (1%)</paragraph>
                                 </td>
                              </tr>
                              <tr>
                                 <td valign="top">
                                    <paragraph>  Papanicolaou smear<br/>  suspicious</paragraph>
                                 </td>
                                 <td align="center" valign="top">
                                    <paragraph>5 (1%) </paragraph>
                                 </td>
                                 <td align="center" valign="top">
                                    <paragraph>0</paragraph>
                                 </td>
                                 <td align="center" valign="top">
                                    <paragraph>8 (2%) </paragraph>
                                 </td>
                              </tr>
                              <tr>
                                 <td valign="top">
                                    <paragraph>  Urinary incontinence</paragraph>
                                 </td>
                                 <td align="center" valign="top">
                                    <paragraph>4 (1%)</paragraph>
                                 </td>
                                 <td align="center" valign="top">
                                    <paragraph>2 (&lt;1%)</paragraph>
                                 </td>
                                 <td align="center" valign="top">
                                    <paragraph>1 (&lt;1%)</paragraph>
                                 </td>
                              </tr>
                              <tr>
                                 <td valign="top">
                                    <paragraph>  Uterine spasm</paragraph>
                                 </td>
                                 <td align="center" valign="top">
                                    <paragraph>7 (2%)</paragraph>
                                 </td>
                                 <td align="center" valign="top">
                                    <paragraph>4 (1%)</paragraph>
                                 </td>
                                 <td align="center" valign="top">
                                    <paragraph>7 (2%)</paragraph>
                                 </td>
                              </tr>
                              <tr>
                                 <td valign="top">
                                    <paragraph>  Vaginal hemorrhage</paragraph>
                                 </td>
                                 <td align="center" valign="top">
                                    <paragraph>5 (1%)</paragraph>
                                 </td>
                                 <td align="center" valign="top">
                                    <paragraph>3 (&lt;1%)</paragraph>
                                 </td>
                                 <td align="center" valign="top">
                                    <paragraph>8 (2%)</paragraph>
                                 </td>
                              </tr>
                              <tr>
                                 <td valign="top">
                                    <paragraph>  Vaginal moniliasis</paragraph>
                                 </td>
                                 <td align="center" valign="top">
                                    <paragraph>5 (1%)</paragraph>
                                 </td>
                                 <td align="center" valign="top">
                                    <paragraph>6 (2%)</paragraph>
                                 </td>
                                 <td align="center" valign="top">
                                    <paragraph>7 (2%)</paragraph>
                                 </td>
                              </tr>
                              <tr>
                                 <td styleCode="Botrule " valign="top">
                                    <paragraph>  Vaginitis</paragraph>
                                 </td>
                                 <td align="center" styleCode="Botrule " valign="top">
                                    <paragraph>13 (4%)</paragraph>
                                 </td>
                                 <td align="center" styleCode="Botrule " valign="top">
                                    <paragraph>13 (4%)</paragraph>
                                 </td>
                                 <td align="center" styleCode="Botrule " valign="top">
                                    <paragraph>10 (3%)</paragraph>
                                 </td>
                              </tr>
                           </tbody>
                        </table>
                        <paragraph>In addition, phargyngitis and sinusitis were reported as two of the more frequent adverse events (&gt;5%) in the PREMPRO clinical study. For pharyngitis, of the 121 events, six events were considered by the investigator causally related to study drug. For sinusitis, of the 73 events, one event was considered as casually related to study drug.</paragraph>
                        <paragraph>During the first year of a 2-year clinical trial with postmenopausal women between 40 and 65 years of age (88% Caucasian), 989 postmenopausal women received continuous regimens of PREMPRO, and 332 received placebo tablets. Table 2 summarizes adverse reactions that occurred at a rate ≥ 1% in at least 1 treatment group.</paragraph>
                        <table ID="_Reftable2" width="100%">
                           <caption>Table 2: All Treatment-Related Adverse Reactions at a Frequency of ≥1%</caption>
                           <col width="28%"/>
                           <col width="18%"/>
                           <col width="18%"/>
                           <col width="18%"/>
                           <col width="18%"/>
                           <tbody>
                              <tr>
                                 <td align="center" styleCode="Botrule Toprule " valign="bottom">
                                    <paragraph>
                                       <content styleCode="bold">Body System</content>
                                       <br/>Adverse event</paragraph>
                                 </td>
                                 <td align="center" styleCode="Botrule Toprule " valign="bottom">
                                    <paragraph>PREMPRO<br/>0.625/2.5<br/>continuous<br/>(N=331)</paragraph>
                                 </td>
                                 <td align="center" styleCode="Botrule Toprule " valign="bottom">
                                    <paragraph>PREMPRO<br/>0.45/1.5<br/>continuous<br/>(N=331)</paragraph>
                                 </td>
                                 <td align="center" styleCode="Botrule Toprule " valign="bottom">
                                    <paragraph>PREMPRO<br/>0.3/1.5<br/>continuous<br/>(N=327)</paragraph>
                                 </td>
                                 <td align="center" styleCode="Botrule Toprule " valign="bottom">
                                    <paragraph>PLACEBO<br/>daily<br/>(N=332)</paragraph>
                                 </td>
                              </tr>
                              <tr>
                                 <td colspan="5" styleCode="Toprule " valign="top"/>
                              </tr>
                              <tr>
                                 <td valign="top">
                                    <paragraph>
                                       <content styleCode="bold">Any adverse event</content>
                                    </paragraph>
                                 </td>
                                 <td align="center" valign="top">
                                    <paragraph>214 (65)</paragraph>
                                 </td>
                                 <td align="center" valign="top">
                                    <paragraph>208 (63)</paragraph>
                                 </td>
                                 <td align="center" valign="top">
                                    <paragraph>188 (57)</paragraph>
                                 </td>
                                 <td align="center" valign="top">
                                    <paragraph>164 (49)</paragraph>
                                 </td>
                              </tr>
                              <tr>
                                 <td valign="top">
                                    <paragraph>
                                       <content styleCode="bold">Body as a Whole</content>
                                    </paragraph>
                                 </td>
                                 <td valign="top"/>
                                 <td valign="top"/>
                                 <td valign="top"/>
                                 <td valign="top"/>
                              </tr>
                              <tr>
                                 <td valign="top">
                                    <paragraph>  Abdominal pain</paragraph>
                                 </td>
                                 <td align="center" valign="top">
                                    <paragraph>38 (11)</paragraph>
                                 </td>
                                 <td align="center" valign="top">
                                    <paragraph>33 (10)</paragraph>
                                 </td>
                                 <td align="center" valign="top">
                                    <paragraph>24 (7)</paragraph>
                                 </td>
                                 <td align="center" valign="top">
                                    <paragraph>21 (6)</paragraph>
                                 </td>
                              </tr>
                              <tr>
                                 <td valign="top">
                                    <paragraph>  Asthenia</paragraph>
                                 </td>
                                 <td align="center" valign="top">
                                    <paragraph>11 (3)</paragraph>
                                 </td>
                                 <td align="center" valign="top">
                                    <paragraph>11 (3)</paragraph>
                                 </td>
                                 <td align="center" valign="top">
                                    <paragraph>12 (4)</paragraph>
                                 </td>
                                 <td align="center" valign="top">
                                    <paragraph>3 (1)</paragraph>
                                 </td>
                              </tr>
                              <tr>
                                 <td valign="top">
                                    <paragraph>  Back pain</paragraph>
                                 </td>
                                 <td align="center" valign="top">
                                    <paragraph>12 (4)</paragraph>
                                 </td>
                                 <td align="center" valign="top">
                                    <paragraph>12 (4)</paragraph>
                                 </td>
                                 <td align="center" valign="top">
                                    <paragraph>8 (2)</paragraph>
                                 </td>
                                 <td align="center" valign="top">
                                    <paragraph>4 (1)</paragraph>
                                 </td>
                              </tr>
                              <tr>
                                 <td valign="top">
                                    <paragraph>  Chest pain</paragraph>
                                 </td>
                                 <td align="center" valign="top">
                                    <paragraph>4 (1)</paragraph>
                                 </td>
                                 <td align="center" valign="top">
                                    <paragraph>2 (1)</paragraph>
                                 </td>
                                 <td align="center" valign="top">
                                    <paragraph>1 (0)</paragraph>
                                 </td>
                                 <td align="center" valign="top">
                                    <paragraph>2 (1)</paragraph>
                                 </td>
                              </tr>
                              <tr>
                                 <td valign="top">
                                    <paragraph>  Generalized edema</paragraph>
                                 </td>
                                 <td align="center" valign="top">
                                    <paragraph>7 (2)</paragraph>
                                 </td>
                                 <td align="center" valign="top">
                                    <paragraph>5 (2)</paragraph>
                                 </td>
                                 <td align="center" valign="top">
                                    <paragraph>6 (2)</paragraph>
                                 </td>
                                 <td align="center" valign="top">
                                    <paragraph>8 (2)</paragraph>
                                 </td>
                              </tr>
                              <tr>
                                 <td valign="top">
                                    <paragraph>  Headache</paragraph>
                                 </td>
                                 <td align="center" valign="top">
                                    <paragraph>45 (14)</paragraph>
                                 </td>
                                 <td align="center" valign="top">
                                    <paragraph>45 (14)</paragraph>
                                 </td>
                                 <td align="center" valign="top">
                                    <paragraph>57 (17)</paragraph>
                                 </td>
                                 <td align="center" valign="top">
                                    <paragraph>46 (14)</paragraph>
                                 </td>
                              </tr>
                              <tr>
                                 <td valign="top">
                                    <paragraph>  Moniliasis</paragraph>
                                 </td>
                                 <td align="center" valign="top">
                                    <paragraph>3 (1)</paragraph>
                                 </td>
                                 <td align="center" valign="top">
                                    <paragraph>6 (2)</paragraph>
                                 </td>
                                 <td align="center" valign="top">
                                    <paragraph>4 (1)</paragraph>
                                 </td>
                                 <td align="center" valign="top">
                                    <paragraph>1 (0)</paragraph>
                                 </td>
                              </tr>
                              <tr>
                                 <td valign="top">
                                    <paragraph>  Pain</paragraph>
                                 </td>
                                 <td align="center" valign="top">
                                    <paragraph>9 (3)</paragraph>
                                 </td>
                                 <td align="center" valign="top">
                                    <paragraph>10 (3)</paragraph>
                                 </td>
                                 <td align="center" valign="top">
                                    <paragraph>17 (5)</paragraph>
                                 </td>
                                 <td align="center" valign="top">
                                    <paragraph>14 (4)</paragraph>
                                 </td>
                              </tr>
                              <tr>
                                 <td valign="top">
                                    <paragraph>  Pelvic pain</paragraph>
                                 </td>
                                 <td align="center" valign="top">
                                    <paragraph>9 (3)</paragraph>
                                 </td>
                                 <td align="center" valign="top">
                                    <paragraph>7 (2)</paragraph>
                                 </td>
                                 <td align="center" valign="top">
                                    <paragraph>5 (2)</paragraph>
                                 </td>
                                 <td align="center" valign="top">
                                    <paragraph>4 (1)</paragraph>
                                 </td>
                              </tr>
                              <tr>
                                 <td valign="top">
                                    <paragraph>
                                       <content styleCode="bold">Cardiovascular System</content>
                                    </paragraph>
                                 </td>
                                 <td valign="top"/>
                                 <td valign="top"/>
                                 <td valign="top"/>
                                 <td valign="top"/>
                              </tr>
                              <tr>
                                 <td valign="top">
                                    <paragraph>  Hypertension</paragraph>
                                 </td>
                                 <td align="center" valign="top">
                                    <paragraph>2 (1)</paragraph>
                                 </td>
                                 <td align="center" valign="top">
                                    <paragraph>3 (1)</paragraph>
                                 </td>
                                 <td align="center" valign="top">
                                    <paragraph>1 (0)</paragraph>
                                 </td>
                                 <td align="center" valign="top">
                                    <paragraph>5 (2)</paragraph>
                                 </td>
                              </tr>
                              <tr>
                                 <td valign="top">
                                    <paragraph>  Migraine</paragraph>
                                 </td>
                                 <td align="center" valign="top">
                                    <paragraph>11 (3)</paragraph>
                                 </td>
                                 <td align="center" valign="top">
                                    <paragraph>8 (2)</paragraph>
                                 </td>
                                 <td align="center" valign="top">
                                    <paragraph>5 (2)</paragraph>
                                 </td>
                                 <td align="center" valign="top">
                                    <paragraph>3 (1)</paragraph>
                                 </td>
                              </tr>
                              <tr>
                                 <td valign="top">
                                    <paragraph>  Palpitation</paragraph>
                                 </td>
                                 <td align="center" valign="top">
                                    <paragraph>1 (0)</paragraph>
                                 </td>
                                 <td align="center" valign="top">
                                    <paragraph>1 (0)</paragraph>
                                 </td>
                                 <td align="center" valign="top">
                                    <paragraph>2 (1)</paragraph>
                                 </td>
                                 <td align="center" valign="top">
                                    <paragraph>4 (1)</paragraph>
                                 </td>
                              </tr>
                              <tr>
                                 <td valign="top">
                                    <paragraph>  Vasodilatation</paragraph>
                                 </td>
                                 <td align="center" valign="top">
                                    <paragraph>0</paragraph>
                                 </td>
                                 <td align="center" valign="top">
                                    <paragraph>3 (1)</paragraph>
                                 </td>
                                 <td align="center" valign="top">
                                    <paragraph>1 (0)</paragraph>
                                 </td>
                                 <td align="center" valign="top">
                                    <paragraph>5 (2)</paragraph>
                                 </td>
                              </tr>
                              <tr>
                                 <td valign="top">
                                    <paragraph>
                                       <content styleCode="bold">Digestive System</content>
                                    </paragraph>
                                 </td>
                                 <td valign="top"/>
                                 <td valign="top"/>
                                 <td valign="top"/>
                                 <td valign="top"/>
                              </tr>
                              <tr>
                                 <td valign="top">
                                    <paragraph>  Constipation</paragraph>
                                 </td>
                                 <td align="center" valign="top">
                                    <paragraph>5 (2)</paragraph>
                                 </td>
                                 <td align="center" valign="top">
                                    <paragraph>7 (2)</paragraph>
                                 </td>
                                 <td align="center" valign="top">
                                    <paragraph>6 (2)</paragraph>
                                 </td>
                                 <td align="center" valign="top">
                                    <paragraph>3 (1)</paragraph>
                                 </td>
                              </tr>
                              <tr>
                                 <td valign="top">
                                    <paragraph>  Diarrhea</paragraph>
                                 </td>
                                 <td align="center" valign="top">
                                    <paragraph>5 (2)</paragraph>
                                 </td>
                                 <td align="center" valign="top">
                                    <paragraph>2 (1)</paragraph>
                                 </td>
                                 <td align="center" valign="top">
                                    <paragraph>6 (2)</paragraph>
                                 </td>
                                 <td align="center" valign="top">
                                    <paragraph>8 (2)</paragraph>
                                 </td>
                              </tr>
                              <tr>
                                 <td valign="top">
                                    <paragraph>  Dyspepsia</paragraph>
                                 </td>
                                 <td align="center" valign="top">
                                    <paragraph>10 (3)</paragraph>
                                 </td>
                                 <td align="center" valign="top">
                                    <paragraph>9 (3)</paragraph>
                                 </td>
                                 <td align="center" valign="top">
                                    <paragraph>6 (2)</paragraph>
                                 </td>
                                 <td align="center" valign="top">
                                    <paragraph>14 (4)</paragraph>
                                 </td>
                              </tr>
                              <tr>
                                 <td valign="top">
                                    <paragraph>  Flatulence</paragraph>
                                 </td>
                                 <td align="center" valign="top">
                                    <paragraph>16 (5)</paragraph>
                                 </td>
                                 <td align="center" valign="top">
                                    <paragraph>18 (5)</paragraph>
                                 </td>
                                 <td align="center" valign="top">
                                    <paragraph>13 (4)</paragraph>
                                 </td>
                                 <td align="center" valign="top">
                                    <paragraph>8 (2)</paragraph>
                                 </td>
                              </tr>
                              <tr>
                                 <td valign="top">
                                    <paragraph>  Increased appetite</paragraph>
                                 </td>
                                 <td align="center" valign="top">
                                    <paragraph>6 (2)</paragraph>
                                 </td>
                                 <td align="center" valign="top">
                                    <paragraph>2 (1)</paragraph>
                                 </td>
                                 <td align="center" valign="top">
                                    <paragraph>0</paragraph>
                                 </td>
                                 <td align="center" valign="top">
                                    <paragraph>2 (1)</paragraph>
                                 </td>
                              </tr>
                              <tr>
                                 <td valign="top">
                                    <paragraph>  Nausea</paragraph>
                                 </td>
                                 <td align="center" valign="top">
                                    <paragraph>13 (4)</paragraph>
                                 </td>
                                 <td align="center" valign="top">
                                    <paragraph>13 (4)</paragraph>
                                 </td>
                                 <td align="center" valign="top">
                                    <paragraph>16 (5)</paragraph>
                                 </td>
                                 <td align="center" valign="top">
                                    <paragraph>16 (5)</paragraph>
                                 </td>
                              </tr>
                              <tr>
                                 <td valign="top">
                                    <paragraph>
                                       <content styleCode="bold">Metabolic and nutritional</content>
                                    </paragraph>
                                 </td>
                                 <td valign="top"/>
                                 <td valign="top"/>
                                 <td valign="top"/>
                                 <td valign="top"/>
                              </tr>
                              <tr>
                                 <td valign="top">
                                    <paragraph>  Peripheral edema</paragraph>
                                 </td>
                                 <td align="center" valign="top">
                                    <paragraph>7 (2)</paragraph>
                                 </td>
                                 <td align="center" valign="top">
                                    <paragraph>8 (2)</paragraph>
                                 </td>
                                 <td align="center" valign="top">
                                    <paragraph>4 (1)</paragraph>
                                 </td>
                                 <td align="center" valign="top">
                                    <paragraph>3 (1)</paragraph>
                                 </td>
                              </tr>
                              <tr>
                                 <td valign="top">
                                    <paragraph>  Weight gain</paragraph>
                                 </td>
                                 <td align="center" valign="top">
                                    <paragraph>9 (3)</paragraph>
                                 </td>
                                 <td align="center" valign="top">
                                    <paragraph>8 (2)</paragraph>
                                 </td>
                                 <td align="center" valign="top">
                                    <paragraph>6 (2)</paragraph>
                                 </td>
                                 <td align="center" valign="top">
                                    <paragraph>14 (4)</paragraph>
                                 </td>
                              </tr>
                              <tr>
                                 <td valign="top">
                                    <paragraph>
                                       <content styleCode="bold">Musculoskeletal System</content>
                                    </paragraph>
                                 </td>
                                 <td valign="top"/>
                                 <td valign="top"/>
                                 <td valign="top"/>
                                 <td valign="top"/>
                              </tr>
                              <tr>
                                 <td valign="top">
                                    <paragraph>  Arthralgia</paragraph>
                                 </td>
                                 <td align="center" valign="top">
                                    <paragraph>2 (1)</paragraph>
                                 </td>
                                 <td align="center" valign="top">
                                    <paragraph>3 (1)</paragraph>
                                 </td>
                                 <td align="center" valign="top">
                                    <paragraph>3 (1)</paragraph>
                                 </td>
                                 <td align="center" valign="top">
                                    <paragraph>5 (2)</paragraph>
                                 </td>
                              </tr>
                              <tr>
                                 <td valign="top">
                                    <paragraph>  Leg cramps</paragraph>
                                 </td>
                                 <td align="center" valign="top">
                                    <paragraph>13 (4)</paragraph>
                                 </td>
                                 <td align="center" valign="top">
                                    <paragraph>7 (2)</paragraph>
                                 </td>
                                 <td align="center" valign="top">
                                    <paragraph>10 (3)</paragraph>
                                 </td>
                                 <td align="center" valign="top">
                                    <paragraph>4 (1)</paragraph>
                                 </td>
                              </tr>
                              <tr>
                                 <td valign="top">
                                    <paragraph>
                                       <content styleCode="bold">Nervous System</content>
                                    </paragraph>
                                 </td>
                                 <td valign="top"/>
                                 <td valign="top"/>
                                 <td valign="top"/>
                                 <td valign="top"/>
                              </tr>
                              <tr>
                                 <td valign="top">
                                    <paragraph>  Anxiety</paragraph>
                                 </td>
                                 <td align="center" valign="top">
                                    <paragraph>5 (2)</paragraph>
                                 </td>
                                 <td align="center" valign="top">
                                    <paragraph>4 (1)</paragraph>
                                 </td>
                                 <td align="center" valign="top">
                                    <paragraph>1 (0)</paragraph>
                                 </td>
                                 <td align="center" valign="top">
                                    <paragraph>4 (1)</paragraph>
                                 </td>
                              </tr>
                              <tr>
                                 <td valign="top">
                                    <paragraph>  Depression</paragraph>
                                 </td>
                                 <td align="center" valign="top">
                                    <paragraph>23 (7)</paragraph>
                                 </td>
                                 <td align="center" valign="top">
                                    <paragraph>11 (3)</paragraph>
                                 </td>
                                 <td align="center" valign="top">
                                    <paragraph>11 (3)</paragraph>
                                 </td>
                                 <td align="center" valign="top">
                                    <paragraph>17 (5)</paragraph>
                                 </td>
                              </tr>
                              <tr>
                                 <td valign="top">
                                    <paragraph>  Dizziness</paragraph>
                                 </td>
                                 <td align="center" valign="top">
                                    <paragraph>3 (1)</paragraph>
                                 </td>
                                 <td align="center" valign="top">
                                    <paragraph>8 (2)</paragraph>
                                 </td>
                                 <td align="center" valign="top">
                                    <paragraph>6 (2)</paragraph>
                                 </td>
                                 <td align="center" valign="top">
                                    <paragraph>5 (2)</paragraph>
                                 </td>
                              </tr>
                              <tr>
                                 <td valign="top">
                                    <paragraph>  Emotional lability</paragraph>
                                 </td>
                                 <td align="center" valign="top">
                                    <paragraph>10 (3)</paragraph>
                                 </td>
                                 <td align="center" valign="top">
                                    <paragraph>10 (3)</paragraph>
                                 </td>
                                 <td align="center" valign="top">
                                    <paragraph>9 (3)</paragraph>
                                 </td>
                                 <td align="center" valign="top">
                                    <paragraph>8 (2)</paragraph>
                                 </td>
                              </tr>
                              <tr>
                                 <td valign="top">
                                    <paragraph>  Insomnia</paragraph>
                                 </td>
                                 <td align="center" valign="top">
                                    <paragraph>8 (2)</paragraph>
                                 </td>
                                 <td align="center" valign="top">
                                    <paragraph>7 (2)</paragraph>
                                 </td>
                                 <td align="center" valign="top">
                                    <paragraph>9 (3)</paragraph>
                                 </td>
                                 <td align="center" valign="top">
                                    <paragraph>14 (4)</paragraph>
                                 </td>
                              </tr>
                              <tr>
                                 <td valign="top">
                                    <paragraph>  Nervousness</paragraph>
                                 </td>
                                 <td align="center" valign="top">
                                    <paragraph>6 (2)</paragraph>
                                 </td>
                                 <td align="center" valign="top">
                                    <paragraph>3 (1)</paragraph>
                                 </td>
                                 <td align="center" valign="top">
                                    <paragraph>4 (1)</paragraph>
                                 </td>
                                 <td align="center" valign="top">
                                    <paragraph>6 (2)</paragraph>
                                 </td>
                              </tr>
                              <tr>
                                 <td valign="top">
                                    <paragraph>
                                       <content styleCode="bold">Skin and Appendages</content>
                                    </paragraph>
                                 </td>
                                 <td valign="top"/>
                                 <td valign="top"/>
                                 <td valign="top"/>
                                 <td valign="top"/>
                              </tr>
                              <tr>
                                 <td valign="top">
                                    <paragraph>  Acne</paragraph>
                                 </td>
                                 <td align="center" valign="top">
                                    <paragraph>7 (2)</paragraph>
                                 </td>
                                 <td align="center" valign="top">
                                    <paragraph>3 (1)</paragraph>
                                 </td>
                                 <td align="center" valign="top">
                                    <paragraph>0</paragraph>
                                 </td>
                                 <td align="center" valign="top">
                                    <paragraph>3 (1)</paragraph>
                                 </td>
                              </tr>
                              <tr>
                                 <td valign="top">
                                    <paragraph>  Alopecia</paragraph>
                                 </td>
                                 <td align="center" valign="top">
                                    <paragraph>1 (0)</paragraph>
                                 </td>
                                 <td align="center" valign="top">
                                    <paragraph>6 (2)</paragraph>
                                 </td>
                                 <td align="center" valign="top">
                                    <paragraph>4 (1)</paragraph>
                                 </td>
                                 <td align="center" valign="top">
                                    <paragraph>2 (1)</paragraph>
                                 </td>
                              </tr>
                              <tr>
                                 <td valign="top">
                                    <paragraph>  Pruritus</paragraph>
                                 </td>
                                 <td align="center" valign="top">
                                    <paragraph>8 (2)</paragraph>
                                 </td>
                                 <td align="center" valign="top">
                                    <paragraph>10 (3)</paragraph>
                                 </td>
                                 <td align="center" valign="top">
                                    <paragraph>9 (3)</paragraph>
                                 </td>
                                 <td align="center" valign="top">
                                    <paragraph>3 (1)</paragraph>
                                 </td>
                              </tr>
                              <tr>
                                 <td valign="top">
                                    <paragraph>  Rash</paragraph>
                                 </td>
                                 <td align="center" valign="top">
                                    <paragraph>0</paragraph>
                                 </td>
                                 <td align="center" valign="top">
                                    <paragraph>6 (2)</paragraph>
                                 </td>
                                 <td align="center" valign="top">
                                    <paragraph>4 (1)</paragraph>
                                 </td>
                                 <td align="center" valign="top">
                                    <paragraph>2 (1)</paragraph>
                                 </td>
                              </tr>
                              <tr>
                                 <td valign="top">
                                    <paragraph>  Skin discoloration</paragraph>
                                 </td>
                                 <td align="center" valign="top">
                                    <paragraph>5 (2)</paragraph>
                                 </td>
                                 <td align="center" valign="top">
                                    <paragraph>1 (0)</paragraph>
                                 </td>
                                 <td align="center" valign="top">
                                    <paragraph>3 (1)</paragraph>
                                 </td>
                                 <td align="center" valign="top">
                                    <paragraph>1 (0)</paragraph>
                                 </td>
                              </tr>
                              <tr>
                                 <td valign="top">
                                    <paragraph>  Sweating</paragraph>
                                 </td>
                                 <td align="center" valign="top">
                                    <paragraph>3 (1)</paragraph>
                                 </td>
                                 <td align="center" valign="top">
                                    <paragraph>1 (0)</paragraph>
                                 </td>
                                 <td align="center" valign="top">
                                    <paragraph>0</paragraph>
                                 </td>
                                 <td align="center" valign="top">
                                    <paragraph>4 (1)</paragraph>
                                 </td>
                              </tr>
                              <tr>
                                 <td valign="top">
                                    <paragraph>
                                       <content styleCode="bold">Urogenital System</content>
                                    </paragraph>
                                 </td>
                                 <td valign="top"/>
                                 <td valign="top"/>
                                 <td valign="top"/>
                                 <td valign="top"/>
                              </tr>
                              <tr>
                                 <td valign="top">
                                    <paragraph>  Breast disorder</paragraph>
                                 </td>
                                 <td align="center" valign="top">
                                    <paragraph>7 (2)</paragraph>
                                 </td>
                                 <td align="center" valign="top">
                                    <paragraph>6 (2)</paragraph>
                                 </td>
                                 <td align="center" valign="top">
                                    <paragraph>5 (2)</paragraph>
                                 </td>
                                 <td align="center" valign="top">
                                    <paragraph>6 (2)</paragraph>
                                 </td>
                              </tr>
                              <tr>
                                 <td valign="top">
                                    <paragraph>  Breast enlargement</paragraph>
                                 </td>
                                 <td align="center" valign="top">
                                    <paragraph>18 (5)</paragraph>
                                 </td>
                                 <td align="center" valign="top">
                                    <paragraph>9 (3)</paragraph>
                                 </td>
                                 <td align="center" valign="top">
                                    <paragraph>5 (2)</paragraph>
                                 </td>
                                 <td align="center" valign="top">
                                    <paragraph>3 (1)</paragraph>
                                 </td>
                              </tr>
                              <tr>
                                 <td valign="top">
                                    <paragraph>  Breast neoplasm</paragraph>
                                 </td>
                                 <td align="center" valign="top">
                                    <paragraph>8 (2)</paragraph>
                                 </td>
                                 <td align="center" valign="top">
                                    <paragraph>7 (2)</paragraph>
                                 </td>
                                 <td align="center" valign="top">
                                    <paragraph>5 (2)</paragraph>
                                 </td>
                                 <td align="center" valign="top">
                                    <paragraph>7 (2)</paragraph>
                                 </td>
                              </tr>
                              <tr>
                                 <td valign="top">
                                    <paragraph>  Breast pain</paragraph>
                                 </td>
                                 <td align="center" valign="top">
                                    <paragraph>87 (26)</paragraph>
                                 </td>
                                 <td align="center" valign="top">
                                    <paragraph>66 (20)</paragraph>
                                 </td>
                                 <td align="center" valign="top">
                                    <paragraph>41 (13)</paragraph>
                                 </td>
                                 <td align="center" valign="top">
                                    <paragraph>26 (8)</paragraph>
                                 </td>
                              </tr>
                              <tr>
                                 <td valign="top">
                                    <paragraph>  Cervix disorder</paragraph>
                                 </td>
                                 <td align="center" valign="top">
                                    <paragraph>7 (2)</paragraph>
                                 </td>
                                 <td align="center" valign="top">
                                    <paragraph>2 (1)</paragraph>
                                 </td>
                                 <td align="center" valign="top">
                                    <paragraph>2 (1)</paragraph>
                                 </td>
                                 <td align="center" valign="top">
                                    <paragraph>0</paragraph>
                                 </td>
                              </tr>
                              <tr>
                                 <td valign="top">
                                    <paragraph>  Dysmenorrhea</paragraph>
                                 </td>
                                 <td align="center" valign="top">
                                    <paragraph>14 (4)</paragraph>
                                 </td>
                                 <td align="center" valign="top">
                                    <paragraph>18 (5)</paragraph>
                                 </td>
                                 <td align="center" valign="top">
                                    <paragraph>9 (3)</paragraph>
                                 </td>
                                 <td align="center" valign="top">
                                    <paragraph>2 (1)</paragraph>
                                 </td>
                              </tr>
                              <tr>
                                 <td valign="top">
                                    <paragraph>  Hematuria</paragraph>
                                 </td>
                                 <td align="center" valign="top">
                                    <paragraph>4 (1)</paragraph>
                                 </td>
                                 <td align="center" valign="top">
                                    <paragraph>3 (1)</paragraph>
                                 </td>
                                 <td align="center" valign="top">
                                    <paragraph>1 (0)</paragraph>
                                 </td>
                                 <td align="center" valign="top">
                                    <paragraph>2 (1)</paragraph>
                                 </td>
                              </tr>
                              <tr>
                                 <td valign="top">
                                    <paragraph>  Leukorrhea</paragraph>
                                 </td>
                                 <td align="center" valign="top">
                                    <paragraph>7 (2)</paragraph>
                                 </td>
                                 <td align="center" valign="top">
                                    <paragraph>14 (4)</paragraph>
                                 </td>
                                 <td align="center" valign="top">
                                    <paragraph>9 (3)</paragraph>
                                 </td>
                                 <td align="center" valign="top">
                                    <paragraph>6 (2)</paragraph>
                                 </td>
                              </tr>
                              <tr>
                                 <td valign="top">
                                    <paragraph>  Metrorrhagia</paragraph>
                                 </td>
                                 <td align="center" valign="top">
                                    <paragraph>7 (2)</paragraph>
                                 </td>
                                 <td align="center" valign="top">
                                    <paragraph>14 (4)</paragraph>
                                 </td>
                                 <td align="center" valign="top">
                                    <paragraph>4 (1)</paragraph>
                                 </td>
                                 <td align="center" valign="top">
                                    <paragraph>1 (0)</paragraph>
                                 </td>
                              </tr>
                              <tr>
                                 <td valign="top">
                                    <paragraph>  Urinary tract infection</paragraph>
                                 </td>
                                 <td align="center" valign="top">
                                    <paragraph>0</paragraph>
                                 </td>
                                 <td align="center" valign="top">
                                    <paragraph>1 (0)</paragraph>
                                 </td>
                                 <td align="center" valign="top">
                                    <paragraph>1 (0)</paragraph>
                                 </td>
                                 <td align="center" valign="top">
                                    <paragraph>4 (1)</paragraph>
                                 </td>
                              </tr>
                              <tr>
                                 <td valign="top">
                                    <paragraph>  Uterine spasm</paragraph>
                                 </td>
                                 <td align="center" valign="top">
                                    <paragraph>13 (4)</paragraph>
                                 </td>
                                 <td align="center" valign="top">
                                    <paragraph>11 (3)</paragraph>
                                 </td>
                                 <td align="center" valign="top">
                                    <paragraph>7 (2)</paragraph>
                                 </td>
                                 <td align="center" valign="top">
                                    <paragraph>2 (1)</paragraph>
                                 </td>
                              </tr>
                              <tr>
                                 <td valign="top">
                                    <paragraph>  Vaginal dryness</paragraph>
                                 </td>
                                 <td align="center" valign="top">
                                    <paragraph>2 (1)</paragraph>
                                 </td>
                                 <td align="center" valign="top">
                                    <paragraph>1 (0)</paragraph>
                                 </td>
                                 <td align="center" valign="top">
                                    <paragraph>0</paragraph>
                                 </td>
                                 <td align="center" valign="top">
                                    <paragraph>6 (2)</paragraph>
                                 </td>
                              </tr>
                              <tr>
                                 <td valign="top">
                                    <paragraph>  Vaginal hemorrhage</paragraph>
                                 </td>
                                 <td align="center" valign="top">
                                    <paragraph>18 (5)</paragraph>
                                 </td>
                                 <td align="center" valign="top">
                                    <paragraph>14 (4)</paragraph>
                                 </td>
                                 <td align="center" valign="top">
                                    <paragraph>7 (2)</paragraph>
                                 </td>
                                 <td align="center" valign="top">
                                    <paragraph>0</paragraph>
                                 </td>
                              </tr>
                              <tr>
                                 <td valign="top">
                                    <paragraph>  Vaginal moniliasis</paragraph>
                                 </td>
                                 <td align="center" valign="top">
                                    <paragraph>13 (4)</paragraph>
                                 </td>
                                 <td align="center" valign="top">
                                    <paragraph>11 (3)</paragraph>
                                 </td>
                                 <td align="center" valign="top">
                                    <paragraph>8 (2)</paragraph>
                                 </td>
                                 <td align="center" valign="top">
                                    <paragraph>5 (2)</paragraph>
                                 </td>
                              </tr>
                              <tr>
                                 <td styleCode="Botrule " valign="top">
                                    <paragraph>  Vaginitis</paragraph>
                                 </td>
                                 <td align="center" styleCode="Botrule " valign="top">
                                    <paragraph>6 (2)</paragraph>
                                 </td>
                                 <td align="center" styleCode="Botrule " valign="top">
                                    <paragraph>8 (2)</paragraph>
                                 </td>
                                 <td align="center" styleCode="Botrule " valign="top">
                                    <paragraph>7 (2)</paragraph>
                                 </td>
                                 <td align="center" styleCode="Botrule " valign="top">
                                    <paragraph>1 (0)</paragraph>
                                 </td>
                              </tr>
                           </tbody>
                        </table>
                        <paragraph>In addition, the following events were considered as related to the study drug with an incidence less than 1%, including accidental injury, infection, myalgia, cough increased, rhinitis, sinusitis, and upper respiratory infection.</paragraph>
                     </text>
                     <effectiveTime value="20250429"/>
                  </section>
               </component>
               <component>
                  <section ID="S6.2">
                     <id root="2d72c3a7-038b-44f1-b1a8-5433a5e86db8"/>
                     <code code="90375-7" codeSystem="2.16.840.1.113883.6.1" displayName="POSTMARKETING EXPERIENCE SECTION"/>
                     <title>6.2 Postmarketing Experience</title>
                     <text>
                        <paragraph>The following adverse reactions have been identified during post-approval use of PREMPRO or PREMPHASE. Because these reactions are reported voluntarily from a population of uncertain size, it is not always possible to reliably estimate their frequency or establish a causal relationship to drug exposure.</paragraph>
                     </text>
                     <effectiveTime value="20250429"/>
                     <component>
                        <section ID="genitourinary">
                           <id root="4b8c1c64-ac3a-4df2-aa05-51d5ffd7d4c4"/>
                           <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                           <text>
                              <paragraph>
                                 <content styleCode="bold">
                                    <content styleCode="italics">Genitourinary System</content>
                                 </content>
                              </paragraph>
                              <paragraph>Abnormal uterine bleeding, dysmenorrhea or pelvic pain, increase in size of uterine leiomyomata, vaginitis, vaginal candidiasis, amenorrhea, changes in cervical secretion, ovarian cancer, endometrial hyperplasia, endometrial cancer.</paragraph>
                           </text>
                           <effectiveTime value="20250429"/>
                        </section>
                     </component>
                     <component>
                        <section ID="breasts">
                           <id root="cf617648-a462-4bd0-916a-41fd81a4706a"/>
                           <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                           <text>
                              <paragraph>
                                 <content styleCode="bold">
                                    <content styleCode="italics">Breasts</content>
                                 </content>
                              </paragraph>
                              <paragraph>Tenderness, enlargement, pain, nipple discharge, galactorrhea, fibrocystic breast changes, breast cancer.</paragraph>
                           </text>
                           <effectiveTime value="20250429"/>
                        </section>
                     </component>
                     <component>
                        <section ID="cardiovascular">
                           <id root="edcc03c7-9b6c-4ab0-8509-76e80372d4f8"/>
                           <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                           <text>
                              <paragraph>
                                 <content styleCode="bold">
                                    <content styleCode="italics">Cardiovascular</content>
                                 </content>
                              </paragraph>
                              <paragraph>Deep and superficial venous thrombosis, pulmonary embolism, superficial thrombophlebitis, myocardial infarction, stroke, increase in blood pressure.</paragraph>
                           </text>
                           <effectiveTime value="20250429"/>
                        </section>
                     </component>
                     <component>
                        <section ID="gastro">
                           <id root="10cada72-2732-4c05-bc8d-9fab0aaeae52"/>
                           <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                           <text>
                              <paragraph>
                                 <content styleCode="bold">
                                    <content styleCode="italics">Gastrointestinal</content>
                                 </content>
                              </paragraph>
                              <paragraph>Nausea, vomiting, abdominal pain, bloating, cholestatic jaundice, increased incidence of gallbladder disease, pancreatitis, changes in appetite, ischemic colitis.</paragraph>
                           </text>
                           <effectiveTime value="20250429"/>
                        </section>
                     </component>
                     <component>
                        <section ID="skin">
                           <id root="7d61b448-6c9a-4bf0-b430-f8098e7024ce"/>
                           <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                           <text>
                              <paragraph>
                                 <content styleCode="bold">
                                    <content styleCode="italics">Skin</content>
                                 </content>
                              </paragraph>
                              <paragraph>Chloasma or melasma that may persist when drug is discontinued, erythema multiforme, erythema nodosum, loss of scalp hair, hirsutism, pruritus, urticaria, rash, acne.</paragraph>
                           </text>
                           <effectiveTime value="20250429"/>
                        </section>
                     </component>
                     <component>
                        <section ID="ID_2975d8a5-aac8-457e-8aec-19d7fbe798d6">
                           <id root="b10ca460-46ab-47a8-8d51-c59144e1616c"/>
                           <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                           <text>
                              <paragraph>
                                 <content styleCode="bold">
                                    <content styleCode="italics">Eyes</content>
                                 </content>
                              </paragraph>
                              <paragraph>Retinal vascular thrombosis, intolerance of contact lenses.</paragraph>
                           </text>
                           <effectiveTime value="20250429"/>
                        </section>
                     </component>
                     <component>
                        <section ID="CNS">
                           <id root="8674860a-4988-4d16-9e01-5ae915936f6d"/>
                           <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                           <text>
                              <paragraph>
                                 <content styleCode="bold">
                                    <content styleCode="italics">Central Nervous System </content>
                                 </content>
                              </paragraph>
                              <paragraph>Headache, migraine, dizziness, mental depression, exacerbation of chorea, mood disturbances, anxiety, irritability, exacerbation of epilepsy, dementia, growth potentiation of benign meningioma.</paragraph>
                           </text>
                           <effectiveTime value="20250429"/>
                        </section>
                     </component>
                     <component>
                        <section ID="misc">
                           <id root="58b2fc1f-fa6a-4a5a-91a2-469ecdfd952d"/>
                           <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                           <text>
                              <paragraph>
                                 <content styleCode="bold">
                                    <content styleCode="italics">Miscellaneous</content>
                                 </content>
                              </paragraph>
                              <paragraph>Increase or decrease in weight, arthralgia, glucose intolerance, edema, changes in libido, exacerbation of asthma, increased triglycerides, hypersensitivity.</paragraph>
                              <paragraph>Additional postmarketing adverse reactions have been reported in patients receiving other forms of hormone therapy.</paragraph>
                           </text>
                           <effectiveTime value="20250429"/>
                        </section>
                     </component>
                  </section>
               </component>
            </section>
         </component>
         <component>
            <section ID="S7">
               <id root="d520c463-d3ff-4159-ac40-ccbb5d43ebf7"/>
               <code code="34073-7" codeSystem="2.16.840.1.113883.6.1" displayName="DRUG INTERACTIONS SECTION"/>
               <title>7 DRUG INTERACTIONS</title>
               <text>
                  <paragraph>Data from a single-dose drug-drug interaction study involving CE and MPA indicate that the pharmacokinetic disposition of both drugs is not altered when the drugs are coadministered. No other clinical drug-drug interaction studies have been conducted with CE plus MPA.</paragraph>
               </text>
               <effectiveTime value="20250429"/>
               <excerpt>
                  <highlight>
                     <text>
                        <list listType="unordered">
                           <item>
                              <caption>•</caption>Inducers and/or inhibitors of CYP3A4 may affect estrogen drug metabolism (<linkHtml href="#S7.1">7.1</linkHtml>)</item>
                           <item>
                              <caption>•</caption>Aminoglutethimide administered concomitantly with MPA may significantly depress the bioavailability of medroxyprogesterone acetate (<linkHtml href="#S7.1">7.1</linkHtml>)</item>
                        </list>
                     </text>
                  </highlight>
               </excerpt>
               <component>
                  <section ID="S7.1">
                     <id root="2f0db19b-b96c-45a2-9a0a-58a93ee0b623"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title>7.1 Metabolic Interactions</title>
                     <text>
                        <paragraph>
                           <content styleCode="italics">In vitro</content> and <content styleCode="italics">in vivo</content> studies have shown that estrogens are metabolized partially by cytochrome P450 3A4 (CYP3A4). Therefore, inducers or inhibitors of CYP3A4 may affect estrogen drug metabolism. Inducers of CYP3A4, such as St. John's wort (<content styleCode="italics">Hypericum perforatum</content>) preparations, phenobarbital, carbamazepine, and rifampin, may reduce plasma concentrations of estrogens, possibly resulting in a decrease in therapeutic effects and/or changes in the uterine bleeding profile. Inhibitors of CYP3A4, such as erythromycin, clarithromycin, ketoconazole, itraconazole, ritonavir and grapefruit juice, may increase plasma concentrations of estrogens and may result in side effects.</paragraph>
                        <paragraph>Aminoglutethimide administered concomitantly with MPA may significantly depress the bioavailability of MPA.</paragraph>
                     </text>
                     <effectiveTime value="20190531"/>
                  </section>
               </component>
            </section>
         </component>
         <component>
            <section ID="S8">
               <id root="b3823d47-a7f4-4f09-809e-55b0e08950a7"/>
               <code code="43684-0" codeSystem="2.16.840.1.113883.6.1" displayName="USE IN SPECIFIC POPULATIONS SECTION"/>
               <title>8 USE IN SPECIFIC POPULATIONS</title>
               <effectiveTime value="20250429"/>
               <excerpt>
                  <highlight>
                     <text>
                        <list listType="unordered">
                           <item>
                              <caption>•</caption>Lactation: Estrogen administration to lactating women has been shown to decrease the quantity and quality of breast milk (<linkHtml href="#S8.3">8.2</linkHtml>)</item>
                           <item>
                              <caption>•</caption>Geriatric Use: An increased risk of probable dementia in women over 65 years of age was reported in the Women's Health Initiative Memory ancillary studies of the Women's Health Initiative (<linkHtml href="#S5.3">5.3</linkHtml>, <linkHtml href="#S8.5">8.5</linkHtml>)</item>
                        </list>
                     </text>
                  </highlight>
               </excerpt>
               <component>
                  <section ID="S8.1">
                     <id root="f8c9389a-4620-402d-af89-aa91e7e587ac"/>
                     <code code="42228-7" codeSystem="2.16.840.1.113883.6.1" displayName="PREGNANCY SECTION"/>
                     <title>8.1 Pregnancy</title>
                     <text>
                        <paragraph>
                           <content styleCode="bold">
                              <content styleCode="italics">Risk Summary</content>
                           </content>
                        </paragraph>
                        <paragraph>PREMPRO and PREMPHASE are not indicated for use during pregnancy.</paragraph>
                        <paragraph>There are no data with the use of PREMPRO and PREMPHASE in pregnant women; however, epidemiologic studies and meta-analyses have not found an increased risk of genital or nongenital birth defects (including cardiac anomalies and limb-reduction defects) following exposure to combined hormonal contraceptives (estrogen and progestins) before conception or during early pregnancy. </paragraph>
                        <paragraph>In the U.S. general population, the estimated background risk of major birth defects and miscarriage in clinically recognized pregnancies is 2% to 4% and 15% to 20%, respectively.</paragraph>
                     </text>
                     <effectiveTime value="20250429"/>
                  </section>
               </component>
               <component>
                  <section ID="S8.3">
                     <id root="10158acd-49ac-4967-b2f0-b16da201b64a"/>
                     <code code="77290-5" codeSystem="2.16.840.1.113883.6.1" displayName="LACTATION SECTION"/>
                     <title>8.2 Lactation</title>
                     <text>
                        <paragraph>
                           <content styleCode="bold">
                              <content styleCode="italics">Risk Summary</content>
                           </content>
                        </paragraph>
                        <paragraph>Estrogens and progestins and metabolites are present in human milk. These hormones can reduce milk production in breast-feeding women. This reduction can occur at any time but is less likely to occur once breast-feeding is well established. The developmental and health benefits of breast-feeding should be considered along with the mother’s clinical need for PREMPRO or PREMPHASE and any potential adverse effects on the breast-fed child from PREMPRO or PREMPHASE or from the underlying maternal condition.</paragraph>
                     </text>
                     <effectiveTime value="20250429"/>
                  </section>
               </component>
               <component>
                  <section ID="S8.4">
                     <id root="91f98f95-7b4d-48a9-992f-90d97686679a"/>
                     <code code="34081-0" codeSystem="2.16.840.1.113883.6.1" displayName="PEDIATRIC USE SECTION"/>
                     <title>8.4 Pediatric Use</title>
                     <text>
                        <paragraph>PREMPRO and PREMPHASE are not indicated in children. Clinical studies have not been conducted in the pediatric population.</paragraph>
                     </text>
                     <effectiveTime value="20190531"/>
                  </section>
               </component>
               <component>
                  <section ID="S8.5">
                     <id root="8814ae98-37a1-409f-ab5a-86d15fa03831"/>
                     <code code="34082-8" codeSystem="2.16.840.1.113883.6.1" displayName="GERIATRIC USE SECTION"/>
                     <title>8.5 Geriatric Use</title>
                     <text>
                        <paragraph>There have not been sufficient numbers of geriatric women involved in clinical studies utilizing PREMPRO or PREMPHASE to determine whether those over 65 years of age differ from younger subjects in their response to PREMPRO or PREMPHASE.</paragraph>
                     </text>
                     <effectiveTime value="20250429"/>
                     <component>
                        <section ID="healthinitiative">
                           <id root="9bc9843c-cf98-43b3-b457-fc0a7cbfce28"/>
                           <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                           <text>
                              <paragraph>
                                 <content styleCode="bold">
                                    <content styleCode="italics">The Women's Health Initiative Study</content>
                                 </content>
                              </paragraph>
                              <paragraph>In the WHI estrogen plus progestin substudy (daily CE [0.625 mg] plus MPA [2.5 mg] versus placebo), there was a higher relative risk of nonfatal stroke and invasive breast cancer in women greater than 65 years of age <content styleCode="italics">[see <linkHtml href="#S14.6">Clinical Studies (14.6)</linkHtml>]</content>.</paragraph>
                              <paragraph>In the WHI estrogen-alone substudy (daily CE [0.625 mg]-alone versus placebo), there was a higher relative risk of stroke in women greater than 65 years of age <content styleCode="italics">[see <linkHtml href="#S14.6">Clinical Studies (14.6)</linkHtml>]</content>.</paragraph>
                           </text>
                           <effectiveTime value="20250429"/>
                        </section>
                     </component>
                     <component>
                        <section ID="memorystudy">
                           <id root="3b36f79c-85a6-432f-b53c-3cc9614c5929"/>
                           <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                           <text>
                              <paragraph>
                                 <content styleCode="bold">
                                    <content styleCode="italics">The Women's Health Initiative Memory Study</content>
                                 </content>
                              </paragraph>
                              <paragraph>In the WHIMS ancillary studies of postmenopausal women 65 to 79 years of age, there was an increased risk of developing probable dementia in women receiving estrogen plus progestin or estrogen-alone when compared to placebo <content styleCode="italics">[see <linkHtml href="#S5.3">Warnings and Precautions (5.3)</linkHtml>, and <linkHtml href="#S14.7">Clinical Studies (14.7)</linkHtml>]</content>.</paragraph>
                              <paragraph>Since both ancillary studies were conducted in women 65 to 79 years of age, it is unknown whether these findings apply to younger postmenopausal women<sup>8 </sup>
                                 <content styleCode="italics">[see <linkHtml href="#S5.3">Warnings and Precautions (5.3)</linkHtml>, and <linkHtml href="#S14.7">Clinical Studies (14.7)</linkHtml>]</content>.</paragraph>
                           </text>
                           <effectiveTime value="20250429"/>
                        </section>
                     </component>
                  </section>
               </component>
               <component>
                  <section ID="S8.6">
                     <id root="6c2a6c5b-dc71-41a4-918b-52682343142b"/>
                     <code code="88828-9" codeSystem="2.16.840.1.113883.6.1" displayName="RENAL IMPAIRMENT SUBSECTION"/>
                     <title>8.6 Renal Impairment</title>
                     <text>
                        <paragraph>The effects of renal impairment on the pharmacokinetics of PREMPRO or PREMPHASE have not been studied.</paragraph>
                     </text>
                     <effectiveTime value="20240215"/>
                  </section>
               </component>
               <component>
                  <section ID="S8.7">
                     <id root="32befff1-392c-419c-8cd4-7cb4151143bd"/>
                     <code code="88829-7" codeSystem="2.16.840.1.113883.6.1" displayName="HEPATIC IMPAIRMENT SUBSECTION"/>
                     <title>8.7 Hepatic Impairment</title>
                     <text>
                        <paragraph>The effects of hepatic impairment on the pharmacokinetics of PREMPRO or PREMPHASE have not been studied.</paragraph>
                     </text>
                     <effectiveTime value="20240215"/>
                  </section>
               </component>
            </section>
         </component>
         <component>
            <section ID="S10">
               <id root="a2afd308-0b0f-4fce-b212-88f8567b5790"/>
               <code code="34088-5" codeSystem="2.16.840.1.113883.6.1" displayName="OVERDOSAGE SECTION"/>
               <title>10 OVERDOSAGE</title>
               <text>
                  <paragraph>Overdosage of estrogen plus progestin may cause nausea, vomiting, breast tenderness, abdominal pain, drowsiness and fatigue, and withdrawal bleeding may occur in women. Treatment of overdose consists of discontinuation of PREMPRO or PREMPHASE therapy with institution of appropriate symptomatic care.</paragraph>
               </text>
               <effectiveTime value="20190531"/>
            </section>
         </component>
         <component>
            <section ID="S11">
               <id root="a0bdd89b-f94c-4c25-b8b5-5c763bbc8eaf"/>
               <code code="34089-3" codeSystem="2.16.840.1.113883.6.1" displayName="DESCRIPTION SECTION"/>
               <title>11 DESCRIPTION</title>
               <text>
                  <paragraph>Premarin (conjugated estrogens tablets, USP) for oral administration contains a mixture obtained exclusively from natural sources, occurring as the sodium salts of water-soluble estrogen sulfates blended to represent the average composition of material derived from pregnant mares' urine. It is a mixture of sodium estrone sulfate and sodium equilin sulfate. It contains as concomitant components, as sodium sulfate conjugates, 17 α-dihydroequilin, 17 α-estradiol and 17 β-dihydroequilin.</paragraph>
                  <paragraph>Medroxyprogesterone acetate is a derivative of progesterone. It is a white to off-white, odorless, crystalline powder, stable in air, melting between 200°C and 210°C. It is freely soluble in chloroform, soluble in acetone and in dioxane, sparingly soluble in alcohol and in methanol, slightly soluble in ether, and insoluble in water. The chemical name for MPA is pregn-4-ene-3, 20-dione, 17-(acetyloxy)-6-methyl-, (6α)-. Its molecular formula is C<sub>24</sub>H<sub>34</sub>O<sub>4</sub>, with a molecular weight of 386.53. Its structural formula is:</paragraph>
                  <renderMultiMedia ID="id3401" referencedObject="MM1"/>
                  <paragraph>PREMPRO 0.3 mg/1.5 mg and 0.45 mg/1.5 mg tablets contain the following inactive ingredients: calcium phosphate tribasic, microcrystalline cellulose, carnauba wax, hypromellose, hydroxypropyl cellulose, sucrose, Eudragit NE 30D, lactose monohydrate, magnesium stearate, polyethylene glycol, titanium dioxide, yellow iron oxide, propylene glycol and black iron oxide.</paragraph>
                  <paragraph>PREMPRO 0.625 mg/2.5 mg tablets contain the following inactive ingredients: calcium phosphate tribasic, microcrystalline cellulose, carnauba wax, hypromellose, hydroxypropyl cellulose, sucrose, Eudragit NE 30D, lactose monohydrate, magnesium stearate, polyethylene glycol, propylene glycol, titanium dioxide, red iron oxide, yellow iron oxide, and black iron oxide.</paragraph>
                  <paragraph>PREMPRO 0.625 mg/5 mg tablets contain the following inactive ingredients: calcium phosphate tribasic, carnauba wax, Eudragit NE 30D, hydroxypropyl cellulose, hypromellose, lactose monohydrate, magnesium stearate, microcrystalline cellulose, polyethylene glycol, sucrose, titanium dioxide, triethyl citrate, FD&amp;C Blue No. 2, black iron oxide, and propylene glycol.</paragraph>
               </text>
               <effectiveTime value="20250429"/>
               <component>
                  <section ID="ID_3faa83bb-bc47-41a6-9a47-ff53681ab739">
                     <id root="285a95ef-2b05-4801-9a4a-7cb34a19a50e"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <text>
                        <paragraph>
                           <content styleCode="bold">PREMPHASE</content>
                        </paragraph>
                        <paragraph>Each maroon Premarin tablets for oral administration contain 0.625 mg of CE and the following inactive ingredients: calcium phosphate tribasic, carnauba wax, hydroxypropyl cellulose, microcrystalline cellulose, powdered cellulose, hypromellose, lactose monohydrate, magnesium stearate, polyethylene glycol, sucrose, titanium dioxide, propylene glycol, FD&amp;C Blue No. 2, and FD&amp;C Red No. 40. These tablets comply with USP Dissolution Test 5.</paragraph>
                        <paragraph>Each light-blue tablet for oral administration contains 0.625 mg of CE, 5 mg of medroxyprogesterone acetate, and the following inactive ingredients: calcium phosphate tribasic, carnauba wax, Eudragit NE 30D, hydroxypropyl cellulose, hypromellose, lactose monohydrate, magnesium stearate, microcrystalline cellulose, polyethylene glycol, sucrose, titanium dioxide, triethyl citrate, FD&amp;C Blue No. 2, black iron oxide, and propylene glycol.</paragraph>
                     </text>
                     <effectiveTime value="20250429"/>
                  </section>
               </component>
               <component>
                  <section ID="ID_e3f63687-96e3-4ef2-8656-5d358a7c24ea">
                     <id root="54954323-6313-4d9b-9597-6e89c30f6d5d"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <text>
                        <paragraph>PREMPRO</paragraph>
                        <table styleCode="Noautorules" width="100%">
                           <col width="25%"/>
                           <col width="75%"/>
                           <tbody>
                              <tr>
                                 <td styleCode="Rrule Botrule Lrule Toprule " valign="top">
                                    <paragraph>
                                       <content styleCode="bold">Tablet Strength</content>
                                    </paragraph>
                                 </td>
                                 <td align="center" styleCode="Rrule Botrule Lrule Toprule " valign="top">
                                    <paragraph>
                                       <content styleCode="bold">Tablet Color Contains</content>
                                    </paragraph>
                                 </td>
                              </tr>
                              <tr>
                                 <td styleCode="Rrule Lrule Botrule " valign="top">
                                    <paragraph>0.3 mg/1.5 mg</paragraph>
                                 </td>
                                 <td styleCode="Rrule Lrule Toprule Botrule " valign="top">
                                    <paragraph>Yellow iron oxide and black iron oxide</paragraph>
                                 </td>
                              </tr>
                              <tr>
                                 <td styleCode="Rrule Lrule Botrule " valign="top">
                                    <paragraph>0.45 mg/1.5 mg</paragraph>
                                 </td>
                                 <td styleCode="Rrule Lrule Toprule Botrule " valign="top">
                                    <paragraph>Yellow iron oxide and black iron oxide</paragraph>
                                 </td>
                              </tr>
                              <tr>
                                 <td styleCode="Rrule Lrule Botrule " valign="top">
                                    <paragraph>0.625 mg/2.5 mg</paragraph>
                                 </td>
                                 <td styleCode="Rrule Lrule Toprule Botrule " valign="top">
                                    <paragraph>Red iron oxide, yellow iron oxide, and black iron oxide</paragraph>
                                 </td>
                              </tr>
                              <tr>
                                 <td styleCode="Rrule Botrule Lrule Toprule " valign="top">
                                    <paragraph>0.625 mg/5 mg</paragraph>
                                 </td>
                                 <td styleCode="Rrule Botrule Lrule Toprule " valign="top">
                                    <paragraph>FD&amp;C Blue No. 2 and black iron oxide</paragraph>
                                 </td>
                              </tr>
                           </tbody>
                        </table>
                        <paragraph>PREMPHASE</paragraph>
                        <table styleCode="Noautorules" width="100%">
                           <col width="25%"/>
                           <col width="75%"/>
                           <tbody>
                              <tr>
                                 <td styleCode="Rrule Botrule Lrule Toprule " valign="top">
                                    <paragraph>
                                       <content styleCode="bold">Tablet Strength</content>
                                    </paragraph>
                                 </td>
                                 <td align="center" styleCode="Rrule Botrule Lrule Toprule " valign="top">
                                    <paragraph>
                                       <content styleCode="bold">Tablet Color Contains</content>
                                    </paragraph>
                                 </td>
                              </tr>
                              <tr>
                                 <td styleCode="Rrule Lrule Botrule " valign="top">
                                    <paragraph>0.625 mg</paragraph>
                                 </td>
                                 <td styleCode="Rrule Lrule Toprule Botrule " valign="top">
                                    <paragraph>FD&amp;C Blue No. 2 and FD&amp;C Red No. 40</paragraph>
                                 </td>
                              </tr>
                              <tr>
                                 <td styleCode="Rrule Botrule Lrule Toprule " valign="top">
                                    <paragraph>0.625 mg/5 mg</paragraph>
                                 </td>
                                 <td styleCode="Rrule Botrule Lrule Toprule " valign="top">
                                    <paragraph>FD&amp;C Blue No. 2 and black iron oxide</paragraph>
                                 </td>
                              </tr>
                           </tbody>
                        </table>
                     </text>
                     <effectiveTime value="20240215"/>
                  </section>
               </component>
               <component>
                  <observationMedia ID="MM1">
                     <text>Chemical Structure</text>
                     <value mediaType="image/jpeg" xsi:type="ED">
                        <reference value="prempro-01.jpg"/>
                     </value>
                  </observationMedia>
               </component>
            </section>
         </component>
         <component>
            <section ID="S12">
               <id root="d7a077e8-7c14-4e7c-b4d2-87e5fed1b2d7"/>
               <code code="34090-1" codeSystem="2.16.840.1.113883.6.1" displayName="CLINICAL PHARMACOLOGY SECTION"/>
               <title>12 CLINICAL PHARMACOLOGY </title>
               <effectiveTime value="20250429"/>
               <component>
                  <section ID="S12.1">
                     <id root="b0d4c9be-b366-49f8-a322-c7c68934b928"/>
                     <code code="43679-0" codeSystem="2.16.840.1.113883.6.1" displayName="MECHANISM OF ACTION SECTION"/>
                     <title>12.1 Mechanism of Action</title>
                     <text>
                        <paragraph>Endogenous estrogens are largely responsible for the development and maintenance of the female reproductive system and secondary sexual characteristics. Although circulating estrogens exist in a dynamic equilibrium of metabolic interconversions, estradiol is the principal intracellular human estrogen and is substantially more potent than its metabolites, estrone and estriol, at the receptor level.</paragraph>
                        <paragraph>The primary source of estrogen in normally cycling adult women is the ovarian follicle, which secretes 70 to 500 mcg of estradiol daily, depending on the phase of the menstrual cycle. After menopause, most endogenous estrogen is produced by conversion of androstenedione, which is secreted by the adrenal cortex, to estrone in the peripheral tissues. Thus, estrone and the sulfate-conjugated form, estrone sulfate, are the most abundant circulating estrogens in postmenopausal women.</paragraph>
                        <paragraph>Estrogens act through binding to nuclear receptors in estrogen-responsive tissues. To date, two estrogen receptors have been identified. These vary in proportion from tissue to tissue.</paragraph>
                        <paragraph>Circulating estrogens modulate the pituitary secretion of the gonadotropins, luteinizing hormone (LH) and FSH, through a negative feedback mechanism. Estrogens act to reduce the elevated levels of these gonadotropins seen in postmenopausal women.</paragraph>
                        <paragraph>Parenterally administered medroxyprogesterone acetate (MPA) inhibits gonadotropin production, which in turn prevents follicular maturation and ovulation; although available data indicate that this does not occur when the usually recommended oral dosage is given as single daily doses. MPA may achieve its beneficial effect on the endometrium in part by decreasing nuclear estrogen receptors and suppression of epithelial DNA synthesis in endometrial tissue. Androgenic and anabolic effects of MPA have been noted, but the drug is apparently devoid of significant estrogenic activity.</paragraph>
                     </text>
                     <effectiveTime value="20190531"/>
                  </section>
               </component>
               <component>
                  <section ID="S12.2">
                     <id root="a07cf7f4-1b02-4944-91ee-a716cb70d5f1"/>
                     <code code="43681-6" codeSystem="2.16.840.1.113883.6.1" displayName="PHARMACODYNAMICS SECTION"/>
                     <title>12.2 Pharmacodynamics</title>
                     <text>
                        <paragraph>Currently, there are no pharmacodynamic data known for PREMPRO or PREMPHASE tablets.</paragraph>
                     </text>
                     <effectiveTime value="20190531"/>
                  </section>
               </component>
               <component>
                  <section ID="S12.3">
                     <id root="d64997c4-aaae-40cc-969d-d35e8fd67e98"/>
                     <code code="43682-4" codeSystem="2.16.840.1.113883.6.1" displayName="PHARMACOKINETICS SECTION"/>
                     <title>12.3 Pharmacokinetics</title>
                     <effectiveTime value="20250429"/>
                     <component>
                        <section ID="absorption">
                           <id root="e0e9337f-aab8-4b07-b2ca-eb77700af849"/>
                           <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                           <text>
                              <paragraph>
                                 <content styleCode="bold">
                                    <content styleCode="italics">Absorption</content>
                                 </content>
                              </paragraph>
                              <paragraph>PREMPRO and PREMPHASE contain a formulation of medroxyprogesterone acetate (MPA) that is immediately released and CE that are slowly released over several hours. Conjugated estrogens are water-soluble and are well-absorbed from the gastrointestinal tract after release from the drug formulation. MPA is well absorbed from the gastrointestinal tract. Table 3 and Table 4 summarize the mean pharmacokinetic parameters for select unconjugated and conjugated estrogens and medroxyprogesterone acetate following administration of PREMPRO to healthy, postmenopausal women.</paragraph>
                              <table ID="_Reftable3" width="100%">
                                 <caption>Table 3: Pharmacokinetic Parameters for Unconjugated and Conjugated Estrogens (CE) and Medroxyprogesterone Acetate (MPA)</caption>
                                 <col width="19%"/>
                                 <col width="10%"/>
                                 <col width="10%"/>
                                 <col width="10%"/>
                                 <col width="11%"/>
                                 <col width="10%"/>
                                 <col width="10%"/>
                                 <col width="10%"/>
                                 <col width="11%"/>
                                 <tfoot>
                                    <tr>
                                       <td align="left" colspan="9" valign="top">BA* = Baseline adjusted<br/>
                                          <content styleCode="bold">C</content>
                                          <sub>max</sub> = peak plasma concentration<br/>
                                          <content styleCode="bold">t</content>
                                          <sub>max</sub> = time peak concentration occurs<br/>
                                          <content styleCode="bold">t</content>
                                          <sub>1/2</sub> = apparent terminal-phase disposition half-life (0.693/λ<sub>z</sub>)<br/>
                                          <content styleCode="bold">AUC</content> = total area under the concentration-time curve</td>
                                    </tr>
                                 </tfoot>
                                 <tbody>
                                    <tr>
                                       <td styleCode="Botrule Toprule " valign="top">
                                          <paragraph>DRUG</paragraph>
                                       </td>
                                       <td align="center" colspan="4" styleCode="Botrule Toprule " valign="top">
                                          <paragraph>2 × 0.625 mg CE/2.5 mg MPA<br/>Combination Tablets<br/>(n = 54)</paragraph>
                                       </td>
                                       <td align="center" colspan="4" styleCode="Botrule Toprule " valign="top">
                                          <paragraph>2 × 0.625 mg CE/5 mg MPA<br/>Combination Tablets<br/>(n = 51)</paragraph>
                                       </td>
                                    </tr>
                                    <tr>
                                       <td styleCode="Toprule " valign="top">
                                          <paragraph>
                                             <content styleCode="bold">PK Parameter</content>
                                             <br/>Arithmetic<br/>Mean (%CV)</paragraph>
                                       </td>
                                       <td align="center" styleCode="Toprule " valign="top">
                                          <paragraph>
                                             <content styleCode="bold">C</content>
                                             <sub>max</sub>
                                             <br/>(pg/mL)</paragraph>
                                       </td>
                                       <td align="center" styleCode="Toprule " valign="top">
                                          <paragraph>
                                             <content styleCode="bold">t</content>
                                             <sub>max</sub>
                                             <br/>(h)</paragraph>
                                       </td>
                                       <td align="center" styleCode="Toprule " valign="top">
                                          <paragraph>
                                             <content styleCode="bold">t</content>
                                             <sub>1/2</sub>
                                             <br/>(h)</paragraph>
                                       </td>
                                       <td align="center" styleCode="Toprule " valign="top">
                                          <paragraph>
                                             <content styleCode="bold">AUC</content>
                                             <br/>(pg∙h/mL)</paragraph>
                                       </td>
                                       <td align="center" styleCode="Toprule " valign="top">
                                          <paragraph>
                                             <content styleCode="bold">C</content>
                                             <sub>max</sub>
                                             <br/>(pg/mL)</paragraph>
                                       </td>
                                       <td align="center" styleCode="Toprule " valign="top">
                                          <paragraph>
                                             <content styleCode="bold">t</content>
                                             <sub>max</sub>
                                             <br/>(h)</paragraph>
                                       </td>
                                       <td align="center" styleCode="Toprule " valign="top">
                                          <paragraph>
                                             <content styleCode="bold">t</content>
                                             <sub>1/2</sub>
                                             <br/>(h)</paragraph>
                                       </td>
                                       <td align="center" styleCode="Toprule " valign="top">
                                          <paragraph>
                                             <content styleCode="bold">AUC</content>
                                             <br/>(pg∙h/mL)</paragraph>
                                       </td>
                                    </tr>
                                    <tr>
                                       <td colspan="9" valign="top">
                                          <paragraph>
                                             <content styleCode="bold">
                                                <content styleCode="italics">Unconjugated Estrogens</content>
                                             </content>
                                          </paragraph>
                                       </td>
                                    </tr>
                                    <tr>
                                       <td valign="top">
                                          <paragraph>Estrone</paragraph>
                                       </td>
                                       <td align="center" valign="top">
                                          <paragraph>175<br/>(23)</paragraph>
                                       </td>
                                       <td align="center" valign="top">
                                          <paragraph>7.6<br/>(24)</paragraph>
                                       </td>
                                       <td align="center" valign="top">
                                          <paragraph>31.6<br/>(23)</paragraph>
                                       </td>
                                       <td align="center" valign="top">
                                          <paragraph>5358<br/>(34)</paragraph>
                                       </td>
                                       <td align="center" valign="top">
                                          <paragraph>124<br/>(43)</paragraph>
                                       </td>
                                       <td align="center" valign="top">
                                          <paragraph>10<br/>(35)</paragraph>
                                       </td>
                                       <td align="center" valign="top">
                                          <paragraph>62.2<br/>(137)</paragraph>
                                       </td>
                                       <td align="center" valign="top">
                                          <paragraph>6303<br/>(40)</paragraph>
                                       </td>
                                    </tr>
                                    <tr>
                                       <td valign="top">
                                          <paragraph>BA* -Estrone</paragraph>
                                       </td>
                                       <td align="center" valign="top">
                                          <paragraph>159<br/>(26)</paragraph>
                                       </td>
                                       <td align="center" valign="top">
                                          <paragraph>7.6<br/>(24)</paragraph>
                                       </td>
                                       <td align="center" valign="top">
                                          <paragraph>16.9<br/>(34)</paragraph>
                                       </td>
                                       <td align="center" valign="top">
                                          <paragraph>3313<br/>(40)</paragraph>
                                       </td>
                                       <td align="center" valign="top">
                                          <paragraph>104<br/>(49)</paragraph>
                                       </td>
                                       <td align="center" valign="top">
                                          <paragraph>10<br/>(35)</paragraph>
                                       </td>
                                       <td align="center" valign="top">
                                          <paragraph>26.0<br/>(100)</paragraph>
                                       </td>
                                       <td align="center" valign="top">
                                          <paragraph>3136<br/>(51)</paragraph>
                                       </td>
                                    </tr>
                                    <tr>
                                       <td valign="top">
                                          <paragraph>Equilin</paragraph>
                                       </td>
                                       <td align="center" valign="top">
                                          <paragraph>71<br/>(31)</paragraph>
                                       </td>
                                       <td align="center" valign="top">
                                          <paragraph>5.8<br/>(34)</paragraph>
                                       </td>
                                       <td align="center" valign="top">
                                          <paragraph>9.9<br/>(35)</paragraph>
                                       </td>
                                       <td align="center" valign="top">
                                          <paragraph>951<br/>(43)</paragraph>
                                       </td>
                                       <td align="center" valign="top">
                                          <paragraph>54<br/>(43)</paragraph>
                                       </td>
                                       <td align="center" valign="top">
                                          <paragraph>8.9<br/>(34)</paragraph>
                                       </td>
                                       <td align="center" valign="top">
                                          <paragraph>15.5<br/>(53)</paragraph>
                                       </td>
                                       <td align="center" valign="top">
                                          <paragraph>1179<br/>(56)</paragraph>
                                       </td>
                                    </tr>
                                    <tr>
                                       <td valign="top">
                                          <paragraph>
                                             <content styleCode="bold">PK Parameter</content>
                                             <br/>Arithmetic<br/>Mean (%CV)</paragraph>
                                       </td>
                                       <td align="center" valign="top">
                                          <paragraph>
                                             <content styleCode="bold">C</content>
                                             <sub>max</sub>
                                             <br/>(ng/mL)</paragraph>
                                       </td>
                                       <td align="center" valign="top">
                                          <paragraph>
                                             <content styleCode="bold">t</content>
                                             <sub>max</sub>
                                             <br/>(h)</paragraph>
                                       </td>
                                       <td align="center" valign="top">
                                          <paragraph>
                                             <content styleCode="bold">t</content>
                                             <sub>1/2</sub>
                                             <br/>(h)</paragraph>
                                       </td>
                                       <td align="center" valign="top">
                                          <paragraph>
                                             <content styleCode="bold">AUC</content>
                                             <br/>(ng∙h/mL)</paragraph>
                                       </td>
                                       <td align="center" valign="top">
                                          <paragraph>
                                             <content styleCode="bold">C</content>
                                             <sub>max</sub>
                                             <br/>(ng/mL)</paragraph>
                                       </td>
                                       <td align="center" valign="top">
                                          <paragraph>
                                             <content styleCode="bold">t</content>
                                             <sub>max</sub>
                                             <br/>(h)</paragraph>
                                       </td>
                                       <td align="center" valign="top">
                                          <paragraph>
                                             <content styleCode="bold">t</content>
                                             <sub>1/2</sub>
                                             <br/>(h)</paragraph>
                                       </td>
                                       <td align="center" valign="top">
                                          <paragraph>
                                             <content styleCode="bold">AUC</content>
                                             <br/>(ng∙h/mL)</paragraph>
                                       </td>
                                    </tr>
                                    <tr>
                                       <td colspan="9" valign="top">
                                          <paragraph>
                                             <content styleCode="bold">
                                                <content styleCode="italics">Conjugated Estrogens</content>
                                             </content>
                                          </paragraph>
                                       </td>
                                    </tr>
                                    <tr>
                                       <td valign="top">
                                          <paragraph>Total Estrone</paragraph>
                                       </td>
                                       <td align="center" valign="top">
                                          <paragraph>6.6<br/>(38)</paragraph>
                                       </td>
                                       <td align="center" valign="top">
                                          <paragraph>6.1<br/>(28)</paragraph>
                                       </td>
                                       <td align="center" valign="top">
                                          <paragraph>20.7<br/>(34)</paragraph>
                                       </td>
                                       <td align="center" valign="top">
                                          <paragraph>116<br/>(59)</paragraph>
                                       </td>
                                       <td align="center" valign="top">
                                          <paragraph>6.3<br/>(48)</paragraph>
                                       </td>
                                       <td align="center" valign="top">
                                          <paragraph>9.1<br/>(29)</paragraph>
                                       </td>
                                       <td align="center" valign="top">
                                          <paragraph>23.6<br/>(36)</paragraph>
                                       </td>
                                       <td align="center" valign="top">
                                          <paragraph>151<br/>(42)</paragraph>
                                       </td>
                                    </tr>
                                    <tr>
                                       <td valign="top">
                                          <paragraph>BA* -Total Estrone</paragraph>
                                       </td>
                                       <td align="center" valign="top">
                                          <paragraph>6.4<br/>(39)</paragraph>
                                       </td>
                                       <td align="center" valign="top">
                                          <paragraph>6.1<br/>(28)</paragraph>
                                       </td>
                                       <td align="center" valign="top">
                                          <paragraph>15.4<br/>(34)</paragraph>
                                       </td>
                                       <td align="center" valign="top">
                                          <paragraph>100<br/>(57)</paragraph>
                                       </td>
                                       <td align="center" valign="top">
                                          <paragraph>6.2<br/>(48)</paragraph>
                                       </td>
                                       <td align="center" valign="top">
                                          <paragraph>9.1<br/>(29)</paragraph>
                                       </td>
                                       <td align="center" valign="top">
                                          <paragraph>20.6<br/>(35)</paragraph>
                                       </td>
                                       <td align="center" valign="top">
                                          <paragraph>139<br/>(40)</paragraph>
                                       </td>
                                    </tr>
                                    <tr>
                                       <td valign="top">
                                          <paragraph>Total Equilin</paragraph>
                                       </td>
                                       <td align="center" valign="top">
                                          <paragraph>5.1<br/>(45)</paragraph>
                                       </td>
                                       <td align="center" valign="top">
                                          <paragraph>4.6<br/>(35)</paragraph>
                                       </td>
                                       <td align="center" valign="top">
                                          <paragraph>11.4<br/>(25)</paragraph>
                                       </td>
                                       <td align="center" valign="top">
                                          <paragraph>50<br/>(70)</paragraph>
                                       </td>
                                       <td align="center" valign="top">
                                          <paragraph>4.2<br/>(52)</paragraph>
                                       </td>
                                       <td align="center" valign="top">
                                          <paragraph>7.0<br/>(36)</paragraph>
                                       </td>
                                       <td align="center" valign="top">
                                          <paragraph>17.2<br/>(131)</paragraph>
                                       </td>
                                       <td align="center" valign="top">
                                          <paragraph>72<br/>(50)</paragraph>
                                       </td>
                                    </tr>
                                    <tr>
                                       <td valign="top">
                                          <paragraph>
                                             <content styleCode="bold">PK Parameter</content>
                                             <br/>Arithmetic Mean<br/>(%CV)</paragraph>
                                       </td>
                                       <td align="center" valign="top">
                                          <paragraph>
                                             <content styleCode="bold">C</content>
                                             <sub>max</sub>
                                             <br/>(ng/mL)</paragraph>
                                       </td>
                                       <td align="center" valign="top">
                                          <paragraph>
                                             <content styleCode="bold">t</content>
                                             <sub>max</sub>
                                             <br/>(h)</paragraph>
                                       </td>
                                       <td align="center" valign="top">
                                          <paragraph>
                                             <content styleCode="bold">t</content>
                                             <sub>1/2</sub>
                                             <br/>(h)</paragraph>
                                       </td>
                                       <td align="center" valign="top">
                                          <paragraph>
                                             <content styleCode="bold">AUC</content>
                                             <br/>(ng∙h/mL)</paragraph>
                                       </td>
                                       <td align="center" valign="top">
                                          <paragraph>
                                             <content styleCode="bold">C</content>
                                             <sub>max</sub>
                                             <br/>(ng/mL)</paragraph>
                                       </td>
                                       <td align="center" valign="top">
                                          <paragraph>
                                             <content styleCode="bold">t</content>
                                             <sub>max</sub>
                                             <br/>(h)</paragraph>
                                       </td>
                                       <td align="center" valign="top">
                                          <paragraph>
                                             <content styleCode="bold">t</content>
                                             <sub>1/2</sub>
                                             <br/>(h)</paragraph>
                                       </td>
                                       <td align="center" valign="top">
                                          <paragraph>
                                             <content styleCode="bold">AUC</content>
                                             <br/>(ng∙h/mL)</paragraph>
                                       </td>
                                    </tr>
                                    <tr>
                                       <td colspan="9" valign="top">
                                          <paragraph>
                                             <content styleCode="bold">
                                                <content styleCode="italics">Medroxyprogesterone Acetate</content>
                                             </content>
                                          </paragraph>
                                       </td>
                                    </tr>
                                    <tr>
                                       <td styleCode="Botrule " valign="top">
                                          <paragraph>
                                             <content styleCode="bold">
                                                <content styleCode="italics">MPA</content>
                                             </content>
                                          </paragraph>
                                       </td>
                                       <td align="center" styleCode="Botrule " valign="top">
                                          <paragraph>1.5<br/>(40)</paragraph>
                                       </td>
                                       <td align="center" styleCode="Botrule " valign="top">
                                          <paragraph>2.8<br/>(54)</paragraph>
                                       </td>
                                       <td align="center" styleCode="Botrule " valign="top">
                                          <paragraph>37.6<br/>(30)</paragraph>
                                       </td>
                                       <td align="center" styleCode="Botrule " valign="top">
                                          <paragraph>37<br/>(30)</paragraph>
                                       </td>
                                       <td align="center" styleCode="Botrule " valign="top">
                                          <paragraph>4.8<br/>(31)</paragraph>
                                       </td>
                                       <td align="center" styleCode="Botrule " valign="top">
                                          <paragraph>2.4<br/>(50)</paragraph>
                                       </td>
                                       <td align="center" styleCode="Botrule " valign="top">
                                          <paragraph>46.3<br/>(39)</paragraph>
                                       </td>
                                       <td align="center" styleCode="Botrule " valign="top">
                                          <paragraph>102<br/>(28)</paragraph>
                                       </td>
                                    </tr>
                                 </tbody>
                              </table>
                              <table ID="_Reftable4" width="100%">
                                 <caption>TABLE 4. Pharmacokinetic Parameters for Unconjugated and Conjugated Estrogens (CE) and Medroxyprogesterone Acetate (MPA)</caption>
                                 <col width="40%"/>
                                 <col width="15%"/>
                                 <col width="15%"/>
                                 <col width="15%"/>
                                 <col width="15%"/>
                                 <tfoot>
                                    <tr>
                                       <td align="left" colspan="5" valign="top">BA* = Baseline adjusted<br/>
                                          <content styleCode="bold">C</content>
                                          <sub>max</sub> = peak plasma concentration<br/>
                                          <content styleCode="bold">t</content>
                                          <sub>max</sub> = time peak concentration occurs<br/>
                                          <content styleCode="bold">t</content>
                                          <sub>1/2</sub> = apparent terminal-phase disposition half-life (0.693/λ<sub>z</sub>)<br/>
                                          <content styleCode="bold">AUC</content> = total area under the concentration-time curve</td>
                                    </tr>
                                 </tfoot>
                                 <tbody>
                                    <tr>
                                       <td styleCode="Botrule Toprule " valign="top">
                                          <paragraph>DRUG</paragraph>
                                       </td>
                                       <td align="center" colspan="4" styleCode="Botrule Toprule " valign="top">
                                          <paragraph>4 × 0.45 mg CE/1.5 mg MPA Combination<br/>(n = 65)</paragraph>
                                       </td>
                                    </tr>
                                    <tr>
                                       <td align="center" styleCode="Toprule Botrule " valign="top">
                                          <paragraph>
                                             <content styleCode="bold">PK Parameter</content>
                                             <br/>Arithmetic Mean (%CV)</paragraph>
                                       </td>
                                       <td align="center" styleCode="Toprule Botrule " valign="top">
                                          <paragraph>
                                             <content styleCode="bold">C</content>
                                             <sub>max</sub>
                                             <br/>(pg/mL)</paragraph>
                                       </td>
                                       <td align="center" styleCode="Toprule Botrule " valign="top">
                                          <paragraph>
                                             <content styleCode="bold">t</content>
                                             <sub>max</sub>
                                             <br/>(h)</paragraph>
                                       </td>
                                       <td align="center" styleCode="Toprule Botrule " valign="top">
                                          <paragraph>
                                             <content styleCode="bold">t</content>
                                             <sub>1/2</sub>
                                             <br/>(h)</paragraph>
                                       </td>
                                       <td align="center" styleCode="Toprule Botrule " valign="top">
                                          <paragraph>
                                             <content styleCode="bold">AUC</content>
                                             <br/>(pg∙h/mL)</paragraph>
                                       </td>
                                    </tr>
                                    <tr>
                                       <td colspan="5" valign="top">
                                          <paragraph>
                                             <content styleCode="bold">
                                                <content styleCode="italics">Unconjugated Estrogens</content>
                                             </content>
                                          </paragraph>
                                       </td>
                                    </tr>
                                    <tr>
                                       <td valign="top">
                                          <paragraph>Estrone</paragraph>
                                       </td>
                                       <td align="center" valign="top">
                                          <paragraph>149<br/>(35)</paragraph>
                                       </td>
                                       <td align="center" valign="top">
                                          <paragraph>8.9<br/>(35)</paragraph>
                                       </td>
                                       <td align="center" valign="top">
                                          <paragraph>37.5<br/>(35)</paragraph>
                                       </td>
                                       <td align="center" valign="top">
                                          <paragraph>6641<br/>(39)</paragraph>
                                       </td>
                                    </tr>
                                    <tr>
                                       <td valign="top">
                                          <paragraph>BA* -Estrone</paragraph>
                                       </td>
                                       <td align="center" valign="top">
                                          <paragraph>130<br/>(40)</paragraph>
                                       </td>
                                       <td align="center" valign="top">
                                          <paragraph>8.9<br/>(35)</paragraph>
                                       </td>
                                       <td align="center" valign="top">
                                          <paragraph>21.2<br/>(35)</paragraph>
                                       </td>
                                       <td align="center" valign="top">
                                          <paragraph>3799<br/>(47)</paragraph>
                                       </td>
                                    </tr>
                                    <tr>
                                       <td styleCode="Botrule " valign="top">
                                          <paragraph>Equilin</paragraph>
                                       </td>
                                       <td align="center" styleCode="Botrule " valign="top">
                                          <paragraph>83<br/>(38)</paragraph>
                                       </td>
                                       <td align="center" styleCode="Botrule " valign="top">
                                          <paragraph>8.3<br/>(48)</paragraph>
                                       </td>
                                       <td align="center" styleCode="Botrule " valign="top">
                                          <paragraph>15.9<br/>(44)</paragraph>
                                       </td>
                                       <td align="center" styleCode="Botrule " valign="top">
                                          <paragraph>1889<br/>(40)</paragraph>
                                       </td>
                                    </tr>
                                    <tr>
                                       <td align="center" styleCode="Botrule " valign="top">
                                          <paragraph>
                                             <content styleCode="bold">PK Parameter</content>
                                             <br/>Arithmetic Mean (%CV)</paragraph>
                                       </td>
                                       <td align="center" styleCode="Botrule " valign="top">
                                          <paragraph>
                                             <content styleCode="bold">C</content>
                                             <sub>max</sub>
                                             <br/>(ng/mL)</paragraph>
                                       </td>
                                       <td align="center" styleCode="Botrule " valign="top">
                                          <paragraph>
                                             <content styleCode="bold">t</content>
                                             <sub>max</sub>
                                             <br/>(h)</paragraph>
                                       </td>
                                       <td align="center" styleCode="Botrule " valign="top">
                                          <paragraph>
                                             <content styleCode="bold">t</content>
                                             <sub>1/2</sub>
                                             <br/>(h)</paragraph>
                                       </td>
                                       <td align="center" styleCode="Botrule " valign="top">
                                          <paragraph>
                                             <content styleCode="bold">AUC</content>
                                             <br/>(ng∙h/mL)</paragraph>
                                       </td>
                                    </tr>
                                    <tr>
                                       <td colspan="5" valign="top">
                                          <paragraph>
                                             <content styleCode="bold">
                                                <content styleCode="italics">Conjugated Estrogens</content>
                                             </content>
                                          </paragraph>
                                       </td>
                                    </tr>
                                    <tr>
                                       <td valign="top">
                                          <paragraph>Total Estrone</paragraph>
                                       </td>
                                       <td align="center" valign="top">
                                          <paragraph>5.4<br/>(49)</paragraph>
                                       </td>
                                       <td align="center" valign="top">
                                          <paragraph>7.9<br/>(48)</paragraph>
                                       </td>
                                       <td align="center" valign="top">
                                          <paragraph>22.4<br/>(53)</paragraph>
                                       </td>
                                       <td align="center" valign="top">
                                          <paragraph>119<br/>(48)</paragraph>
                                       </td>
                                    </tr>
                                    <tr>
                                       <td valign="top">
                                          <paragraph>BA* -Total Estrone</paragraph>
                                       </td>
                                       <td align="center" valign="top">
                                          <paragraph>5.2<br/>(48)</paragraph>
                                       </td>
                                       <td align="center" valign="top">
                                          <paragraph>7.9<br/>(48)</paragraph>
                                       </td>
                                       <td align="center" valign="top">
                                          <paragraph>15.1<br/>(29)</paragraph>
                                       </td>
                                       <td align="center" valign="top">
                                          <paragraph>100<br/>(47)</paragraph>
                                       </td>
                                    </tr>
                                    <tr>
                                       <td styleCode="Botrule " valign="top">
                                          <paragraph>Total Equilin</paragraph>
                                       </td>
                                       <td align="center" styleCode="Botrule " valign="top">
                                          <paragraph>4.3<br/>(42)</paragraph>
                                       </td>
                                       <td align="center" styleCode="Botrule " valign="top">
                                          <paragraph>6.5<br/>(45)</paragraph>
                                       </td>
                                       <td align="center" styleCode="Botrule " valign="top">
                                          <paragraph>11.6<br/>(31)</paragraph>
                                       </td>
                                       <td align="center" styleCode="Botrule " valign="top">
                                          <paragraph>74<br/>(48)</paragraph>
                                       </td>
                                    </tr>
                                    <tr>
                                       <td align="center" styleCode="Botrule " valign="top">
                                          <paragraph>
                                             <content styleCode="bold">PK Parameter</content>
                                             <br/>Arithmetic Mean (%CV)</paragraph>
                                       </td>
                                       <td align="center" styleCode="Botrule " valign="top">
                                          <paragraph>
                                             <content styleCode="bold">C</content>
                                             <sub>max</sub>
                                             <br/>(ng/mL)</paragraph>
                                       </td>
                                       <td align="center" styleCode="Botrule " valign="top">
                                          <paragraph>
                                             <content styleCode="bold">t</content>
                                             <sub>max</sub>
                                             <br/>(h)</paragraph>
                                       </td>
                                       <td align="center" styleCode="Botrule " valign="top">
                                          <paragraph>
                                             <content styleCode="bold">t</content>
                                             <sub>1/2</sub>
                                             <br/>(h)</paragraph>
                                       </td>
                                       <td align="center" styleCode="Botrule " valign="top">
                                          <paragraph>
                                             <content styleCode="bold">AUC</content>
                                             <br/>(ng∙h/mL)</paragraph>
                                       </td>
                                    </tr>
                                    <tr>
                                       <td colspan="5" valign="top">
                                          <paragraph>
                                             <content styleCode="bold">
                                                <content styleCode="italics">Medroxyprogesterone Acetate</content>
                                             </content>
                                          </paragraph>
                                       </td>
                                    </tr>
                                    <tr>
                                       <td styleCode="Botrule " valign="top">
                                          <paragraph>
                                             <content styleCode="bold">
                                                <content styleCode="italics">MPA</content>
                                             </content>
                                          </paragraph>
                                       </td>
                                       <td align="center" styleCode="Botrule " valign="top">
                                          <paragraph>0.7<br/>(66)</paragraph>
                                       </td>
                                       <td align="center" styleCode="Botrule " valign="top">
                                          <paragraph>2.0<br/>(52)</paragraph>
                                       </td>
                                       <td align="center" styleCode="Botrule " valign="top">
                                          <paragraph>26.2<br/>(35)</paragraph>
                                       </td>
                                       <td align="center" styleCode="Botrule " valign="top">
                                          <paragraph>5.0<br/>(61)</paragraph>
                                       </td>
                                    </tr>
                                 </tbody>
                              </table>
                           </text>
                           <effectiveTime value="20250429"/>
                           <component>
                              <section ID="ID_a5f19bb9-9476-4333-9b9b-0d0a96e3178d">
                                 <id root="e52414db-c48a-4492-b3cc-c488aa78d118"/>
                                 <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                                 <text>
                                    <paragraph>Food-Effect: Single dose studies in healthy, postmenopausal women were conducted to investigate any potential drug interaction when PREMPRO or PREMPHASE is administered with a high-fat breakfast. Administration with food decreased the C<sub>max</sub> of total estrone by 18 to 34% and increased total equilin C<sub>max</sub> by 38% compared to the fasting state, with no other effect on the rate or extent of absorption of other conjugated or unconjugated estrogens. Administration with food approximately doubles MPA C<sub>max</sub> and increases MPA AUC by approximately 20 to 30%.</paragraph>
                                 </text>
                                 <effectiveTime value="20250429"/>
                              </section>
                           </component>
                           <component>
                              <section ID="ID_b5ecd9c1-6ccf-40e2-8b38-c55b8e2fa9b9">
                                 <id root="398c9b86-c652-42b5-8bc2-6bd9c3df798b"/>
                                 <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                                 <text>
                                    <paragraph>Dose Proportionality: The C<sub>max</sub> and AUC values for MPA observed in two separate pharmacokinetic studies conducted with 2 PREMPRO 0.625 mg/2.5 mg or 2 PREMPRO or PREMPHASE 0.625 mg/5 mg tablets exhibited nonlinear dose proportionality; doubling the MPA dose from 2 × 2.5 to 2 × 5 mg increased the mean C<sub>max</sub> and AUC by 3.2- and 2.8-fold, respectively.</paragraph>
                                    <paragraph>The dose proportionality of estrogens and medroxyprogesterone acetate was assessed by combining pharmacokinetic data across another two studies totaling 61 healthy, postmenopausal women. Single CE doses of 2 × 0.3 mg, 2 × 0.45 mg, or 2 × 0.625 mg were administered either alone or in combination with medroxyprogesterone acetate doses of 2 × 1.5 mg or 2 × 2.5 mg. Most of the estrogen components demonstrated dose proportionality; however, several estrogen components did not. Medroxyprogesterone acetate pharmacokinetic parameters increased in a dose-proportional manner.</paragraph>
                                 </text>
                                 <effectiveTime value="20250429"/>
                              </section>
                           </component>
                        </section>
                     </component>
                     <component>
                        <section ID="distribution">
                           <id root="fde90c52-18c9-4e69-97af-7699da099fed"/>
                           <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                           <text>
                              <paragraph>
                                 <content styleCode="bold">
                                    <content styleCode="italics">Distribution</content>
                                 </content>
                              </paragraph>
                              <paragraph>The distribution of exogenous estrogens is similar to that of endogenous estrogens. Estrogens are widely distributed in the body and are generally found in higher concentrations in the sex hormone target organs. Estrogens circulate in the blood largely bound to SHBG and albumin. MPA is approximately 90% bound to plasma proteins, but does not bind to SHBG.</paragraph>
                           </text>
                           <effectiveTime value="20250429"/>
                        </section>
                     </component>
                     <component>
                        <section ID="s13">
                           <id root="7e45b78c-ac92-4ca9-a0bf-93e60d31475f"/>
                           <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                           <text>
                              <paragraph>
                                 <content styleCode="bold">
                                    <content styleCode="italics">Metabolism</content>
                                 </content>
                              </paragraph>
                              <paragraph>Exogenous estrogens are metabolized in the same manner as endogenous estrogens. Circulating estrogens exist in a dynamic equilibrium of metabolic interconversions. These transformations take place mainly in the liver. Estradiol is converted reversibly to estrone, and both can be converted to estriol, which is a major urinary metabolite. Estrogens also undergo enterohepatic recirculation via sulfate and glucuronide conjugation in the liver, biliary secretion of conjugates into the intestine, and hydrolysis in the intestine followed by reabsorption. In postmenopausal women, a significant proportion of the circulating estrogens exist as sulfate conjugates, especially estrone sulfate, which serves as a circulating reservoir for the formation of more active estrogens. Metabolism and elimination of MPA occur primarily in the liver via hydroxylation, with subsequent conjugation and elimination in the urine.</paragraph>
                           </text>
                           <effectiveTime value="20250429"/>
                        </section>
                     </component>
                     <component>
                        <section ID="s14">
                           <id root="48de00e5-3539-489b-a280-cef2692a07d5"/>
                           <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                           <text>
                              <paragraph>
                                 <content styleCode="bold">
                                    <content styleCode="italics">Excretion</content>
                                 </content>
                              </paragraph>
                              <paragraph>Estradiol, estrone, and estriol are excreted in the urine along with glucuronide and sulfate conjugates. Most metabolites of MPA are excreted as glucuronide conjugates, with only minor amounts excreted as sulfates.</paragraph>
                           </text>
                           <effectiveTime value="20250429"/>
                        </section>
                     </component>
                     <component>
                        <section ID="s15">
                           <id root="6e18d6ac-69d3-460e-a4dd-3b0c52a53ea4"/>
                           <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                           <text>
                              <paragraph>
                                 <content styleCode="bold">
                                    <content styleCode="italics">Use in Specific Populations</content>
                                 </content>
                              </paragraph>
                              <paragraph>No pharmacokinetic studies were conducted in specific populations, including patients with renal or hepatic impairment.</paragraph>
                           </text>
                           <effectiveTime value="20250429"/>
                        </section>
                     </component>
                  </section>
               </component>
            </section>
         </component>
         <component>
            <section ID="S13">
               <id root="67ece524-d652-4736-b396-05ae91d2f068"/>
               <code code="43680-8" codeSystem="2.16.840.1.113883.6.1" displayName="NONCLINICAL TOXICOLOGY SECTION"/>
               <title>13 NONCLINICAL TOXICOLOGY</title>
               <effectiveTime value="20250429"/>
               <component>
                  <section ID="S13.1">
                     <id root="e18a965e-742c-43b1-8a81-8b198893d472"/>
                     <code code="34083-6" codeSystem="2.16.840.1.113883.6.1" displayName="CARCINOGENESIS &amp; MUTAGENESIS &amp; IMPAIRMENT OF FERTILITY SECTION"/>
                     <title>13.1 Carcinogenesis, Mutagenesis, Impairment of Fertility</title>
                     <text>
                        <paragraph>Long-term continuous administration of natural and synthetic estrogens in certain animal species increases the frequency of carcinomas of the breasts, uterus, cervix, vagina, testis, and liver <content styleCode="italics">[see <linkHtml href="#S5.2">Warnings and Precautions (5.2)</linkHtml>]</content>.</paragraph>
                        <paragraph>MPA was not mutagenic in a battery of in vitro or in vivo genetic toxicity assays <content styleCode="italics">[see <linkHtml href="#S5.7">Warnings and Precautions (5.7)</linkHtml>]</content>.</paragraph>
                     </text>
                     <effectiveTime value="20250429"/>
                  </section>
               </component>
            </section>
         </component>
         <component>
            <section ID="S14">
               <id root="f1137739-1990-4792-8269-a2db74d6094f"/>
               <code code="34092-7" codeSystem="2.16.840.1.113883.6.1" displayName="CLINICAL STUDIES SECTION"/>
               <title>14 CLINICAL STUDIES</title>
               <effectiveTime value="20250429"/>
               <component>
                  <section ID="S14.1">
                     <id root="994681f4-d43b-40e0-b643-2eb6211d0be5"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title>14.1 Effects on Vasomotor Symptoms</title>
                     <text>
                        <paragraph>In the first year of the Health and Osteoporosis, Progestin and Estrogen (HOPE) Study, a total of 2,805 postmenopausal women (average age 53.3 ± 4.9 years) were randomly assigned to one of eight treatment groups of either placebo or CE, with or without MPA. Efficacy for vasomotor symptoms was assessed during the first 12 weeks of treatment in a subset of symptomatic women (n = 241) who had at least seven moderate to severe hot flushes daily, or at least 50 moderate to severe hot flushes during the week before randomization. With PREMPRO 0.625 mg/2.5 mg, 0.45 mg/1.5 mg, and 0.3 mg/1.5 mg, the relief of both the frequency and severity of moderate to severe vasomotor symptoms was shown to be statistically improved compared to placebo at weeks 4 and 12. Table 5 shows the adjusted mean number of hot flushes in the PREMPRO 0.625 mg/2.5 mg, 0.45 mg/1.5 mg, 0.3 mg/1.5 mg, and placebo groups during the initial 12-week period.</paragraph>
                        <table ID="_Reftable5" width="100%">
                           <caption>Table 5: Summary Tabulation of the Number of Hot Flushes Per Day – Mean Values and Comparisons Between the Active Treatment Groups and the Placebo Group – Patients with At Least 7 Moderate to Severe Flushes Per Day or At Least 50 Per Week at Baseline, Last Observation Carries Forward (LOCF)</caption>
                           <col width="20%"/>
                           <col width="20%"/>
                           <col width="20%"/>
                           <col width="20%"/>
                           <col width="20%"/>
                           <tbody>
                              <tr>
                                 <td styleCode="Toprule " valign="top">
                                    <paragraph>Treatment<footnote ID="_RefID0EL4CI">Identified by dosage (mg) of Premarin/MPA or placebo.</footnote>
                                       <br/>(No. of Patients)</paragraph>
                                 </td>
                                 <td align="center" colspan="3" styleCode="Toprule " valign="top">
                                    <paragraph>
                                       <br/>-------------------No. of Hot Flushes/Day-----------------</paragraph>
                                 </td>
                                 <td styleCode="Toprule " valign="top"/>
                              </tr>
                              <tr>
                                 <td styleCode="Botrule " valign="top">
                                    <paragraph>Time Period<br/>(week)</paragraph>
                                 </td>
                                 <td align="center" styleCode="Botrule " valign="top">
                                    <paragraph>Baseline<br/>Mean ± SD</paragraph>
                                 </td>
                                 <td align="center" styleCode="Botrule " valign="top">
                                    <paragraph>Observed<br/>Mean ± SD</paragraph>
                                 </td>
                                 <td align="center" styleCode="Botrule " valign="top">
                                    <paragraph>Mean<br/>Change ± SD</paragraph>
                                 </td>
                                 <td align="center" styleCode="Botrule " valign="top">
                                    <paragraph>p-Values<br/>vs. Placebo<footnote ID="_RefID0EJ5CI">There were no statistically significant differences between the 0.625 mg/2.5 mg, 0.45 mg/1.5 mg, and 0.3 mg/1.5 mg groups at any time period.</footnote>
                                    </paragraph>
                                 </td>
                              </tr>
                              <tr>
                                 <td align="center" styleCode="Toprule " valign="top">
                                    <paragraph>0.625 mg/2.5 mg<br/>(n = 34)</paragraph>
                                 </td>
                                 <td styleCode="Toprule " valign="top"/>
                                 <td styleCode="Toprule " valign="top"/>
                                 <td styleCode="Toprule " valign="top"/>
                                 <td styleCode="Toprule " valign="top"/>
                              </tr>
                              <tr>
                                 <td align="center" valign="top">
                                    <paragraph>4</paragraph>
                                 </td>
                                 <td align="center" valign="top">
                                    <paragraph>11.98 ± 3.54</paragraph>
                                 </td>
                                 <td align="center" valign="top">
                                    <paragraph>3.19 ± 3.74</paragraph>
                                 </td>
                                 <td align="center" valign="top">
                                    <paragraph>-8.78 ± 4.72</paragraph>
                                 </td>
                                 <td align="center" valign="top">
                                    <paragraph>&lt;0.001</paragraph>
                                 </td>
                              </tr>
                              <tr>
                                 <td align="center" valign="top">
                                    <paragraph>12</paragraph>
                                 </td>
                                 <td align="center" valign="top">
                                    <paragraph>11.98 ± 3.54</paragraph>
                                 </td>
                                 <td align="center" valign="top">
                                    <paragraph>1.16 ± 2.22</paragraph>
                                 </td>
                                 <td align="center" valign="top">
                                    <paragraph>-10.82 ± 4.61</paragraph>
                                 </td>
                                 <td align="center" valign="top">
                                    <paragraph>&lt;0.001</paragraph>
                                 </td>
                              </tr>
                              <tr>
                                 <td align="center" valign="top">
                                    <paragraph>0.45 mg/1.5 mg<br/>(n = 29)</paragraph>
                                 </td>
                                 <td valign="top"/>
                                 <td valign="top"/>
                                 <td valign="top"/>
                                 <td valign="top"/>
                              </tr>
                              <tr>
                                 <td align="center" valign="top">
                                    <paragraph>4</paragraph>
                                 </td>
                                 <td align="center" valign="top">
                                    <paragraph>12.61 ± 4.29</paragraph>
                                 </td>
                                 <td align="center" valign="top">
                                    <paragraph>3.64 ± 3.61</paragraph>
                                 </td>
                                 <td align="center" valign="top">
                                    <paragraph>-8.98 ± 4.74</paragraph>
                                 </td>
                                 <td align="center" valign="top">
                                    <paragraph>&lt;0.001</paragraph>
                                 </td>
                              </tr>
                              <tr>
                                 <td align="center" valign="top">
                                    <paragraph>12</paragraph>
                                 </td>
                                 <td align="center" valign="top">
                                    <paragraph>12.61 ± 4.29</paragraph>
                                 </td>
                                 <td align="center" valign="top">
                                    <paragraph>1.69 ± 3.36</paragraph>
                                 </td>
                                 <td align="center" valign="top">
                                    <paragraph>-10.92 ± 4.63</paragraph>
                                 </td>
                                 <td align="center" valign="top">
                                    <paragraph>&lt;0.001</paragraph>
                                 </td>
                              </tr>
                              <tr>
                                 <td align="center" valign="top">
                                    <paragraph>0.3 mg/1.5 mg<br/>(n = 33)</paragraph>
                                 </td>
                                 <td valign="top"/>
                                 <td valign="top"/>
                                 <td valign="top"/>
                                 <td valign="top"/>
                              </tr>
                              <tr>
                                 <td align="center" valign="top">
                                    <paragraph>4</paragraph>
                                 </td>
                                 <td align="center" valign="top">
                                    <paragraph>11.30 ± 3.13</paragraph>
                                 </td>
                                 <td align="center" valign="top">
                                    <paragraph>3.70 ± 3.29</paragraph>
                                 </td>
                                 <td align="center" valign="top">
                                    <paragraph>-7.60 ± 4.71</paragraph>
                                 </td>
                                 <td align="center" valign="top">
                                    <paragraph>&lt;0.001</paragraph>
                                 </td>
                              </tr>
                              <tr>
                                 <td align="center" valign="top">
                                    <paragraph>12</paragraph>
                                 </td>
                                 <td align="center" valign="top">
                                    <paragraph>11.30 ± 3.13</paragraph>
                                 </td>
                                 <td align="center" valign="top">
                                    <paragraph>1.31 ± 2.82</paragraph>
                                 </td>
                                 <td align="center" valign="top">
                                    <paragraph>-10.00 ± 4.60</paragraph>
                                 </td>
                                 <td align="center" valign="top">
                                    <paragraph>&lt;0.001</paragraph>
                                 </td>
                              </tr>
                              <tr>
                                 <td align="center" valign="top">
                                    <paragraph>Placebo<br/>(n = 28)</paragraph>
                                 </td>
                                 <td valign="top"/>
                                 <td valign="top"/>
                                 <td valign="top"/>
                                 <td valign="top"/>
                              </tr>
                              <tr>
                                 <td align="center" valign="top">
                                    <paragraph>4</paragraph>
                                 </td>
                                 <td align="center" valign="top">
                                    <paragraph>11.69 ± 3.87</paragraph>
                                 </td>
                                 <td align="center" valign="top">
                                    <paragraph>7.89 ± 5.28</paragraph>
                                 </td>
                                 <td align="center" valign="top">
                                    <paragraph>-3.80 ± 4.71</paragraph>
                                 </td>
                                 <td align="center" valign="top">
                                    <paragraph>-</paragraph>
                                 </td>
                              </tr>
                              <tr>
                                 <td align="center" styleCode="Botrule " valign="top">
                                    <paragraph>12</paragraph>
                                 </td>
                                 <td align="center" styleCode="Botrule " valign="top">
                                    <paragraph>11.69 ± 3.87</paragraph>
                                 </td>
                                 <td align="center" styleCode="Botrule " valign="top">
                                    <paragraph>5.71 ± 5.22</paragraph>
                                 </td>
                                 <td align="center" styleCode="Botrule " valign="top">
                                    <paragraph>-5.98 ± 4.60</paragraph>
                                 </td>
                                 <td align="center" styleCode="Botrule " valign="top">
                                    <paragraph>-</paragraph>
                                 </td>
                              </tr>
                           </tbody>
                        </table>
                     </text>
                     <effectiveTime value="20250429"/>
                  </section>
               </component>
               <component>
                  <section ID="S14.2">
                     <id root="bb9bdc29-92b7-4e71-9b67-42c5c0d12738"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title>14.2 Effects on Vulvar and Vaginal Atrophy</title>
                     <text>
                        <paragraph>Results of vaginal maturation indexes at cycles 6 and 13 showed that the differences from placebo were statistically significant (p &lt; 0.001) for all treatment groups.</paragraph>
                     </text>
                     <effectiveTime value="20190531"/>
                  </section>
               </component>
               <component>
                  <section ID="S14.3">
                     <id root="895fe010-b616-4e7e-a8d4-4d233c4bb76b"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title>14.3 Effects on the Endometrium</title>
                     <text>
                        <paragraph>In a 1-year clinical trial of 1,376 women (average age 54 ± 4.6 years) randomized to PREMPRO 0.625 mg/2.5 mg (n = 340), PREMPRO 0.625 mg/5 mg (n = 338), PREMPHASE 0.625 mg/5 mg (n = 351), or Premarin 0.625 mg alone (n = 347), results of evaluable biopsies at 12 months (n = 279, 274, 277, and 283, respectively) showed a reduced risk of endometrial hyperplasia in the two PREMPRO treatment groups (less than 1%) and in the PREMPHASE treatment group (less than 1%; 1% when focal hyperplasia was included) compared to the Premarin group (8%; 20% when focal hyperplasia was included), see <linkHtml href="#_Reftable6">Table 6</linkHtml>.</paragraph>
                        <table ID="_Reftable6" width="100%">
                           <caption>Table 6: Incidence of Endometrial Hyperplasia After One Year of Treatment</caption>
                           <col width="36%"/>
                           <col width="16%"/>
                           <col width="16%"/>
                           <col width="16%"/>
                           <col width="16%"/>
                           <tbody>
                              <tr>
                                 <td styleCode="Toprule " valign="top"/>
                                 <td align="center" colspan="4" styleCode="Toprule " valign="top">
                                    <paragraph>--------------------------Groups-------------------------</paragraph>
                                 </td>
                              </tr>
                              <tr>
                                 <td valign="top"/>
                                 <td align="center" valign="top">
                                    <paragraph>PREMPRO</paragraph>
                                 </td>
                                 <td align="center" valign="top">
                                    <paragraph>PREMPRO</paragraph>
                                 </td>
                                 <td align="center" valign="top">
                                    <paragraph>PREMPHASE</paragraph>
                                 </td>
                                 <td align="center" valign="top">
                                    <paragraph>Premarin</paragraph>
                                 </td>
                              </tr>
                              <tr>
                                 <td styleCode="Botrule " valign="top"/>
                                 <td align="center" styleCode="Botrule " valign="top">
                                    <paragraph>0.625 mg/2.5 mg</paragraph>
                                 </td>
                                 <td align="center" styleCode="Botrule " valign="top">
                                    <paragraph>0.625 mg/5 mg</paragraph>
                                 </td>
                                 <td align="center" styleCode="Botrule " valign="top">
                                    <paragraph>0.625 mg/5 mg</paragraph>
                                 </td>
                                 <td align="center" styleCode="Botrule " valign="top">
                                    <paragraph>0.625 mg</paragraph>
                                 </td>
                              </tr>
                              <tr>
                                 <td styleCode="Toprule " valign="top">
                                    <paragraph>Total number of patients</paragraph>
                                 </td>
                                 <td align="center" styleCode="Toprule " valign="top">
                                    <paragraph>340</paragraph>
                                 </td>
                                 <td align="center" styleCode="Toprule " valign="top">
                                    <paragraph>338</paragraph>
                                 </td>
                                 <td align="center" styleCode="Toprule " valign="top">
                                    <paragraph>351</paragraph>
                                 </td>
                                 <td align="center" styleCode="Toprule " valign="top">
                                    <paragraph>347</paragraph>
                                 </td>
                              </tr>
                              <tr>
                                 <td valign="top">
                                    <paragraph>Number of patients with evaluable biopsies</paragraph>
                                 </td>
                                 <td align="center" valign="top">
                                    <paragraph>279</paragraph>
                                 </td>
                                 <td align="center" valign="top">
                                    <paragraph>274</paragraph>
                                 </td>
                                 <td align="center" valign="top">
                                    <paragraph>277</paragraph>
                                 </td>
                                 <td align="center" valign="top">
                                    <paragraph>283</paragraph>
                                 </td>
                              </tr>
                              <tr>
                                 <td valign="top">
                                    <paragraph>No. (%) of patients with biopsies:</paragraph>
                                 </td>
                                 <td valign="top"/>
                                 <td valign="top"/>
                                 <td valign="top"/>
                                 <td valign="top"/>
                              </tr>
                              <tr>
                                 <td valign="top">
                                    <paragraph>• All focal and non-focal hyperplasia</paragraph>
                                 </td>
                                 <td align="center" valign="top">
                                    <paragraph>2 (&lt;1)<footnote ID="_Reft6.1">Significant (p &lt; 0.001) in comparison with Premarin (0.625 mg) alone.</footnote>
                                    </paragraph>
                                 </td>
                                 <td align="center" valign="top">
                                    <paragraph>0 (0)<footnoteRef IDREF="_Reft6.1"/>
                                    </paragraph>
                                 </td>
                                 <td align="center" valign="top">
                                    <paragraph>3 (1)<footnoteRef IDREF="_Reft6.1"/>
                                    </paragraph>
                                 </td>
                                 <td align="center" valign="top">
                                    <paragraph>57 (20)</paragraph>
                                 </td>
                              </tr>
                              <tr>
                                 <td styleCode="Botrule " valign="top">
                                    <paragraph>• Excluding focal cystic hyperplasia</paragraph>
                                 </td>
                                 <td align="center" styleCode="Botrule " valign="top">
                                    <paragraph>2 (&lt;1)<footnoteRef IDREF="_Reft6.1"/>
                                    </paragraph>
                                 </td>
                                 <td align="center" styleCode="Botrule " valign="top">
                                    <paragraph>0 (0)<footnoteRef IDREF="_Reft6.1"/>
                                    </paragraph>
                                 </td>
                                 <td align="center" styleCode="Botrule " valign="top">
                                    <paragraph>1 (&lt;1)<footnoteRef IDREF="_Reft6.1"/>
                                    </paragraph>
                                 </td>
                                 <td align="center" styleCode="Botrule " valign="top">
                                    <paragraph>25 (8)</paragraph>
                                 </td>
                              </tr>
                           </tbody>
                        </table>
                        <paragraph>In the first year of the Health and Osteoporosis, Progestin and Estrogen (HOPE) Study, 2,001 women (average age 53.3 ± 4.9 years), of whom 88% were Caucasian, were treated with either Premarin 0.625 mg alone (n = 348), Premarin 0.45 mg alone (n = 338), Premarin 0.3 mg alone (n = 326) or PREMPRO 0.625 mg/2.5 mg (n = 331), PREMPRO 0.45 mg/1.5 mg (n = 331) or PREMPRO 0.3 mg/1.5 mg (n = 327). Results of evaluable endometrial biopsies at 12 months showed a reduced risk of endometrial hyperplasia or cancer in the PREMPRO treatment groups compared with the corresponding Premarin alone treatment groups, except for the PREMPRO 0.3 mg/1.5 mg and Premarin 0.3 mg alone groups, in each of which there was only 1 case, see <linkHtml href="#_Reftable7">Table 7</linkHtml>.</paragraph>
                        <paragraph>No endometrial hyperplasia or cancer was noted in those patients treated with the continuous combined regimens who continued for a second year in the osteoporosis and metabolic substudy of the HOPE study, see <linkHtml href="#_Reftable8">Table 8</linkHtml>.</paragraph>
                        <table ID="_Reftable7" width="100%">
                           <caption>Table 7: Incidence of Endometrial Hyperplasia/Cancer<footnote ID="_Reft7.a">All cases of hyperplasia/cancer were endometrial hyperplasia, except for 1 patient in the Premarin 0.3 mg group diagnosed with endometrial cancer based on endometrial biopsy and 1 patient in the Premarin/MPA 0.45 mg/1.5 mg group diagnosed with endometrial cancer based on endometrial biopsy.</footnote> After One Year of Treatment<footnote ID="_RefID0EQFDI">Two (2) primary pathologists evaluated each endometrial biopsy. Where there was lack of agreement on the presence or absence of hyperplasia/cancer between the two, a third pathologist adjudicated (consensus).</footnote>
                           </caption>
                           <col width="28%"/>
                           <col width="13%"/>
                           <col width="12%"/>
                           <col width="12%"/>
                           <col width="12%"/>
                           <col width="12%"/>
                           <col width="11%"/>
                           <tbody>
                              <tr>
                                 <td styleCode="Toprule " valign="top"/>
                                 <td align="center" colspan="6" styleCode="Toprule " valign="top">
                                    <paragraph>-----------------------------------Groups---------------------------------</paragraph>
                                 </td>
                              </tr>
                              <tr>
                                 <td styleCode="Botrule " valign="bottom">
                                    <paragraph>
                                       <content styleCode="bold">Patient</content>
                                    </paragraph>
                                 </td>
                                 <td align="center" styleCode="Botrule " valign="top">
                                    <paragraph>Prempro<br/>0.625 mg/2.5 mg</paragraph>
                                 </td>
                                 <td align="center" styleCode="Botrule " valign="top">
                                    <paragraph>Premarin<br/>0.625 mg</paragraph>
                                 </td>
                                 <td align="center" styleCode="Botrule " valign="top">
                                    <paragraph>Prempro<br/>0.45 mg/1.5 mg</paragraph>
                                 </td>
                                 <td align="center" styleCode="Botrule " valign="top">
                                    <paragraph>Premarin<br/>0.45 mg</paragraph>
                                 </td>
                                 <td align="center" styleCode="Botrule " valign="top">
                                    <paragraph>Prempro<br/>0.3 mg/1.5 mg</paragraph>
                                 </td>
                                 <td align="center" styleCode="Botrule " valign="top">
                                    <paragraph>Premarin<br/>0.3 mg</paragraph>
                                 </td>
                              </tr>
                              <tr>
                                 <td styleCode="Toprule " valign="top">
                                    <paragraph>Total number of patients</paragraph>
                                 </td>
                                 <td align="center" styleCode="Toprule " valign="top">
                                    <paragraph>331</paragraph>
                                 </td>
                                 <td align="center" styleCode="Toprule " valign="top">
                                    <paragraph>348</paragraph>
                                 </td>
                                 <td align="center" styleCode="Toprule " valign="top">
                                    <paragraph>331</paragraph>
                                 </td>
                                 <td align="center" styleCode="Toprule " valign="top">
                                    <paragraph>338</paragraph>
                                 </td>
                                 <td align="center" styleCode="Toprule " valign="top">
                                    <paragraph>327</paragraph>
                                 </td>
                                 <td align="center" styleCode="Toprule " valign="top">
                                    <paragraph>326</paragraph>
                                 </td>
                              </tr>
                              <tr>
                                 <td valign="top">
                                    <paragraph>Number of patients with evaluable biopsies</paragraph>
                                 </td>
                                 <td align="center" valign="top">
                                    <paragraph>278</paragraph>
                                 </td>
                                 <td align="center" valign="top">
                                    <paragraph>249</paragraph>
                                 </td>
                                 <td align="center" valign="top">
                                    <paragraph>272</paragraph>
                                 </td>
                                 <td align="center" valign="top">
                                    <paragraph>279</paragraph>
                                 </td>
                                 <td align="center" valign="top">
                                    <paragraph>271</paragraph>
                                 </td>
                                 <td align="center" valign="top">
                                    <paragraph>269</paragraph>
                                 </td>
                              </tr>
                              <tr>
                                 <td valign="top">
                                    <paragraph>No. (%) of patients with biopsies:</paragraph>
                                 </td>
                                 <td valign="top"/>
                                 <td valign="top"/>
                                 <td valign="top"/>
                                 <td valign="top"/>
                                 <td valign="top"/>
                                 <td valign="top"/>
                              </tr>
                              <tr>
                                 <td styleCode="Botrule " valign="top">
                                    <paragraph>• Hyperplasia/cancer<footnoteRef IDREF="_Reft7.a"/>
                                       <br/>(consensus<footnote ID="_RefID0EQIDI">For an endometrial biopsy to be counted as consensus endometrial hyperplasia or cancer, at least 2 pathologists had to agree on the diagnosis.</footnote>)</paragraph>
                                 </td>
                                 <td align="center" styleCode="Botrule " valign="top">
                                    <paragraph>0 (0)<footnote ID="_Reft7.d">Significant (p &lt; 0.05) in comparison with corresponding dose of Premarin alone.</footnote>
                                    </paragraph>
                                 </td>
                                 <td align="center" styleCode="Botrule " valign="top">
                                    <paragraph>20 (8)</paragraph>
                                 </td>
                                 <td align="center" styleCode="Botrule " valign="top">
                                    <paragraph>1 (&lt;1)<footnoteRef IDREF="_Reft7.a"/>
                                       <sup>,</sup>
                                       <footnoteRef IDREF="_Reft7.d"/>
                                    </paragraph>
                                 </td>
                                 <td align="center" styleCode="Botrule " valign="top">
                                    <paragraph>9 (3)</paragraph>
                                 </td>
                                 <td align="center" styleCode="Botrule " valign="top">
                                    <paragraph>1 (&lt;1)<footnote ID="_RefID0EBJDI">Non-significant in comparison with corresponding dose of Premarin alone.</footnote>
                                    </paragraph>
                                 </td>
                                 <td align="center" styleCode="Botrule " valign="top">
                                    <paragraph>1 (&lt;1)<footnoteRef IDREF="_Reft7.a"/>
                                    </paragraph>
                                 </td>
                              </tr>
                           </tbody>
                        </table>
                        <table ID="_Reftable8" width="100%">
                           <caption>Table 8: Osteoporosis and Metabolic Substudy, Incidence of Endometrial Hyperplasia/Cancer<footnote ID="_Reffn8.a">All cases of hyperplasia/cancer were endometrial hyperplasia in patients who continued for a second year in the osteoporosis and metabolic substudy of the HOPE study.</footnote> After Two Years of Treatment<footnote ID="_Reffn8.b">Two (2) primary pathologists evaluated each endometrial biopsy. Where there was lack of agreement on the presence or absence of hyperplasia/cancer between the two, a third pathologist adjudicated (consensus).</footnote>
                           </caption>
                           <col width="28%"/>
                           <col width="12%"/>
                           <col width="13%"/>
                           <col width="12%"/>
                           <col width="12%"/>
                           <col width="12%"/>
                           <col width="11%"/>
                           <tbody>
                              <tr>
                                 <td styleCode="Toprule " valign="top"/>
                                 <td align="center" colspan="6" styleCode="Toprule " valign="top">
                                    <paragraph>-------------------------------Groups------------------------------</paragraph>
                                 </td>
                              </tr>
                              <tr>
                                 <td styleCode="Botrule " valign="middle">
                                    <paragraph>
                                       <content styleCode="bold">Patient</content>
                                    </paragraph>
                                 </td>
                                 <td align="center" styleCode="Botrule " valign="top">
                                    <paragraph>Prempro<br/>0.625 mg/2.5 mg</paragraph>
                                 </td>
                                 <td align="center" styleCode="Botrule " valign="top">
                                    <paragraph>Premarin<br/>0.625 mg</paragraph>
                                 </td>
                                 <td align="center" styleCode="Botrule " valign="top">
                                    <paragraph>Prempro<br/>0.45 mg/1.5 mg</paragraph>
                                 </td>
                                 <td align="center" styleCode="Botrule " valign="top">
                                    <paragraph>Premarin<br/>0.45 mg</paragraph>
                                 </td>
                                 <td align="center" styleCode="Botrule " valign="top">
                                    <paragraph>Prempro<br/>0.3 mg/1.5 mg</paragraph>
                                 </td>
                                 <td align="center" styleCode="Botrule " valign="top">
                                    <paragraph>Premarin <br/>0.3 mg</paragraph>
                                 </td>
                              </tr>
                              <tr>
                                 <td styleCode="Toprule " valign="top">
                                    <paragraph>Total number of patients</paragraph>
                                 </td>
                                 <td align="center" styleCode="Toprule " valign="top">
                                    <paragraph>75</paragraph>
                                 </td>
                                 <td align="center" styleCode="Toprule " valign="top">
                                    <paragraph>65</paragraph>
                                 </td>
                                 <td align="center" styleCode="Toprule " valign="top">
                                    <paragraph>75</paragraph>
                                 </td>
                                 <td align="center" styleCode="Toprule " valign="top">
                                    <paragraph>74</paragraph>
                                 </td>
                                 <td align="center" styleCode="Toprule " valign="top">
                                    <paragraph>79</paragraph>
                                 </td>
                                 <td align="center" styleCode="Toprule " valign="top">
                                    <paragraph>73</paragraph>
                                 </td>
                              </tr>
                              <tr>
                                 <td valign="top">
                                    <paragraph>Number of patients with evaluable biopsies</paragraph>
                                 </td>
                                 <td align="center" valign="top">
                                    <paragraph>62</paragraph>
                                 </td>
                                 <td align="center" valign="top">
                                    <paragraph>55</paragraph>
                                 </td>
                                 <td align="center" valign="top">
                                    <paragraph>69</paragraph>
                                 </td>
                                 <td align="center" valign="top">
                                    <paragraph>67</paragraph>
                                 </td>
                                 <td align="center" valign="top">
                                    <paragraph>75</paragraph>
                                 </td>
                                 <td align="center" valign="top">
                                    <paragraph>63</paragraph>
                                 </td>
                              </tr>
                              <tr>
                                 <td valign="top">
                                    <paragraph>No. (%) of patients with biopsies:</paragraph>
                                 </td>
                                 <td valign="top"/>
                                 <td valign="top"/>
                                 <td valign="top"/>
                                 <td valign="top"/>
                                 <td valign="top"/>
                                 <td valign="top"/>
                              </tr>
                              <tr>
                                 <td styleCode="Botrule " valign="top">
                                    <paragraph>• Hyperplasia/cancer<footnoteRef IDREF="_Reffn8.a"/>
                                       <br/>(consensus<footnote ID="_RefID0EPMDI">For an endometrial biopsy to be counted as consensus endometrial hyperplasia or cancer, at least 2 pathologists had to agree on the diagnosis.</footnote>)</paragraph>
                                 </td>
                                 <td align="center" styleCode="Botrule " valign="top">
                                    <paragraph>0 (0)<footnote ID="_Reffn8.d">Significant (p &lt; 0.05) in comparison with corresponding dose of Premarin alone.</footnote>
                                    </paragraph>
                                 </td>
                                 <td align="center" styleCode="Botrule " valign="top">
                                    <paragraph>15 (27)</paragraph>
                                 </td>
                                 <td align="center" styleCode="Botrule " valign="top">
                                    <paragraph>0 (0)<footnoteRef IDREF="_Reffn8.d"/>
                                    </paragraph>
                                 </td>
                                 <td align="center" styleCode="Botrule " valign="top">
                                    <paragraph>10 (15)</paragraph>
                                 </td>
                                 <td align="center" styleCode="Botrule " valign="top">
                                    <paragraph>0 (0)<footnoteRef IDREF="_Reffn8.d"/>
                                    </paragraph>
                                 </td>
                                 <td align="center" styleCode="Botrule " valign="top">
                                    <paragraph>2 (3)</paragraph>
                                 </td>
                              </tr>
                           </tbody>
                        </table>
                     </text>
                     <effectiveTime value="20250429"/>
                  </section>
               </component>
               <component>
                  <section ID="S14.4">
                     <id root="d89e5008-400f-4e7c-968b-a7990603853a"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title>14.4 Effects on Uterine Bleeding or Spotting</title>
                     <text>
                        <paragraph>The effects of PREMPRO on uterine bleeding or spotting, as recorded on daily diary cards, were evaluated in 2 clinical trials. Results are shown in Figures 1 and 2.</paragraph>
                        <renderMultiMedia ID="fig1" referencedObject="MM2">
                           <caption>Figure 1. Patients With Cumulative Amenorrhea Over Time Percentages of Women With No Bleeding Or Spotting at a Given Cycle Through Cycle 13 Intent-To-Treat Population, LOCF </caption>
                        </renderMultiMedia>
                        <paragraph>Note: The percentage of patients who were amenorrheic in a given cycle and through cycle 13 is shown. If data were missing, the bleeding value from the last reported day was carried forward (LOCF).</paragraph>
                        <renderMultiMedia ID="fig2" referencedObject="MM3">
                           <caption>Figure 2. Patients With Cumulative Amenorrhea Over Time Percentages of Women With No Bleeding or Spotting at a Given Cycle Through Cycle 13 Intent-To-Treat Population, LOCF </caption>
                        </renderMultiMedia>
                        <paragraph>Note: The percentage of patients who were amenorrheic in a given cycle and through cycle 13 is shown. If data were missing, the bleeding value from the last reported day was carried forward (LOCF).</paragraph>
                     </text>
                     <effectiveTime value="20250429"/>
                     <component>
                        <observationMedia ID="MM2">
                           <text>Figure 1</text>
                           <value mediaType="image/jpeg" xsi:type="ED">
                              <reference value="prempro-02.jpg"/>
                           </value>
                        </observationMedia>
                     </component>
                     <component>
                        <observationMedia ID="MM3">
                           <text>Figure 2</text>
                           <value mediaType="image/jpeg" xsi:type="ED">
                              <reference value="prempro-03.jpg"/>
                           </value>
                        </observationMedia>
                     </component>
                  </section>
               </component>
               <component>
                  <section ID="S14.5">
                     <id root="ca1ba15f-1015-4732-862b-97629fc4e947"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title>14.5 Effects on Bone Mineral Density</title>
                     <effectiveTime value="20250429"/>
                     <component>
                        <section ID="healthandosteo">
                           <id root="4562f174-96ff-48e2-b7aa-f86d7fc30114"/>
                           <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                           <text>
                              <paragraph>
                                 <content styleCode="italics">Health and Osteoporosis, Progestin and Estrogen (HOPE) Study</content>
                              </paragraph>
                              <paragraph>The HOPE study was a double-blind, randomized, placebo/active-drug-controlled, multicenter study of healthy postmenopausal women with an intact uterus. Subjects (mean age 53.3 ± 4.9 years) were 2.3 ± 0.9 years on average since menopause and took one 600 mg tablet of elemental calcium (Caltrate™) daily. Subjects were not given Vitamin D supplements. They were treated with PREMPRO 0.625 mg/2.5 mg, 0.45 mg/1.5 mg or 0.3 mg/1.5 mg, comparable doses of Premarin alone, or placebo. Prevention of bone loss was assessed by measurement of bone mineral density (BMD), primarily at the anteroposterior lumbar spine (L<sub>2</sub> to L<sub>4</sub>). Secondarily, BMD measurements of the total body, femoral neck, and trochanter were also analyzed. Serum osteocalcin, urinary calcium, and N-telopeptide were used as bone turnover markers (BTM) at cycles 6, 13, 19, and 26.</paragraph>
                           </text>
                           <effectiveTime value="20190531"/>
                        </section>
                     </component>
                     <component>
                        <section ID="Gee2cc9ea-d140-40a5-be87-5c91034004eb">
                           <id root="042b70d4-599a-4979-9e94-d2d6cb733516"/>
                           <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                           <text>
                              <paragraph>
                                 <content styleCode="italics">Intent-to-treat subjects</content>
                              </paragraph>
                              <paragraph>All active treatment groups showed significant differences from placebo in each of the four BMD endpoints. These significant differences were seen at cycles 6, 13, 19, and 26.</paragraph>
                              <paragraph>The percent changes from baseline to final evaluation are shown in Table 9.</paragraph>
                              <table ID="_Reftable9" width="100%">
                                 <caption>Table 9: Percent Change in Bone Mineral Density: Comparison Between Active and Placebo Groups in the Intent-To-Treat Population, LOCF</caption>
                                 <col width="27%"/>
                                 <col width="10%"/>
                                 <col width="20%"/>
                                 <col width="28%"/>
                                 <col width="15%"/>
                                 <tbody>
                                    <tr>
                                       <td styleCode="Botrule Toprule " valign="bottom">
                                          <paragraph>Region Evaluated Treatment Group<footnote ID="_RefID0E3QDI">Identified by dosage (mg/mg) of Premarin/MPA or placebo.</footnote>
                                          </paragraph>
                                       </td>
                                       <td align="center" styleCode="Botrule Toprule " valign="bottom">
                                          <paragraph>No. of Subjects</paragraph>
                                       </td>
                                       <td align="center" styleCode="Botrule Toprule " valign="bottom">
                                          <paragraph>Baseline<br/>(g/cm<sup>2</sup>)<br/>Mean ± SD</paragraph>
                                       </td>
                                       <td align="center" styleCode="Botrule Toprule " valign="bottom">
                                          <paragraph>Change from<br/>Baseline (%) Adjusted<br/>Mean ± SE</paragraph>
                                       </td>
                                       <td align="center" styleCode="Botrule Toprule " valign="bottom">
                                          <paragraph>p-Value<br/>vs.<br/>Placebo</paragraph>
                                       </td>
                                    </tr>
                                    <tr>
                                       <td styleCode="Toprule " valign="top">
                                          <paragraph>L<sub>2</sub> to L<sub>4</sub> BMD</paragraph>
                                       </td>
                                       <td styleCode="Toprule " valign="top"/>
                                       <td styleCode="Toprule " valign="top"/>
                                       <td styleCode="Toprule " valign="top"/>
                                       <td styleCode="Toprule " valign="top"/>
                                    </tr>
                                    <tr>
                                       <td valign="top">
                                          <paragraph>  0.625/2.5</paragraph>
                                       </td>
                                       <td align="center" valign="top">
                                          <paragraph>81</paragraph>
                                       </td>
                                       <td align="center" valign="top">
                                          <paragraph>1.14 ± 0.16</paragraph>
                                       </td>
                                       <td align="center" valign="top">
                                          <paragraph>3.28 ± 0.37</paragraph>
                                       </td>
                                       <td align="center" valign="top">
                                          <paragraph>&lt;0.001</paragraph>
                                       </td>
                                    </tr>
                                    <tr>
                                       <td valign="top">
                                          <paragraph>  0.45/1.5</paragraph>
                                       </td>
                                       <td align="center" valign="top">
                                          <paragraph>89</paragraph>
                                       </td>
                                       <td align="center" valign="top">
                                          <paragraph>1.16 ± 0.14</paragraph>
                                       </td>
                                       <td align="center" valign="top">
                                          <paragraph>2.18 ± 0.35</paragraph>
                                       </td>
                                       <td align="center" valign="top">
                                          <paragraph>&lt;0.001</paragraph>
                                       </td>
                                    </tr>
                                    <tr>
                                       <td valign="top">
                                          <paragraph>  0.3/1.5</paragraph>
                                       </td>
                                       <td align="center" valign="top">
                                          <paragraph>90</paragraph>
                                       </td>
                                       <td align="center" valign="top">
                                          <paragraph>1.14 ± 0.15</paragraph>
                                       </td>
                                       <td align="center" valign="top">
                                          <paragraph>1.71 ± 0.35</paragraph>
                                       </td>
                                       <td align="center" valign="top">
                                          <paragraph>&lt;0.001</paragraph>
                                       </td>
                                    </tr>
                                    <tr>
                                       <td valign="top">
                                          <paragraph>  Placebo</paragraph>
                                       </td>
                                       <td align="center" valign="top">
                                          <paragraph>85</paragraph>
                                       </td>
                                       <td align="center" valign="top">
                                          <paragraph>1.14 ± 0.14</paragraph>
                                       </td>
                                       <td align="center" valign="top">
                                          <paragraph>-2.45 ± 0.36</paragraph>
                                       </td>
                                       <td valign="top"/>
                                    </tr>
                                    <tr>
                                       <td valign="top">
                                          <paragraph>Total body BMD</paragraph>
                                       </td>
                                       <td valign="top"/>
                                       <td valign="top"/>
                                       <td valign="top"/>
                                       <td valign="top"/>
                                    </tr>
                                    <tr>
                                       <td valign="top">
                                          <paragraph>  0.625/2.5</paragraph>
                                       </td>
                                       <td align="center" valign="top">
                                          <paragraph>81</paragraph>
                                       </td>
                                       <td align="center" valign="top">
                                          <paragraph>1.14 ± 0.08</paragraph>
                                       </td>
                                       <td align="center" valign="top">
                                          <paragraph>0.87 ± 0.17</paragraph>
                                       </td>
                                       <td align="center" valign="top">
                                          <paragraph>&lt;0.001</paragraph>
                                       </td>
                                    </tr>
                                    <tr>
                                       <td valign="top">
                                          <paragraph>  0.45/1.5</paragraph>
                                       </td>
                                       <td align="center" valign="top">
                                          <paragraph>89</paragraph>
                                       </td>
                                       <td align="center" valign="top">
                                          <paragraph>1.14 ± 0.07</paragraph>
                                       </td>
                                       <td align="center" valign="top">
                                          <paragraph>0.59 ± 0.17</paragraph>
                                       </td>
                                       <td align="center" valign="top">
                                          <paragraph>&lt;0.001</paragraph>
                                       </td>
                                    </tr>
                                    <tr>
                                       <td valign="top">
                                          <paragraph>  0.3/1.5</paragraph>
                                       </td>
                                       <td align="center" valign="top">
                                          <paragraph>91</paragraph>
                                       </td>
                                       <td align="center" valign="top">
                                          <paragraph>1.13 ± 0.08</paragraph>
                                       </td>
                                       <td align="center" valign="top">
                                          <paragraph>0.60 ± 0.16</paragraph>
                                       </td>
                                       <td align="center" valign="top">
                                          <paragraph>&lt;0.001</paragraph>
                                       </td>
                                    </tr>
                                    <tr>
                                       <td valign="top">
                                          <paragraph>  Placebo</paragraph>
                                       </td>
                                       <td align="center" valign="top">
                                          <paragraph>85</paragraph>
                                       </td>
                                       <td align="center" valign="top">
                                          <paragraph>1.13 ± 0.08</paragraph>
                                       </td>
                                       <td align="center" valign="top">
                                          <paragraph>-1.50 ± 0.17</paragraph>
                                       </td>
                                       <td valign="top"/>
                                    </tr>
                                    <tr>
                                       <td valign="top">
                                          <paragraph>Femoral neck BMD</paragraph>
                                       </td>
                                       <td valign="top"/>
                                       <td valign="top"/>
                                       <td valign="top"/>
                                       <td valign="top"/>
                                    </tr>
                                    <tr>
                                       <td valign="top">
                                          <paragraph>  0.625/2.5</paragraph>
                                       </td>
                                       <td align="center" valign="top">
                                          <paragraph>81</paragraph>
                                       </td>
                                       <td align="center" valign="top">
                                          <paragraph>0.89 ± 0.14</paragraph>
                                       </td>
                                       <td align="center" valign="top">
                                          <paragraph>1.62 ± 0.46</paragraph>
                                       </td>
                                       <td align="center" valign="top">
                                          <paragraph>&lt;0.001</paragraph>
                                       </td>
                                    </tr>
                                    <tr>
                                       <td valign="top">
                                          <paragraph>  0.45/1.5</paragraph>
                                       </td>
                                       <td align="center" valign="top">
                                          <paragraph>89</paragraph>
                                       </td>
                                       <td align="center" valign="top">
                                          <paragraph>0.89 ± 0.12</paragraph>
                                       </td>
                                       <td align="center" valign="top">
                                          <paragraph>1.48 ± 0.44</paragraph>
                                       </td>
                                       <td align="center" valign="top">
                                          <paragraph>&lt;0.001</paragraph>
                                       </td>
                                    </tr>
                                    <tr>
                                       <td valign="top">
                                          <paragraph>  0.3/1.5</paragraph>
                                       </td>
                                       <td align="center" valign="top">
                                          <paragraph>91</paragraph>
                                       </td>
                                       <td align="center" valign="top">
                                          <paragraph>0.86 ± 0.11</paragraph>
                                       </td>
                                       <td align="center" valign="top">
                                          <paragraph>1.31 ± 0.43</paragraph>
                                       </td>
                                       <td align="center" valign="top">
                                          <paragraph>&lt;0.001</paragraph>
                                       </td>
                                    </tr>
                                    <tr>
                                       <td valign="top">
                                          <paragraph>  Placebo</paragraph>
                                       </td>
                                       <td align="center" valign="top">
                                          <paragraph>85</paragraph>
                                       </td>
                                       <td align="center" valign="top">
                                          <paragraph>0.88 ± 0.14</paragraph>
                                       </td>
                                       <td align="center" valign="top">
                                          <paragraph>-1.72 ± 0.45</paragraph>
                                       </td>
                                       <td valign="top"/>
                                    </tr>
                                    <tr>
                                       <td valign="top">
                                          <paragraph>Femoral trochanter BMD</paragraph>
                                       </td>
                                       <td valign="top"/>
                                       <td valign="top"/>
                                       <td valign="top"/>
                                       <td valign="top"/>
                                    </tr>
                                    <tr>
                                       <td valign="top">
                                          <paragraph>  0.625/2.5</paragraph>
                                       </td>
                                       <td align="center" valign="top">
                                          <paragraph>81</paragraph>
                                       </td>
                                       <td align="center" valign="top">
                                          <paragraph>0.77 ± 0.14</paragraph>
                                       </td>
                                       <td align="center" valign="top">
                                          <paragraph>3.35 ± 0.59</paragraph>
                                       </td>
                                       <td align="center" valign="top">
                                          <paragraph>0.002</paragraph>
                                       </td>
                                    </tr>
                                    <tr>
                                       <td valign="top">
                                          <paragraph>  0.45/1.5</paragraph>
                                       </td>
                                       <td align="center" valign="top">
                                          <paragraph>89</paragraph>
                                       </td>
                                       <td align="center" valign="top">
                                          <paragraph>0.76 ± 0.12</paragraph>
                                       </td>
                                       <td align="center" valign="top">
                                          <paragraph>2.84 ± 0.57</paragraph>
                                       </td>
                                       <td align="center" valign="top">
                                          <paragraph>0.011</paragraph>
                                       </td>
                                    </tr>
                                    <tr>
                                       <td valign="top">
                                          <paragraph>  0.3/1.5</paragraph>
                                       </td>
                                       <td align="center" valign="top">
                                          <paragraph>91</paragraph>
                                       </td>
                                       <td align="center" valign="top">
                                          <paragraph>0.76 ± 0.12</paragraph>
                                       </td>
                                       <td align="center" valign="top">
                                          <paragraph>3.93 ± 0.56</paragraph>
                                       </td>
                                       <td align="center" valign="top">
                                          <paragraph>&lt;0.001</paragraph>
                                       </td>
                                    </tr>
                                    <tr>
                                       <td styleCode="Botrule " valign="top">
                                          <paragraph>  Placebo</paragraph>
                                       </td>
                                       <td align="center" styleCode="Botrule " valign="top">
                                          <paragraph>85</paragraph>
                                       </td>
                                       <td align="center" styleCode="Botrule " valign="top">
                                          <paragraph>0.75 ± 0.12</paragraph>
                                       </td>
                                       <td align="center" styleCode="Botrule " valign="top">
                                          <paragraph>0.81 ± 0.58</paragraph>
                                       </td>
                                       <td styleCode="Botrule " valign="top"/>
                                    </tr>
                                 </tbody>
                              </table>
                              <paragraph>Figure 3 shows the cumulative percentage of subjects with percent changes from baseline in spine BMD equal to or greater than the percent change shown on the x-axis. </paragraph>
                              <renderMultiMedia ID="fig3" referencedObject="MM4">
                                 <caption>Figure 3. Cumulative Percent of Subjects With Changes from Baseline in Spine BMD of Given Magnitude or Greater in PREMARIN/MPA and Placebo Groups </caption>
                              </renderMultiMedia>
                              <paragraph>The mean percent changes from baseline in L<sub>2</sub> to L<sub>4</sub> BMD for women who completed the bone density study are shown with standard error bars by treatment group in Figure 4. Significant differences between each of the PREMPRO dosage groups and placebo were found at cycles 6, 13, 19, and 26.</paragraph>
                              <renderMultiMedia ID="fig4" referencedObject="MM5">
                                 <caption>Figure 4. Adjusted Mean (SE) Percent Change from Baseline at Each Cycle in Spine BMD: Subjects Completing in PREMARIN/MPA Groups and Placebo </caption>
                              </renderMultiMedia>
                              <paragraph>The bone turnover markers, serum osteocalcin and urinary N-telopeptide, significantly decreased (p &lt; 0.001) in all active-treatment groups at cycles 6, 13, 19, and 26 compared with the placebo group. Larger mean decreases from baseline were seen with the active groups than with the placebo group. Significant differences from placebo were seen less frequently in urine calcium; only with PREMPRO 0.625 mg/2.5 mg and 0.45 mg/1.5 mg were there significantly larger mean decreases than with placebo at 3 or more of the 4 time points.</paragraph>
                           </text>
                           <effectiveTime value="20250429"/>
                           <component>
                              <observationMedia ID="MM4">
                                 <text>Figure 3</text>
                                 <value mediaType="image/jpeg" xsi:type="ED">
                                    <reference value="prempro-04.jpg"/>
                                 </value>
                              </observationMedia>
                           </component>
                           <component>
                              <observationMedia ID="MM5">
                                 <text>Figure 4</text>
                                 <value mediaType="image/jpeg" xsi:type="ED">
                                    <reference value="prempro-05.jpg"/>
                                 </value>
                              </observationMedia>
                           </component>
                        </section>
                     </component>
                  </section>
               </component>
               <component>
                  <section ID="S14.6">
                     <id root="5580deb0-6412-4211-83b6-de462841c197"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title>14.6 Women's Health Initiative Studies</title>
                     <text>
                        <paragraph>The WHI enrolled approximately 27,000 predominantly healthy postmenopausal women in two substudies to assess the risks and benefits of daily oral CE (0.625 mg)-alone or in combination with MPA (2.5 mg) compared to placebo in the prevention of certain chronic diseases. The primary endpoint was the incidence of CHD (defined as nonfatal MI, silent MI and CHD death), with invasive breast cancer as the primary adverse outcome. A "global index" included the earliest occurrence of CHD, invasive breast cancer, stroke, PE, endometrial cancer (only in the CE plus MPA substudy), colorectal cancer, hip fracture, or death due to other causes. These substudies did not evaluate the effects of CE plus MPA or CE-alone on menopausal symptoms.</paragraph>
                     </text>
                     <effectiveTime value="20250429"/>
                     <component>
                        <section ID="G6a91e3bd-fada-4769-b673-db51a6a79391">
                           <id root="8ee0d282-89ed-4c49-8ffe-2c3dcc4cb8f7"/>
                           <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                           <text>
                              <paragraph>
                                 <content styleCode="italics">WHI Estrogen Plus Progestin Substudy</content>
                              </paragraph>
                              <paragraph>The WHI estrogen plus progestin substudy was stopped early. According to the predefined stopping rule, after an average follow-up of 5.6 years of treatment, the increased risk of invasive breast cancer and cardiovascular events exceeded the specified benefits included in the "global index." The absolute excess risk of events included in the "global index" was 19 per 10,000 women-years.</paragraph>
                              <paragraph>For those outcomes included in the WHI "global index" that reached statistical significance after 5.6 years of follow-up, the absolute excess risks per 10,000 women-years in the group treated with CE plus MPA were 7 more CHD events, 8 more strokes, 10 more PEs, and 8 more invasive breast cancers, while the absolute risk reductions per 10,000 women-years were 6 fewer colorectal cancers and 5 fewer hip fractures.</paragraph>
                              <paragraph>Results of the CE plus MPA substudy, which included 16,608 women (average 63 years of age, range 50 to 79; 83.9% White, 6.8% Black, 5.4% Hispanic, 3.9% Other) are presented in Table 10. These results reflect centrally adjudicated data after an average follow-up of 5.6 years.</paragraph>
                              <table ID="_Reftable10" width="100%">
                                 <caption>TABLE 10: Relative and Absolute Risk Seen in the Estrogen Plus Progestin Substudy of WHI at an Average of 5.6 Years<footnote ID="_RefID0E4XDI">Adapted from numerous WHI publications. WHI publications can be viewed at <linkHtml href="http://www.nhlbi.nih.gov/whi">www.nhlbi.nih.gov/whi</linkHtml>.</footnote>
                                    <sup>,</sup>
                                    <footnote ID="_RefID0E6XDI">Results are based on centrally adjudicated data.</footnote>
                                 </caption>
                                 <col width="30%"/>
                                 <col width="30%"/>
                                 <col width="20%"/>
                                 <col width="20%"/>
                                 <tbody>
                                    <tr>
                                       <td styleCode="Toprule " valign="top"/>
                                       <td align="center" styleCode="Toprule " valign="top">
                                          <paragraph>Relative Risk<br/>CE/MPA vs. Placebo<br/>(95% nCI<footnote ID="_RefID0EZYDI">Nominal confidence intervals unadjusted for multiple looks and multiple comparisons.</footnote>)</paragraph>
                                       </td>
                                       <td align="center" styleCode="Botrule Toprule " valign="top">
                                          <paragraph>
                                             <br/>CE/MPA<br/>n = 8,506</paragraph>
                                       </td>
                                       <td align="center" styleCode="Botrule Toprule " valign="top">
                                          <paragraph>
                                             <br/>Placebo<br/>n = 8,102</paragraph>
                                       </td>
                                    </tr>
                                    <tr>
                                       <td styleCode="Botrule " valign="middle">
                                          <paragraph>Event</paragraph>
                                       </td>
                                       <td styleCode="Botrule " valign="top"/>
                                       <td align="center" colspan="2" styleCode="Botrule " valign="top">
                                          <paragraph>Absolute Risk per 10,000<br/>Women-Years</paragraph>
                                       </td>
                                    </tr>
                                    <tr>
                                       <td styleCode="Toprule " valign="top">
                                          <paragraph>CHD events</paragraph>
                                       </td>
                                       <td align="center" styleCode="Toprule " valign="top">
                                          <paragraph>1.23 (0.99–1.53)</paragraph>
                                       </td>
                                       <td align="center" styleCode="Toprule " valign="top">
                                          <paragraph>41</paragraph>
                                       </td>
                                       <td align="center" styleCode="Toprule " valign="top">
                                          <paragraph>34</paragraph>
                                       </td>
                                    </tr>
                                    <tr>
                                       <td valign="top">
                                          <paragraph>  <content styleCode="italics">Non-fatal MI</content>
                                          </paragraph>
                                       </td>
                                       <td align="center" valign="top">
                                          <paragraph>
                                             <content styleCode="italics">1.28 (1.00–1.63)</content>
                                          </paragraph>
                                       </td>
                                       <td align="center" valign="top">
                                          <paragraph>
                                             <content styleCode="italics">31</content>
                                          </paragraph>
                                       </td>
                                       <td align="center" valign="top">
                                          <paragraph>
                                             <content styleCode="italics">25</content>
                                          </paragraph>
                                       </td>
                                    </tr>
                                    <tr>
                                       <td valign="top">
                                          <paragraph>  <content styleCode="italics">CHD death</content>
                                          </paragraph>
                                       </td>
                                       <td align="center" valign="top">
                                          <paragraph>
                                             <content styleCode="italics">1.10 (0.70–1.75)</content>
                                          </paragraph>
                                       </td>
                                       <td align="center" valign="top">
                                          <paragraph>
                                             <content styleCode="italics">8</content>
                                          </paragraph>
                                       </td>
                                       <td align="center" valign="top">
                                          <paragraph>
                                             <content styleCode="italics">8</content>
                                          </paragraph>
                                       </td>
                                    </tr>
                                    <tr>
                                       <td valign="top">
                                          <paragraph>All Strokes</paragraph>
                                       </td>
                                       <td align="center" valign="top">
                                          <paragraph>1.31 (1.03–1.68)</paragraph>
                                       </td>
                                       <td align="center" valign="top">
                                          <paragraph>33</paragraph>
                                       </td>
                                       <td align="center" valign="top">
                                          <paragraph>25</paragraph>
                                       </td>
                                    </tr>
                                    <tr>
                                       <td valign="top">
                                          <paragraph>  <content styleCode="italics">Ischemic stroke</content>
                                          </paragraph>
                                       </td>
                                       <td align="center" valign="top">
                                          <paragraph>
                                             <content styleCode="italics">1.44 (1.09–1.90)</content>
                                          </paragraph>
                                       </td>
                                       <td align="center" valign="top">
                                          <paragraph>
                                             <content styleCode="italics">26</content>
                                          </paragraph>
                                       </td>
                                       <td align="center" valign="top">
                                          <paragraph>
                                             <content styleCode="italics">18</content>
                                          </paragraph>
                                       </td>
                                    </tr>
                                    <tr>
                                       <td valign="top">
                                          <paragraph>Deep vein thrombosis<footnote ID="_Reffn10.d">Not included in "global index."</footnote>
                                          </paragraph>
                                       </td>
                                       <td align="center" valign="top">
                                          <paragraph>1.95 (1.43–2.67)</paragraph>
                                       </td>
                                       <td align="center" valign="top">
                                          <paragraph>26</paragraph>
                                       </td>
                                       <td align="center" valign="top">
                                          <paragraph>13</paragraph>
                                       </td>
                                    </tr>
                                    <tr>
                                       <td valign="top">
                                          <paragraph>Pulmonary embolism</paragraph>
                                       </td>
                                       <td align="center" valign="top">
                                          <paragraph>2.13 (1.45–3.11)</paragraph>
                                       </td>
                                       <td align="center" valign="top">
                                          <paragraph>18</paragraph>
                                       </td>
                                       <td align="center" valign="top">
                                          <paragraph>8</paragraph>
                                       </td>
                                    </tr>
                                    <tr>
                                       <td valign="top">
                                          <paragraph>Invasive breast cancer<footnote ID="_RefID0EV2DI">Includes metastatic and non-metastatic breast cancer, with the exception of <content styleCode="italics">in situ</content> breast cancer. </footnote>
                                          </paragraph>
                                       </td>
                                       <td align="center" valign="top">
                                          <paragraph>1.24 (1.01–1.54)</paragraph>
                                       </td>
                                       <td align="center" valign="top">
                                          <paragraph>41</paragraph>
                                       </td>
                                       <td align="center" valign="top">
                                          <paragraph>33</paragraph>
                                       </td>
                                    </tr>
                                    <tr>
                                       <td valign="top">
                                          <paragraph>Colorectal cancer</paragraph>
                                       </td>
                                       <td align="center" valign="top">
                                          <paragraph>0.61 (0.42–0.87)</paragraph>
                                       </td>
                                       <td align="center" valign="top">
                                          <paragraph>10</paragraph>
                                       </td>
                                       <td align="center" valign="top">
                                          <paragraph>16</paragraph>
                                       </td>
                                    </tr>
                                    <tr>
                                       <td valign="top">
                                          <paragraph>Endometrial cancer<footnoteRef IDREF="_Reffn10.d"/>
                                          </paragraph>
                                       </td>
                                       <td align="center" valign="top">
                                          <paragraph>0.81 (0.48–1.36)</paragraph>
                                       </td>
                                       <td align="center" valign="top">
                                          <paragraph>6</paragraph>
                                       </td>
                                       <td align="center" valign="top">
                                          <paragraph>7</paragraph>
                                       </td>
                                    </tr>
                                    <tr>
                                       <td valign="top">
                                          <paragraph>Cervical cancer<footnoteRef IDREF="_Reffn10.d"/>
                                          </paragraph>
                                       </td>
                                       <td align="center" valign="top">
                                          <paragraph>1.44 (0.47–4.42)</paragraph>
                                       </td>
                                       <td align="center" valign="top">
                                          <paragraph>2</paragraph>
                                       </td>
                                       <td align="center" valign="top">
                                          <paragraph>1</paragraph>
                                       </td>
                                    </tr>
                                    <tr>
                                       <td valign="top">
                                          <paragraph>Hip fracture</paragraph>
                                       </td>
                                       <td align="center" valign="top">
                                          <paragraph>0.67 (0.47–0.96)</paragraph>
                                       </td>
                                       <td align="center" valign="top">
                                          <paragraph>11</paragraph>
                                       </td>
                                       <td align="center" valign="top">
                                          <paragraph>16</paragraph>
                                       </td>
                                    </tr>
                                    <tr>
                                       <td valign="top">
                                          <paragraph>Vertebral fractures<footnoteRef IDREF="_Reffn10.d"/>
                                          </paragraph>
                                       </td>
                                       <td align="center" valign="top">
                                          <paragraph>0.65 (0.46–0.92)</paragraph>
                                       </td>
                                       <td align="center" valign="top">
                                          <paragraph>11</paragraph>
                                       </td>
                                       <td align="center" valign="top">
                                          <paragraph>17</paragraph>
                                       </td>
                                    </tr>
                                    <tr>
                                       <td valign="top">
                                          <paragraph>Lower arm/wrist fractures<footnoteRef IDREF="_Reffn10.d"/>
                                          </paragraph>
                                       </td>
                                       <td align="center" valign="top">
                                          <paragraph>0.71 (0.59–0.85)</paragraph>
                                       </td>
                                       <td align="center" valign="top">
                                          <paragraph>44</paragraph>
                                       </td>
                                       <td align="center" valign="top">
                                          <paragraph>62</paragraph>
                                       </td>
                                    </tr>
                                    <tr>
                                       <td valign="top">
                                          <paragraph>Total fractures<footnoteRef IDREF="_Reffn10.d"/>
                                          </paragraph>
                                       </td>
                                       <td align="center" valign="top">
                                          <paragraph>0.76 (0.69–0.83)</paragraph>
                                       </td>
                                       <td align="center" valign="top">
                                          <paragraph>152</paragraph>
                                       </td>
                                       <td align="center" valign="top">
                                          <paragraph>199</paragraph>
                                       </td>
                                    </tr>
                                    <tr>
                                       <td valign="top">
                                          <paragraph>Overall Mortality<footnote ID="_RefID0ES4DI">All deaths, except from breast or colorectal cancer, definite or probable CHD, PE or cerebrovascular disease.</footnote>
                                          </paragraph>
                                       </td>
                                       <td align="center" valign="top">
                                          <paragraph>1.00 (0.83–1.19)</paragraph>
                                       </td>
                                       <td align="center" valign="top">
                                          <paragraph>52</paragraph>
                                       </td>
                                       <td align="center" valign="top">
                                          <paragraph>52</paragraph>
                                       </td>
                                    </tr>
                                    <tr>
                                       <td styleCode="Botrule " valign="top">
                                          <paragraph>Global Index<footnote ID="_RefID0E14DI">A subset of the events was combined in a "global index" defined as the earliest occurrence of CHD events, invasive breast cancer, stroke, pulmonary embolism, colorectal cancer, hip fracture, or death due to other causes.</footnote>
                                          </paragraph>
                                       </td>
                                       <td align="center" styleCode="Botrule " valign="top">
                                          <paragraph>1.13 (1.02–1.25)</paragraph>
                                       </td>
                                       <td align="center" styleCode="Botrule " valign="top">
                                          <paragraph>184</paragraph>
                                       </td>
                                       <td align="center" styleCode="Botrule " valign="top">
                                          <paragraph>165</paragraph>
                                       </td>
                                    </tr>
                                 </tbody>
                              </table>
                              <paragraph>Timing of the initiation of estrogen plus progestin therapy relative to the start of menopause may affect the overall risk benefit profile. The WHI estrogen plus progestin substudy stratified by age showed in women 50 to 59 years of age, a non-significant trend toward reduced risk for overall mortality <content styleCode="italics">[hazard ratio (HR) 0.69 (95% CI, 0.44–1.07)]</content>.</paragraph>
                           </text>
                           <effectiveTime value="20250429"/>
                        </section>
                     </component>
                     <component>
                        <section ID="Gd7189322-bd14-4f03-8601-0b50e65db89b">
                           <id root="01e4f000-088c-4adb-954a-314653e4ebaa"/>
                           <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                           <text>
                              <paragraph>
                                 <content styleCode="italics">WHI Estrogen-Alone Substudy</content>
                              </paragraph>
                              <paragraph>The WHI estrogen-alone substudy was stopped early because an increased risk of stroke was observed, and it was deemed that no further information would be obtained regarding the risks and benefits of estrogen-alone in predetermined primary endpoints.</paragraph>
                              <paragraph>Results of the estrogen-alone substudy, which included 10,739 women (average 63 years of age, range 50 to 79; 75.3% White, 15.1% Black, 6.1% Hispanic, 3.6% Other) after an average follow-up of 7.1 years, are presented in <linkHtml href="#Table11">Table 11</linkHtml>.</paragraph>
                              <table ID="Table11" width="100%">
                                 <caption>Table 11: Relative and Absolute Risk Seen in the Estrogen-Alone Substudy of WHI<footnote ID="_RefID0E15DI">Adapted from numerous WHI publications. WHI publications can be viewed at <linkHtml href="http://www.nhlbi.nih.gov/whi">www.nhlbi.nih.gov/whi</linkHtml>.</footnote>
                                 </caption>
                                 <col width="30%"/>
                                 <col width="30%"/>
                                 <col width="20%"/>
                                 <col width="20%"/>
                                 <tbody>
                                    <tr>
                                       <td styleCode="Toprule " valign="top"/>
                                       <td align="center" styleCode="Toprule " valign="top">
                                          <paragraph>Relative Risk<br/>CE vs. Placebo<br/>(95% nCI<footnote ID="_RefID0EU6DI">Nominal confidence intervals unadjusted for multiple looks and multiple comparisons.</footnote>)</paragraph>
                                       </td>
                                       <td align="center" styleCode="Botrule Toprule " valign="top">
                                          <paragraph>
                                             <br/>CE<br/>n = 5,310</paragraph>
                                       </td>
                                       <td align="center" styleCode="Botrule Toprule " valign="top">
                                          <paragraph>
                                             <br/>Placebo<br/>n = 5,429</paragraph>
                                       </td>
                                    </tr>
                                    <tr>
                                       <td styleCode="Botrule " valign="top">
                                          <paragraph>Event</paragraph>
                                       </td>
                                       <td styleCode="Botrule " valign="top"/>
                                       <td align="center" colspan="2" styleCode="Botrule " valign="top">
                                          <paragraph>Absolute Risk per 10,000<br/>Women-Years</paragraph>
                                       </td>
                                    </tr>
                                    <tr>
                                       <td styleCode="Toprule " valign="top">
                                          <paragraph>CHD events<footnote ID="_Reffn11.c">Results are based on centrally adjudicated data for an average follow-up of 7.1 years.</footnote>
                                          </paragraph>
                                       </td>
                                       <td align="center" styleCode="Toprule " valign="top">
                                          <paragraph>0.95 (0.78–1.16)</paragraph>
                                       </td>
                                       <td align="center" styleCode="Toprule " valign="top">
                                          <paragraph>54</paragraph>
                                       </td>
                                       <td align="center" styleCode="Toprule " valign="top">
                                          <paragraph>57</paragraph>
                                       </td>
                                    </tr>
                                    <tr>
                                       <td valign="top">
                                          <paragraph>  <content styleCode="italics">Non-fatal MI</content>
                                             <footnoteRef IDREF="_Reffn11.c"/>
                                          </paragraph>
                                       </td>
                                       <td align="center" valign="top">
                                          <paragraph>
                                             <content styleCode="italics">0.91 (0.73–1.14)</content>
                                          </paragraph>
                                       </td>
                                       <td align="center" valign="top">
                                          <paragraph>
                                             <content styleCode="italics">40</content>
                                          </paragraph>
                                       </td>
                                       <td align="center" valign="top">
                                          <paragraph>
                                             <content styleCode="italics">43</content>
                                          </paragraph>
                                       </td>
                                    </tr>
                                    <tr>
                                       <td valign="top">
                                          <paragraph>  <content styleCode="italics">CHD death</content>
                                             <footnoteRef IDREF="_Reffn11.c"/>
                                          </paragraph>
                                       </td>
                                       <td align="center" valign="top">
                                          <paragraph>
                                             <content styleCode="italics">1.01 (0.71–1.43)</content>
                                          </paragraph>
                                       </td>
                                       <td align="center" valign="top">
                                          <paragraph>
                                             <content styleCode="italics">16</content>
                                          </paragraph>
                                       </td>
                                       <td align="center" valign="top">
                                          <paragraph>
                                             <content styleCode="italics">16</content>
                                          </paragraph>
                                       </td>
                                    </tr>
                                    <tr>
                                       <td valign="top">
                                          <paragraph>All Strokes<footnoteRef IDREF="_Reffn11.c"/>
                                          </paragraph>
                                       </td>
                                       <td align="center" valign="top">
                                          <paragraph>1.33 (1.05–1.68)</paragraph>
                                       </td>
                                       <td align="center" valign="top">
                                          <paragraph>45</paragraph>
                                       </td>
                                       <td align="center" valign="top">
                                          <paragraph>33</paragraph>
                                       </td>
                                    </tr>
                                    <tr>
                                       <td valign="top">
                                          <paragraph>  <content styleCode="italics">Ischemic stroke</content>
                                             <footnoteRef IDREF="_Reffn11.c"/>
                                          </paragraph>
                                       </td>
                                       <td align="center" valign="top">
                                          <paragraph>
                                             <content styleCode="italics">1.55 (1.19–2.01)</content>
                                          </paragraph>
                                       </td>
                                       <td align="center" valign="top">
                                          <paragraph>
                                             <content styleCode="italics">38</content>
                                          </paragraph>
                                       </td>
                                       <td align="center" valign="top">
                                          <paragraph>
                                             <content styleCode="italics">25</content>
                                          </paragraph>
                                       </td>
                                    </tr>
                                    <tr>
                                       <td valign="top">
                                          <paragraph>Deep vein thrombosis<footnoteRef IDREF="_Reffn11.c"/>
                                             <sup>,</sup>
                                             <footnote ID="_Reffn11.d">Not included in "global index."</footnote>
                                          </paragraph>
                                       </td>
                                       <td align="center" valign="top">
                                          <paragraph>1.47 (1.06–2.06)</paragraph>
                                       </td>
                                       <td align="center" valign="top">
                                          <paragraph>23</paragraph>
                                       </td>
                                       <td align="center" valign="top">
                                          <paragraph>15</paragraph>
                                       </td>
                                    </tr>
                                    <tr>
                                       <td valign="top">
                                          <paragraph>Pulmonary embolism<footnoteRef IDREF="_Reffn11.c"/>
                                          </paragraph>
                                       </td>
                                       <td align="center" valign="top">
                                          <paragraph>1.37 (0.90–2.07)</paragraph>
                                       </td>
                                       <td align="center" valign="top">
                                          <paragraph>14</paragraph>
                                       </td>
                                       <td align="center" valign="top">
                                          <paragraph>10</paragraph>
                                       </td>
                                    </tr>
                                    <tr>
                                       <td valign="top">
                                          <paragraph>Invasive breast cancer<footnoteRef IDREF="_Reffn11.c"/>
                                          </paragraph>
                                       </td>
                                       <td align="center" valign="top">
                                          <paragraph>0.80 (0.62–1.04)</paragraph>
                                       </td>
                                       <td align="center" valign="top">
                                          <paragraph>28</paragraph>
                                       </td>
                                       <td align="center" valign="top">
                                          <paragraph>34</paragraph>
                                       </td>
                                    </tr>
                                    <tr>
                                       <td valign="top">
                                          <paragraph>Colorectal cancer<footnote ID="_Reffn11.e">Results are based on an average follow-up of 6.8 years.</footnote>
                                          </paragraph>
                                       </td>
                                       <td align="center" valign="top">
                                          <paragraph>1.08 (0.75–1.55)</paragraph>
                                       </td>
                                       <td align="center" valign="top">
                                          <paragraph>17</paragraph>
                                       </td>
                                       <td align="center" valign="top">
                                          <paragraph>16</paragraph>
                                       </td>
                                    </tr>
                                    <tr>
                                       <td valign="top">
                                          <paragraph>Hip fracture<footnoteRef IDREF="_Reffn11.c"/>
                                          </paragraph>
                                       </td>
                                       <td align="center" valign="top">
                                          <paragraph>0.65 (0.45–0.94)</paragraph>
                                       </td>
                                       <td align="center" valign="top">
                                          <paragraph>12</paragraph>
                                       </td>
                                       <td align="center" valign="top">
                                          <paragraph>19</paragraph>
                                       </td>
                                    </tr>
                                    <tr>
                                       <td valign="top">
                                          <paragraph>Vertebral fractures<footnoteRef IDREF="_Reffn11.c"/>
                                             <sup>,</sup>
                                             <footnoteRef IDREF="_Reffn11.d"/>
                                          </paragraph>
                                       </td>
                                       <td align="center" valign="top">
                                          <paragraph>0.64 (0.44–0.93)</paragraph>
                                       </td>
                                       <td align="center" valign="top">
                                          <paragraph>11</paragraph>
                                       </td>
                                       <td align="center" valign="top">
                                          <paragraph>18</paragraph>
                                       </td>
                                    </tr>
                                    <tr>
                                       <td valign="top">
                                          <paragraph>Lower arm/wrist fractures<footnoteRef IDREF="_Reffn11.c"/>
                                             <sup>,</sup>
                                             <footnoteRef IDREF="_Reffn11.d"/>
                                          </paragraph>
                                       </td>
                                       <td align="center" valign="top">
                                          <paragraph>0.58 (0.47–0.72)</paragraph>
                                       </td>
                                       <td align="center" valign="top">
                                          <paragraph>35</paragraph>
                                       </td>
                                       <td align="center" valign="top">
                                          <paragraph>59</paragraph>
                                       </td>
                                    </tr>
                                    <tr>
                                       <td valign="top">
                                          <paragraph>Total fractures<footnoteRef IDREF="_Reffn11.c"/>
                                             <sup>,</sup>
                                             <footnoteRef IDREF="_Reffn11.d"/>
                                          </paragraph>
                                       </td>
                                       <td align="center" valign="top">
                                          <paragraph>0.71 (0.64–0.80)</paragraph>
                                       </td>
                                       <td align="center" valign="top">
                                          <paragraph>144</paragraph>
                                       </td>
                                       <td align="center" valign="top">
                                          <paragraph>197</paragraph>
                                       </td>
                                    </tr>
                                    <tr>
                                       <td valign="top">
                                          <paragraph>Death due to other causes<footnoteRef IDREF="_Reffn11.e"/>
                                             <sup>,</sup>
                                             <footnote ID="_RefID0ECFAK">All deaths, except from breast or colorectal cancer, definite or probable CHD, PE or cerebrovascular disease.</footnote>
                                          </paragraph>
                                       </td>
                                       <td align="center" valign="top">
                                          <paragraph>1.08 (0.88–1.32)</paragraph>
                                       </td>
                                       <td align="center" valign="top">
                                          <paragraph>53</paragraph>
                                       </td>
                                       <td align="center" valign="top">
                                          <paragraph>50</paragraph>
                                       </td>
                                    </tr>
                                    <tr>
                                       <td valign="top">
                                          <paragraph>Overall mortality<footnoteRef IDREF="_Reffn11.c"/>
                                             <sup>,</sup>
                                             <footnoteRef IDREF="_Reffn11.d"/>
                                          </paragraph>
                                       </td>
                                       <td align="center" valign="top">
                                          <paragraph>1.04 (0.88–1.22)</paragraph>
                                       </td>
                                       <td align="center" valign="top">
                                          <paragraph>79</paragraph>
                                       </td>
                                       <td align="center" valign="top">
                                          <paragraph>75</paragraph>
                                       </td>
                                    </tr>
                                    <tr>
                                       <td styleCode="Botrule " valign="top">
                                          <paragraph>Global Index<footnote ID="_RefID0EVFAK">A subset of the events was combined in a "global index" defined as the earliest occurrence of CHD events, invasive breast cancer, stroke, pulmonary embolism, colorectal cancer, hip fracture, or death due to other causes. </footnote>
                                          </paragraph>
                                       </td>
                                       <td align="center" styleCode="Botrule " valign="top">
                                          <paragraph>1.02 (0.92–1.13)</paragraph>
                                       </td>
                                       <td align="center" styleCode="Botrule " valign="top">
                                          <paragraph>206</paragraph>
                                       </td>
                                       <td align="center" styleCode="Botrule " valign="top">
                                          <paragraph>201</paragraph>
                                       </td>
                                    </tr>
                                 </tbody>
                              </table>
                              <paragraph>For those outcomes included in the WHI "global index" that reached statistical significance, the absolute excess risk per 10,000 women-years in the group treated with CE-alone was 12 more strokes while the absolute risk reduction per 10,000 women-years was 7 fewer hip fractures.<sup>9</sup> The absolute excess risk of events included in the "global index" was a non-significant 5 events per 10,000 women-years. There was no difference between the groups in terms of all-cause mortality.</paragraph>
                              <paragraph>No overall difference for primary CHD events (nonfatal MI, silent MI and CHD death) and invasive breast cancer incidence in women receiving CE-alone compared with placebo was reported in final centrally adjudicated results from the estrogen-alone substudy, after an average follow up of 7.1 years.</paragraph>
                              <paragraph>Centrally adjudicated results for stroke events from the estrogen-alone substudy, after an average follow-up of 7.1 years, reported no significant difference in distribution of stroke subtype or severity, including fatal strokes, in women receiving CE-alone compared to placebo. Estrogen-alone increased the risk for ischemic stroke, and this excess risk was present in all subgroups of women examined.<sup>10</sup>
                              </paragraph>
                              <paragraph>Timing of the initiation of estrogen-alone therapy relative to the start of menopause may affect the overall risk benefit profile. The WHI estrogen-alone substudy, stratified by age, showed in women 50 to 59 years of age a non-significant trend toward reduced risk for CHD [HR 0.63 (95% CI, 0.36–1.09)] and overall mortality <content styleCode="italics">[HR 0.71 (95% CI, 0.46–1.11)]</content>.</paragraph>
                           </text>
                           <effectiveTime value="20250429"/>
                        </section>
                     </component>
                  </section>
               </component>
               <component>
                  <section ID="S14.7">
                     <id root="4f558b2a-eea1-4bc9-81cd-6bdece03371f"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title>14.7 Women's Health Initiative Memory Study</title>
                     <text>
                        <paragraph>The WHIMS estrogen plus progestin ancillary study of WHI enrolled 4,532 predominantly healthy postmenopausal women 65 years of age and older (47% were 65 to 69 years of age; 35% were 70 to 74 years of age; and 18% were 75 years of age and older) to evaluate the effects of daily CE (0.625 mg) plus MPA (2.5 mg) on the incidence of probable dementia (primary outcome) compared to placebo.</paragraph>
                        <paragraph>After an average follow-up of 4 years, the relative risk of probable dementia for CE plus MPA versus placebo was 2.05 (95% CI, 1.21–3.48). The absolute risk of probable dementia for CE plus MPA versus placebo was 45 versus 22 cases per 10,000 women-years. Probable dementia as defined in this study included Alzheimer's disease (AD), vascular dementia (VaD) and mixed types (having features of both AD and VaD). The most common classification of probable dementia in the treatment group and the placebo group was AD. Since the ancillary study was conducted in women 65 to 79 years of age, it is unknown whether these findings apply to younger postmenopausal women <content styleCode="italics">[see <linkHtml href="#S5.3">Warnings and Precautions (5.3)</linkHtml>, and <linkHtml href="#S8.5">Use in Specific Populations (8.5)</linkHtml>]</content>.</paragraph>
                        <paragraph>The WHIMS estrogen-alone ancillary study of WHI enrolled 2,947 predominantly healthy hysterectomized postmenopausal women 65 to 79 years of age and older (45% were 65 to 69 years of age; 36% were 70 to 74 years of age; 19% were 75 years of age and older) to evaluate the effects of daily CE (0.625 mg)-alone on the incidence of probable dementia (primary outcome) compared to placebo.</paragraph>
                        <paragraph>After an average follow-up of 5.2 years, the relative risk of probable dementia for CE-alone versus placebo was 1.49 (95% CI, 0.83–2.66). The absolute risk of probable dementia for CE‑alone versus placebo was 37 versus 25 cases per 10,000 women-years. Probable dementia as defined in this study included AD, VaD and mixed types (having features of both AD and VaD). The most common classification of probable dementia in the treatment group and the placebo group was AD. Since the ancillary study was conducted in women 65 to 79 years of age, it is unknown whether these findings apply to younger postmenopausal women <content styleCode="italics">[see <linkHtml href="#S5.3">Warnings and Precautions (5.3)</linkHtml>, and <linkHtml href="#S8.5">Use in Specific Populations (8.5)</linkHtml>]</content>.</paragraph>
                        <paragraph>When data from the two populations were pooled as planned in the WHIMS protocol, the reported overall relative risk for probable dementia was 1.76 (95% CI, 1.19–2.60). Differences between groups became apparent in the first year of treatment. It is unknown whether these findings apply to younger postmenopausal women <content styleCode="italics">[see <linkHtml href="#S5.3">Warnings and Precautions (5.3)</linkHtml>, and <linkHtml href="#S8.5">Use in Specific Populations (8.5)</linkHtml>]</content>.</paragraph>
                     </text>
                     <effectiveTime value="20250429"/>
                  </section>
               </component>
            </section>
         </component>
         <component>
            <section ID="S15">
               <id root="02013161-311a-4b4b-b461-d7e6fdd84516"/>
               <code code="34093-5" codeSystem="2.16.840.1.113883.6.1" displayName="REFERENCES SECTION"/>
               <title>15 REFERENCES</title>
               <text>
                  <list listType="ordered">
                     <item>
                        <caption>1.</caption>Rossouw JE, et al. Postmenopausal Hormone Therapy and Risk of Cardiovascular Disease by Age and Years Since Menopause. <content styleCode="italics">JAMA</content>. 2007;297:1465–1477.</item>
                     <item>
                        <caption>2.</caption>Hsia J, et al. Conjugated Equine Estrogens and Coronary Heart Disease. <content styleCode="italics">Arch Int Med.</content> 2006;166:357–365.</item>
                     <item>
                        <caption>3.</caption>Cushman M, et al. Estrogen Plus Progestin and Risk of Venous Thrombosis. <content styleCode="italics">JAMA</content>. 2004;292:1573–1580.</item>
                     <item>
                        <caption>4.</caption>Curb JD, et al. Venous Thrombosis and Conjugated Equine Estrogen in Women Without a Uterus. <content styleCode="italics">Arch Int Med</content>. 2006;166:772–780.</item>
                     <item>
                        <caption>5.</caption>Stefanick ML, et al. Effects of Conjugated Equine Estrogens on Breast Cancer and Mammography Screening in Postmenopausal Women With Hysterectomy. <content styleCode="italics">JAMA</content>. 2006;295:1647-1657.</item>
                     <item>
                        <caption>6.</caption>Chlebowski RT, et al. Influence of Estrogen Plus Progestin on Breast Cancer and Mammography in Healthy Postmenopausal Women. <content styleCode="italics">JAMA</content>. 2003;289:3234–3253.</item>
                     <item>
                        <caption>7.</caption>Anderson GL, et al. Effects of Estrogen Plus Progestin on Gynecologic Cancers and Associated Diagnostic Procedures. <content styleCode="italics">JAMA</content>. 2003;290:1739–1748. </item>
                     <item>
                        <caption>8.</caption>Shumaker SA, et al. Conjugated Equine Estrogens and Incidence of Probable Dementia and Mild Cognitive Impairment in Postmenopausal Women. <content styleCode="italics">JAMA</content>. 2004;291:2947–2958.</item>
                     <item>
                        <caption>9.</caption>Jackson RD, et al. Effects of Conjugated Equine Estrogen on Risk of Fractures and BMD in Postmenopausal Women With Hysterectomy: Results From the Women's Health Initiative Randomized Trial. <content styleCode="italics">J Bone Miner Res</content>. 2006;21:817–828.</item>
                     <item>
                        <caption>10.</caption>Hendrix SL, et al. Effects of Conjugated Equine Estrogen on Stroke in the Women's Health Initiative. <content styleCode="italics">Circulation</content>. 2006;113:2425–2434.</item>
                  </list>
               </text>
               <effectiveTime value="20240220"/>
            </section>
         </component>
         <component>
            <section ID="S16">
               <id root="a30f6254-f50f-4e19-ba04-d38710e57996"/>
               <code code="34069-5" codeSystem="2.16.840.1.113883.6.1" displayName="HOW SUPPLIED SECTION"/>
               <title>16 HOW SUPPLIED/STORAGE AND HANDLING</title>
               <effectiveTime value="20190531"/>
               <component>
                  <section ID="S16.1">
                     <id root="a39c36e1-5e70-4e6e-8507-3beaf897cb2a"/>
                     <code code="34069-5" codeSystem="2.16.840.1.113883.6.1" displayName="HOW SUPPLIED SECTION"/>
                     <title>16.1 How Supplied </title>
                     <text>
                        <paragraph>PREMPRO therapy consists of a single tablet to be taken once daily. </paragraph>
                        <paragraph>
                           <content styleCode="bold">PREMPRO 0.3 mg/1.5 mg</content>
                        </paragraph>
                        <paragraph>NDC 0046-1105-11, carton includes 1 blister card containing 28 oval, cream tablets.</paragraph>
                        <paragraph>
                           <content styleCode="bold">PREMPRO 0.45 mg/1.5 mg</content>
                        </paragraph>
                        <paragraph>NDC 0046-1106-11, carton includes 1 blister card containing 28 oval, gold tablets.</paragraph>
                        <paragraph>
                           <content styleCode="bold">PREMPRO 0.625 mg/2.5 mg</content>
                        </paragraph>
                        <paragraph>NDC 0046-1107-11, carton includes 1 blister card containing 28 oval, peach tablets.</paragraph>
                        <paragraph>
                           <content styleCode="bold">PREMPRO 0.625 mg/5 mg</content>
                        </paragraph>
                        <paragraph>NDC 0046-1108-11, carton includes 1 blister card containing 28 oval, light-blue tablets.</paragraph>
                        <paragraph>
                           <content styleCode="bold">PREMPHASE</content> therapy consists of two separate tablets; one maroon Premarin tablet taken daily on days 1 through 14 and one light-blue tablet taken on days 15 through 28.</paragraph>
                        <paragraph>NDC 0046-2575-12, carton includes 1 blister card containing 28 tablets (14 oval, maroon Premarin tablets and 14 oval, light-blue tablets).</paragraph>
                        <paragraph>The appearance of PREMPRO tablets is a trademark of Pfizer Inc.</paragraph>
                        <paragraph>The appearance of PREMARIN tablets is a trademark of Pfizer Inc. The appearance of the conjugated estrogens/medroxyprogesterone acetate combination tablets is a trademark.</paragraph>
                     </text>
                     <effectiveTime value="20190531"/>
                  </section>
               </component>
               <component>
                  <section ID="S16.2">
                     <id root="63a4aabf-24c9-4919-a856-2ae14d9e42f2"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title>16.2 Storage and Handling</title>
                     <text>
                        <paragraph>
                           <content styleCode="bold">Store at 20° to 25°C (68° to 77°F); excursions permitted to 15° to 30°C (59° to 86°F) [see USP Controlled Room Temperature].</content>
                        </paragraph>
                     </text>
                     <effectiveTime value="20190531"/>
                  </section>
               </component>
            </section>
         </component>
         <component>
            <section ID="S17">
               <id root="ac621c68-3cb8-4ec3-9183-6ad39a2bb443"/>
               <code code="34076-0" codeSystem="2.16.840.1.113883.6.1" displayName="INFORMATION FOR PATIENTS SECTION"/>
               <title>17 PATIENT COUNSELING INFORMATION</title>
               <text>
                  <paragraph>Advise the patients to read the <linkHtml href="#patientinsert">FDA-approved Patient Labeling</linkHtml> (Patient Information).</paragraph>
               </text>
               <effectiveTime value="20250429"/>
               <component>
                  <section ID="S17.1">
                     <id root="7d6af224-6d8a-4e91-9294-5f241b178a48"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title>17.1 Abnormal Vaginal Bleeding</title>
                     <text>
                        <paragraph>Inform postmenopausal women of the importance of reporting abnormal vaginal bleeding to their healthcare provider as soon as possible <content styleCode="italics">[see <linkHtml href="#S5.2">Warnings and Precautions (5.2)</linkHtml>]</content>.</paragraph>
                     </text>
                     <effectiveTime value="20190531"/>
                  </section>
               </component>
               <component>
                  <section ID="S17.2">
                     <id root="c9d78395-4c8d-4cc9-9ef8-df4ceae35eaa"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title>17.2 Possible Serious Adverse Reactions with Estrogen Plus Progestin Therapy</title>
                     <text>
                        <paragraph>Inform postmenopausal women of possible serious adverse reactions of estrogen plus progestin therapy including Cardiovascular Disorders, Malignant Neoplasms, and Probable Dementia <content styleCode="italics">[see <linkHtml href="#S5.1">Warnings and Precautions (5.1</linkHtml>, <linkHtml href="#S5.2">5.2</linkHtml>, <linkHtml href="#S5.3">5.3)</linkHtml>]</content>. </paragraph>
                     </text>
                     <effectiveTime value="20190531"/>
                  </section>
               </component>
               <component>
                  <section ID="S17.3">
                     <id root="09932d61-1fc4-4cef-a3cc-bc09f362d090"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title>17.3 Possible Less Serious but Common Adverse Reactions with Estrogen Plus Progestin Therapy</title>
                     <text>
                        <paragraph>Inform postmenopausal women of possible less serious but common adverse reactions of estrogen plus progestin therapy such as headache, breast pain and tenderness, nausea and vomiting.</paragraph>
                     </text>
                     <effectiveTime value="20190531"/>
                  </section>
               </component>
            </section>
         </component>
         <component>
            <section ID="ID_6a38a069-433d-4505-ac2a-dfe9f2e52d82">
               <id root="e5af6c19-c305-458c-8856-41ab588c45f6"/>
               <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
               <text>
                  <table width="100%">
                     <col width="100%"/>
                     <tbody>
                        <tr>
                           <td styleCode="Botrule Toprule " valign="top">
                              <paragraph>This product's labeling may have been updated. For the most recent prescribing information, please visit <linkHtml href="http://www.pfizer.com">www.pfizer.com</linkHtml>.</paragraph>
                           </td>
                        </tr>
                     </tbody>
                  </table>
                  <renderMultiMedia ID="id5056" referencedObject="MM6"/>
                  <paragraph>LAB-0502-11.0</paragraph>
               </text>
               <effectiveTime value="20250429"/>
               <component>
                  <observationMedia ID="MM6">
                     <text>Logo</text>
                     <value mediaType="image/jpeg" xsi:type="ED">
                        <reference value="prempro-06.jpg"/>
                     </value>
                  </observationMedia>
               </component>
            </section>
         </component>
         <component>
            <section ID="patientinsert">
               <id root="a86fd431-7d4b-47a6-804e-9bf3dab62e81"/>
               <code code="42230-3" codeSystem="2.16.840.1.113883.6.1" displayName="SPL PATIENT PACKAGE INSERT SECTION"/>
               <title>PATIENT INFORMATION</title>
               <text>
                  <paragraph>PREMPRO<sup>®</sup>
                     <br/>(Conjugated Estrogens/Medroxyprogesterone Acetate Tablets)<br/>PREMPHASE<sup>®</sup>
                     <br/>(Conjugated Estrogens plus Medroxyprogesterone Acetate Tablets)</paragraph>
                  <paragraph>Read this PATIENT INFORMATION before you start taking PREMPRO or PREMPHASE and read what you get each time you refill your PREMPRO or PREMPHASE prescription. There may be new information. This information does not take the place of talking to your healthcare provider about your medical condition or your treatment.</paragraph>
                  <table width="100%">
                     <col width="100%"/>
                     <tbody>
                        <tr>
                           <td styleCode="Rrule Botrule Lrule Toprule " valign="top">
                              <paragraph>
                                 <content styleCode="bold">What is the most important information I should know about PREMPRO and PREMPHASE (combinations of estrogens and a progestin)?</content>
                              </paragraph>
                              <list listType="unordered">
                                 <item>
                                    <caption>•</caption>Do not use estrogens with progestins to prevent heart disease, heart attacks, strokes, or dementia (decline of brain function)</item>
                                 <item>
                                    <caption>•</caption>Using estrogens with progestins may increase your chances of getting heart attacks, strokes, breast cancer, or blood clots</item>
                                 <item>
                                    <caption>•</caption>Using estrogens with progestins may increase your chance of getting dementia, based on a study of women 65 years of age or older</item>
                                 <item>
                                    <caption>•</caption>Do not use estrogen-alone to prevent heart disease, heart attacks, strokes or dementia</item>
                                 <item>
                                    <caption>•</caption>Using estrogen-alone may increase your chance of getting cancer of the uterus (womb)</item>
                                 <item>
                                    <caption>•</caption>Using estrogen-alone may increase your chances of getting strokes or blood clots</item>
                                 <item>
                                    <caption>•</caption>Using estrogen-alone may increase your chance of getting dementia, based on a study of women 65 years of age or older</item>
                                 <item>
                                    <caption>•</caption>You and your healthcare provider should talk regularly about whether you still need treatment with PREMPRO or PREMPHASE</item>
                              </list>
                           </td>
                        </tr>
                     </tbody>
                  </table>
                  <paragraph>
                     <content styleCode="bold">What is PREMPRO or PREMPHASE?</content>
                  </paragraph>
                  <paragraph>PREMPRO or PREMPHASE are medicines that contain two kinds of hormones, estrogens and a progestin.</paragraph>
                  <paragraph>
                     <content styleCode="bold">What is PREMPRO or PREMPHASE used for?</content>
                  </paragraph>
                  <paragraph>PREMPRO or PREMPHASE is used after menopause to:</paragraph>
                  <list listType="unordered">
                     <item>
                        <caption>•</caption>
                        <content styleCode="bold">Reduce moderate to severe hot flushes</content>
                        <br/>Estrogens are hormones made by a woman's ovaries. The ovaries normally stop making estrogens when a woman is between 45 and 55 years old. This drop in body estrogen levels causes the "change of life" or menopause (the end of monthly menstrual periods). Sometimes, both ovaries are removed during an operation before natural menopause takes place. The sudden drop in estrogen levels causes "surgical menopause."<br/>When the estrogen levels begin dropping, some women get very uncomfortable symptoms, such as feelings of warmth in the face, neck, and chest, or sudden strong feelings of heat and sweating ("hot flushes"). In some women the symptoms are mild, and they will not need to take estrogens. In other women, symptoms can be more severe.</item>
                     <item>
                        <caption>•</caption>
                        <content styleCode="bold">Treat menopausal changes in and around the vagina</content>
                        <br/>You and your healthcare provider should talk regularly about whether you still need treatment with PREMPRO or PREMPHASE to control these problems. If you use PREMPRO or PREMPHASE only to treat your menopausal changes in and around your vagina, talk with your healthcare provider about whether a topical vaginal product would be better for you.</item>
                     <item>
                        <caption>•</caption>
                        <content styleCode="bold">Help reduce your chances of getting osteoporosis (thin weak bones)</content>
                        <br/>Osteoporosis from menopause is a thinning of the bones that makes them weaker and easier to break. If you use PREMPRO or PREMPHASE only to prevent osteoporosis due to menopause, talk with your healthcare provider about whether a different treatment or medicine without estrogens might be better for you. Weight-bearing exercise, like walking or running, and taking calcium (1500 mg per day of elemental calcium) and vitamin D (400–800 IU per day) supplements may also lower your chances of getting postmenopausal osteoporosis. It is important to talk about exercise and supplements with your healthcare provider before starting them.<br/>You and your healthcare provider should talk regularly about whether you still need treatment with PREMPRO or PREMPHASE. </item>
                  </list>
                  <paragraph>
                     <content styleCode="bold">Who should not take PREMPRO or PREMPHASE?</content>
                  </paragraph>
                  <paragraph>
                     <content styleCode="bold">Do not take PREMPRO or PREMPHASE if you have had your uterus (womb) removed (hysterectomy).</content>
                  </paragraph>
                  <paragraph>PREMPRO and PREMPHASE contain a progestin to decrease the chance of getting cancer of the uterus. If you do not have a uterus, you do not need a progestin and you should not take PREMPRO or PREMPHASE.</paragraph>
                  <paragraph>
                     <content styleCode="bold">Do not take PREMPRO or PREMPHASE if you:</content>
                  </paragraph>
                  <list listType="unordered">
                     <item>
                        <caption>•</caption>
                        <content styleCode="bold">Have unusual vaginal bleeding</content>
                     </item>
                     <item>
                        <caption>•</caption>
                        <content styleCode="bold">Currently have or have had certain cancers</content>
                        <br/>Estrogens may increase the chance of getting certain types of cancers, including cancer of the breast or uterus. If you have or have had cancer, talk with your healthcare provider about whether you should use PREMPRO or PREMPHASE.</item>
                     <item>
                        <caption>•</caption>
                        <content styleCode="bold">Had a stroke or heart attack</content>
                     </item>
                     <item>
                        <caption>•</caption>
                        <content styleCode="bold">Currently have or have had blood clots</content>
                     </item>
                     <item>
                        <caption>•</caption>
                        <content styleCode="bold">Currently have or have had liver problems</content>
                     </item>
                     <item>
                        <caption>•</caption>
                        <content styleCode="bold">
                           <content styleCode="underline">Have been diagnosed with a bleeding disorder</content>
                        </content>
                     </item>
                     <item>
                        <caption>•</caption>
                        <content styleCode="bold">Are allergic to PREMPRO or PREMPHASE or any of their ingredients</content>
                        <br/>See the list of ingredients in PREMPRO and PREMPHASE at the end of this leaflet.</item>
                  </list>
                  <paragraph>
                     <content styleCode="bold">Tell your healthcare provider</content>
                  </paragraph>
                  <list listType="unordered">
                     <item>
                        <caption>•</caption>
                        <content styleCode="bold">If you have any unusual vaginal bleeding</content>
                        <br/>Vaginal bleeding after menopause may be a warning sign of cancer of the uterus (womb). Your healthcare provider should check any unusual vaginal bleeding to find out the cause.</item>
                     <item>
                        <caption>•</caption>
                        <content styleCode="bold">About all of your medical problems</content>
                        <br/>Your healthcare provider may need to check you more carefully if you have certain conditions, such as asthma (wheezing), epilepsy (seizures), diabetes, migraine, endometriosis, lupus, problems with your heart, liver, thyroid, kidneys, or have high calcium levels in your blood.</item>
                     <item>
                        <caption>•</caption>
                        <content styleCode="bold">About all the medicines you take</content>
                        <br/>This includes prescription and nonprescription medicines, vitamins, and herbal supplements. Some medicines may affect how PREMPRO or PREMPHASE works. PREMPRO or PREMPHASE may also affect how your other medicines work. </item>
                     <item>
                        <caption>•</caption>
                        <content styleCode="bold">If you are going to have surgery or will be on bedrest</content>
                        <br/>You may need to stop taking PREMPRO or PREMPHASE.</item>
                     <item>
                        <caption>•</caption>
                        <content styleCode="bold">If you are pregnant or think you may be pregnant</content>
                        <paragraph>PREMPRO and PREMPHASE are not for pregnant women.</paragraph>
                     </item>
                     <item>
                        <caption>•</caption>
                        <content styleCode="bold">If you are breastfeeding</content>
                        <br/>The hormones in PREMPRO and PREMPHASE can pass into your breast milk.</item>
                  </list>
                  <paragraph>
                     <content styleCode="bold">How should I take PREMPRO or PREMPHASE?</content>
                  </paragraph>
                  <list listType="unordered">
                     <item>
                        <caption>•</caption>Take one PREMPRO or PREMPHASE tablet at the same time each day</item>
                     <item>
                        <caption>•</caption>If you miss a dose, take it as soon as possible<br/>If it is almost time for your next dose, skip the missed dose and go back to your normal schedule. Do not take 2 doses at the same time. </item>
                     <item>
                        <caption>•</caption>Estrogens should be used at the lowest dose possible for your treatment only as long as needed<br/>You and your healthcare provider should talk regularly (for example, every 3 to 6 months) about the dose you are taking and whether you still need treatment with PREMPRO or PREMPHASE.</item>
                  </list>
                  <paragraph>
                     <content styleCode="bold">What are the possible side effects of PREMPRO or PREMPHASE?</content>
                  </paragraph>
                  <paragraph>
                     <content styleCode="bold">Side effects are grouped by how serious they are and how often they happen when you are treated.</content>
                  </paragraph>
                  <paragraph>
                     <content styleCode="bold">Serious, but less common side effects include:</content>
                  </paragraph>
                  <list listType="unordered">
                     <item>
                        <caption>•</caption>Heart attack</item>
                     <item>
                        <caption>•</caption>Stroke</item>
                     <item>
                        <caption>•</caption>Blood clots</item>
                     <item>
                        <caption>•</caption>Breast cancer</item>
                     <item>
                        <caption>•</caption>Cancer of the lining of the uterus (womb)</item>
                     <item>
                        <caption>•</caption>Cancer of the ovary</item>
                     <item>
                        <caption>•</caption>Dementia</item>
                     <item>
                        <caption>•</caption>High or low blood calcium</item>
                     <item>
                        <caption>•</caption>Gallbladder disease</item>
                     <item>
                        <caption>•</caption>Visual abnormalities</item>
                     <item>
                        <caption>•</caption>High blood pressure</item>
                     <item>
                        <caption>•</caption>High levels of fat (triglycerides) in your blood</item>
                     <item>
                        <caption>•</caption>Liver problems</item>
                     <item>
                        <caption>•</caption>Changes in your thyroid hormone levels</item>
                     <item>
                        <caption>•</caption>Fluid retention</item>
                     <item>
                        <caption>•</caption>Cancer changes of endometriosis</item>
                     <item>
                        <caption>•</caption>Enlargement of benign tumors of the uterus ("fibroids")</item>
                     <item>
                        <caption>•</caption>Severe allergic reactions</item>
                     <item>
                        <caption>•</caption>Changes in certain laboratory test results, such as high blood sugar</item>
                  </list>
                  <paragraph>
                     <content styleCode="bold">Call your healthcare provider right away if you get any of the following warning signs or any other unusual symptoms that concern you:</content>
                  </paragraph>
                  <list listType="unordered">
                     <item>
                        <caption>•</caption>New breast lumps</item>
                     <item>
                        <caption>•</caption>Unusual vaginal bleeding </item>
                     <item>
                        <caption>•</caption>Changes in vision or speech</item>
                     <item>
                        <caption>•</caption>Sudden new severe headaches</item>
                     <item>
                        <caption>•</caption>Severe pains in your chest or legs with or without shortness of breath, weakness and fatigue</item>
                     <item>
                        <caption>•</caption>Swelling of the face, lips, and tongue with or without red itchy bumps</item>
                  </list>
                  <paragraph>
                     <content styleCode="bold">Common side effects of PREMPRO or PREMPHASE include:</content>
                  </paragraph>
                  <list listType="unordered">
                     <item>
                        <caption>•</caption>Headache</item>
                     <item>
                        <caption>•</caption>Breast pain</item>
                     <item>
                        <caption>•</caption>Irregular vaginal bleeding or spotting </item>
                     <item>
                        <caption>•</caption>Stomach or abdominal cramps, bloating</item>
                     <item>
                        <caption>•</caption>Nausea and vomiting </item>
                     <item>
                        <caption>•</caption>Hair loss</item>
                     <item>
                        <caption>•</caption>Fluid retention</item>
                     <item>
                        <caption>•</caption>Vaginal yeast infection</item>
                  </list>
                  <paragraph>These are not all the possible side effects of PREMPRO or PREMPHASE. For more information, ask your healthcare provider or pharmacist for advice about side effects. You may report side effects to Pfizer Inc. at 1-800-438-1985 or to FDA at 1-800-FDA-1088. </paragraph>
                  <paragraph>
                     <content styleCode="bold">What can I do to lower my chances of getting a serious side effect with PREMPRO or PREMPHASE?</content>
                  </paragraph>
                  <list listType="unordered">
                     <item>
                        <caption>•</caption>Talk with your healthcare provider regularly about whether you should continue taking PREMPRO or PREMPHASE</item>
                     <item>
                        <caption>•</caption>See your healthcare provider right away if you get vaginal bleeding while taking PREMPRO or PREMPHASE</item>
                     <item>
                        <caption>•</caption>Have a pelvic exam, breast exam and mammogram (breast X-ray) every year unless your healthcare provider tells you something else<br/>If members of your family have had breast cancer or if you have ever had breast lumps or an abnormal mammogram, you may need to have breast exams more often. </item>
                     <item>
                        <caption>•</caption>If you have high blood pressure, high cholesterol (fat in the blood), diabetes, are overweight, or if you use tobacco, you may have higher chances for getting heart disease<br/>Ask your healthcare provider for ways to lower your chances of getting heart disease.</item>
                  </list>
                  <paragraph>
                     <content styleCode="bold">General Information about the safe and effective use of PREMPRO and PREMPHASE</content>
                  </paragraph>
                  <paragraph>Medicines are sometimes prescribed for conditions that are not mentioned in patient information leaflets. Do not take PREMPRO or PREMPHASE for conditions for which it was not prescribed. Do not give PREMPRO or PREMPHASE to other people, even if they have the same symptoms you have. It may harm them. </paragraph>
                  <paragraph>
                     <content styleCode="bold">Keep PREMPRO and PREMPHASE out of the reach of children.</content>
                  </paragraph>
                  <paragraph>This leaflet provides a summary of the most important information about PREMPRO and PREMPHASE. If you would like more information, talk with your healthcare provider or pharmacist. You can ask for information about PREMPRO and PREMPHASE that is written for health professionals.</paragraph>
                  <paragraph>
                     <content styleCode="bold">What are the ingredients in PREMPRO and PREMPHASE?</content>
                  </paragraph>
                  <paragraph>PREMPRO contains the same conjugated estrogens found in Premarin, which are a mixture of sodium estrone sulfate and sodium equilin sulfate and other components, including sodium sulfate conjugates, 17α-dihydroequilin, 17α-estradiol and 17β-dihydroequilin. PREMPRO also contains either 1.5, 2.5, or 5 mg of medroxyprogesterone acetate.</paragraph>
                  <paragraph>PREMPRO 0.3 mg/1.5 mg and 0.45 mg/1.5 mg tablets also contain calcium phosphate tribasic, microcrystalline cellulose, lactose monohydrate, carnauba wax, hypromellose, magnesium stearate, polyethylene glycol, sucrose, hydroxypropyl cellulose, Eudragit NE 30D, titanium dioxide, yellow iron oxide, propylene glycol and black iron oxide. </paragraph>
                  <paragraph>PREMPRO 0.625 mg/2.5 mg tablets also contain calcium phosphate tribasic, microcrystalline cellulose, carnauba wax, lactose monohydrate, hypromellose, magnesium stearate, polyethylene glycol, sucrose, hydroxypropyl cellulose, Eudragit NE 30D, propylene glycol, titanium dioxide, red iron oxide, yellow iron oxide, and black iron oxide.</paragraph>
                  <paragraph>PREMPRO 0.625 mg/5 mg tablets also contain calcium phosphate tribasic, carnauba wax, Eudragit NE 30D, hydroxypropyl cellulose, hypromellose, lactose monohydrate, magnesium stearate, microcrystalline cellulose, polyethylene glycol, sucrose, titanium dioxide, triethyl citrate, FD&amp;C Blue No. 2, black iron oxide, and propylene glycol.</paragraph>
                  <paragraph>PREMPHASE is two separate tablets. One tablet (maroon color) is 0.625 mg of Premarin, which is a mixture of sodium estrone sulfate and sodium equilin sulfate and other components, including sodium sulfate conjugates, 17 α-dihydroequilin, 17 α-estradiol and 17 β-dihydroequilin. The maroon tablet also contains calcium phosphate tribasic, carnauba wax, hydroxypropyl cellulose, microcrystalline cellulose, powdered cellulose, hypromellose, lactose monohydrate, magnesium stearate, polyethylene glycol, sucrose, titanium dioxide, propylene glycol, FD&amp;C Blue No. 2, FD&amp;C Red No. 40. The second tablet (light-blue color) contains 0.625 mg of the same ingredients as the maroon color tablet plus 5 mg of medroxyprogesterone acetate. The light-blue tablet also contains calcium phosphate tribasic, carnauba wax, Eudragit NE 30D, hydroxypropyl cellulose, hypromellose, lactose monohydrate, magnesium stearate, microcrystalline cellulose, polyethylene glycol, sucrose, titanium dioxide, triethyl citrate, FD&amp;C Blue No. 2, black iron oxide, and propylene glycol.</paragraph>
                  <paragraph>PREMPRO therapy consists of a single tablet to be taken once daily.</paragraph>
                  <paragraph>
                     <content styleCode="bold">PREMPRO 0.3 mg/1.5 mg</content>
                  </paragraph>
                  <paragraph>Blister Card - Each carton includes 1 blister card containing 28 oval, cream tablets. Each tablet contains 0.3 mg of the conjugated estrogens found in Premarin tablets and 1.5 mg of medroxyprogesterone acetate for oral administration. </paragraph>
                  <paragraph>
                     <content styleCode="bold">PREMPRO 0.45 mg/1.5 mg</content>
                  </paragraph>
                  <paragraph>Blister Card - Each carton includes 1 blister card containing 28 oval, gold tablets. Each tablet contains 0.45 mg of the conjugated estrogens found in Premarin tablets and 1.5 mg of medroxyprogesterone acetate for oral administration.</paragraph>
                  <paragraph>
                     <content styleCode="bold">PREMPRO 0.625 mg/2.5 mg</content>
                  </paragraph>
                  <paragraph>Blister Card - Each carton includes 1 blister card containing 28 oval, peach tablets. Each tablet contains 0.625 mg of the conjugated estrogens found in Premarin tablets and 2.5 mg of medroxyprogesterone acetate for oral administration.</paragraph>
                  <paragraph>
                     <content styleCode="bold">PREMPRO 0.625 mg/5 mg</content>
                  </paragraph>
                  <paragraph>Blister Card - Each carton includes 1 blister card containing 28 oval, light-blue tablets. Each tablet contains 0.625 mg of the conjugated estrogens found in Premarin tablets and 5 mg of medroxyprogesterone acetate for oral administration.</paragraph>
                  <paragraph>PREMPHASE therapy consists of two separate tablets; one maroon Premarin tablet taken daily on days 1 through 14 and one light-blue tablet taken on days 15 through 28.</paragraph>
                  <paragraph>Each carton includes 1 blister pack containing 28 tablets. One blister pack contains 14 oval, maroon Premarin tablets containing 0.625 mg of conjugated estrogens and 14 oval, light-blue tablets that contain 0.625 mg of the conjugated estrogens found in Premarin tablets and 5 mg of medroxyprogesterone acetate for oral administration.</paragraph>
                  <paragraph>The appearance of PREMPRO tablets is a trademark of Pfizer Inc.</paragraph>
                  <paragraph>The appearance of PREMARIN tablets is a trademark of Pfizer Inc. The appearance of the conjugated estrogens/medroxyprogesterone acetate combination tablets is a trademark.</paragraph>
                  <paragraph>
                     <content styleCode="bold">Store at 20° to 25°C (68° to 77°F); excursions permitted to 15° to 30°C (59° to 86°F) [see USP Controlled Room Temperature].</content>
                  </paragraph>
                  <table width="100%">
                     <col width="100%"/>
                     <tbody>
                        <tr>
                           <td styleCode="Botrule Toprule " valign="top">
                              <paragraph>This product's labeling may have been updated. For the most recent prescribing information, please visit <linkHtml href="http://www.pfizer.com">www.pfizer.com</linkHtml>.</paragraph>
                           </td>
                        </tr>
                     </tbody>
                  </table>
                  <renderMultiMedia ID="id5252" referencedObject="MM23"/>
                  <paragraph>LAB-0504-11.0<br/>Revised 04/2025</paragraph>
               </text>
               <effectiveTime value="20250429"/>
               <component>
                  <observationMedia ID="MM23">
                     <text>Logo</text>
                     <value mediaType="image/jpeg" xsi:type="ED">
                        <reference value="prempro-06a.jpg"/>
                     </value>
                  </observationMedia>
               </component>
            </section>
         </component>
         <component>
            <section ID="ID_4616a296-83b4-44d1-84da-a3dedff8229e">
               <id root="16e0ea99-6e39-4f5c-b7c4-44c7492b8903"/>
               <code code="51945-4" codeSystem="2.16.840.1.113883.6.1" displayName="PACKAGE LABEL.PRINCIPAL DISPLAY PANEL"/>
               <title>PRINCIPAL DISPLAY PANEL - 28 Tablet 0.625 mg / 5 mg Blister Pack</title>
               <text>
                  <paragraph>START HERE<br/>Rx only<br/>NDC 0046-2575-12</paragraph>
                  <paragraph>DAY 1 → DAY 2 → DAY 3 → DAY 4 → DAY 5 → DAY 6 → DAY 7</paragraph>
                  <paragraph>14 maroon tablets of 0.625 mg conjugated estrogens</paragraph>
                  <paragraph>DAY 14 ← DAY 13 ← DAY 12 ← DAY 11 ← DAY 10 ← DAY 9 ← DAY 8</paragraph>
                  <paragraph>PREMPHASE<sup>®</sup> (conjugated estrogens/medroxyprogesterone acetate tablets)</paragraph>
                  <paragraph>DAY 15 → DAY 16 → DAY 17 → DAY 18 → DAY 19 → DAY 20 → DAY 21</paragraph>
                  <paragraph>14 light-blue tablets of 0.625 mg conjugated estrogens/5 mg medroxyprogesterone acetate</paragraph>
                  <paragraph>DAY 28 ← DAY 27 ← DAY 26 ← DAY 25 ← DAY 24 ← DAY 23 ← DAY 22</paragraph>
                  <renderMultiMedia ID="id5280" referencedObject="MM7"/>
               </text>
               <effectiveTime value="20240215"/>
               <component>
                  <observationMedia ID="MM7">
                     <text>PRINCIPAL DISPLAY PANEL - 28 Tablet 0.625 mg / 5 mg Blister Pack</text>
                     <value mediaType="image/jpeg" xsi:type="ED">
                        <reference value="prempro-07.jpg"/>
                     </value>
                  </observationMedia>
               </component>
            </section>
         </component>
         <component>
            <section ID="ID_fe47a81d-7663-447a-b32b-9616aef6c9b3">
               <id root="ffd1c34f-e83d-4f02-af9a-45ae82190cb3"/>
               <code code="51945-4" codeSystem="2.16.840.1.113883.6.1" displayName="PACKAGE LABEL.PRINCIPAL DISPLAY PANEL"/>
               <title>PRINCIPAL DISPLAY PANEL - Kit Carton</title>
               <text>
                  <paragraph>NDC 0046-2575-12</paragraph>
                  <paragraph>Pfizer</paragraph>
                  <paragraph>PREMPHASE<sup>®</sup>
                     <br/>(conjugated estrogens/medroxyprogesterone <br/>acetate tablets)</paragraph>
                  <paragraph>14 maroon tablets of 0.625 mg conjugated estrogens</paragraph>
                  <paragraph>14 light-blue tablets of 0.625 mg conjugated estrogens/ <br/>5 mg medroxyprogesterone acetate</paragraph>
                  <paragraph>Package contains 1 blister card <br/>of 28 tablets</paragraph>
                  <paragraph>Rx only</paragraph>
                  <renderMultiMedia ID="id5306" referencedObject="MM8"/>
               </text>
               <effectiveTime value="20190531"/>
               <component>
                  <observationMedia ID="MM8">
                     <text>PRINCIPAL DISPLAY PANEL - Kit Carton</text>
                     <value mediaType="image/jpeg" xsi:type="ED">
                        <reference value="prempro-08.jpg"/>
                     </value>
                  </observationMedia>
               </component>
            </section>
         </component>
         <component>
            <section ID="PDP1">
               <id root="48e7d721-4083-41cc-8aa4-3d1c95363e5d"/>
               <code code="51945-4" codeSystem="2.16.840.1.113883.6.1" displayName="PACKAGE LABEL.PRINCIPAL DISPLAY PANEL"/>
               <title>PRINCIPAL DISPLAY PANEL - 0.3 mg / 1.5 mg Blister Card</title>
               <text>
                  <paragraph>28 Tablets<br/>NDC 0046-1105-11</paragraph>
                  <paragraph>WEEK 1<br/>WEEK 2<br/>WEEK 3<br/>WEEK 4</paragraph>
                  <paragraph>Pfizer</paragraph>
                  <paragraph>PREMPRO<sup>®</sup>
                     <br/>(conjugated estrogens/medroxyprogesterone acetate tablets)</paragraph>
                  <paragraph>0.3 mg / 1.5 mg</paragraph>
                  <paragraph>Each cream tablet contains 0.3 mg of Premarin<sup>®</sup> brand of<br/>conjugated estrogens and 1.5 mg of medroxyprogesterone acetate.</paragraph>
                  <paragraph>Directions for Use: Take one tablet each day until all tablets <br/>have been taken. See accompanying information.</paragraph>
                  <paragraph>Store at 20° to 25°C (68° to 77°F); excursions permitted<br/>to 15° to 30°C (59° to 86°F).<br/>[See USP Controlled Room Temperature]</paragraph>
                  <paragraph>Note: Package not child resistant. Keep this and all<br/>medications out of the reach of children.</paragraph>
                  <paragraph>PREMPRO 0.3 mg/1.5 mg</paragraph>
                  <paragraph>Distributed by<br/>Wyeth Pharmaceuticals LLC<br/>A subsidiary of Pfizer Inc.<br/>Philadelphia, PA 19101</paragraph>
                  <paragraph>www.PREMPRO.com</paragraph>
                  <paragraph>Rx only</paragraph>
                  <paragraph>PAA224096</paragraph>
                  <paragraph>WEEK 1<br/>WEEK 2<br/>WEEK 3<br/>WEEK 4</paragraph>
                  <paragraph>LOT XXXXXXX<br/>EXP YYYY-MMM</paragraph>
                  <renderMultiMedia ID="id5355" referencedObject="MM9"/>
               </text>
               <effectiveTime value="20240215"/>
               <component>
                  <observationMedia ID="MM9">
                     <text>PRINCIPAL DISPLAY PANEL - 0.3 mg / 1.5 mg Blister Card</text>
                     <value mediaType="image/jpeg" xsi:type="ED">
                        <reference value="prempro-09.jpg"/>
                     </value>
                  </observationMedia>
               </component>
            </section>
         </component>
         <component>
            <section ID="PDP2">
               <id root="4deb0b1f-90e4-401d-a7d5-0fe576d882ed"/>
               <code code="51945-4" codeSystem="2.16.840.1.113883.6.1" displayName="PACKAGE LABEL.PRINCIPAL DISPLAY PANEL"/>
               <title>PRINCIPAL DISPLAY PANEL - 0.3 mg / 1.5 mg Blister Card Carton</title>
               <text>
                  <paragraph>NDC 0046-1105-11</paragraph>
                  <paragraph>Pfizer</paragraph>
                  <paragraph>PREMPRO<sup>®</sup>
                     <br/>(conjugated estrogens/<br/>medroxyprogesterone<br/>acetate tablets)</paragraph>
                  <paragraph>0.3 mg / 1.5 mg</paragraph>
                  <paragraph>Package contains 1 blister card of 28 tablets.</paragraph>
                  <paragraph>www.PREMPRO.com<br/>Rx only</paragraph>
                  <renderMultiMedia ID="id5380" referencedObject="MM10"/>
               </text>
               <effectiveTime value="20240215"/>
               <component>
                  <observationMedia ID="MM10">
                     <text>PRINCIPAL DISPLAY PANEL - 0.3 mg / 1.5 mg Blister Card Carton</text>
                     <value mediaType="image/jpeg" xsi:type="ED">
                        <reference value="prempro-10.jpg"/>
                     </value>
                  </observationMedia>
               </component>
            </section>
         </component>
         <component>
            <section ID="PDP6">
               <id root="e9f91378-10a6-4d9a-bb44-9ff48c9d0f36"/>
               <code code="51945-4" codeSystem="2.16.840.1.113883.6.1" displayName="PACKAGE LABEL.PRINCIPAL DISPLAY PANEL"/>
               <title>PRINCIPAL DISPLAY PANEL - 0.45 mg / 1.5 mg Blister Card</title>
               <text>
                  <paragraph>28 Tablets<br/>NDC 0046-1106-11</paragraph>
                  <paragraph>WEEK 1<br/>WEEK 2<br/>WEEK 3<br/>WEEK 4</paragraph>
                  <paragraph>Pfizer</paragraph>
                  <paragraph>PREMPRO<sup>®</sup>
                     <br/>(conjugated estrogens/medroxyprogesterone acetate tablets)</paragraph>
                  <paragraph>0.45 mg / 1.5 mg</paragraph>
                  <paragraph>Each gold tablet contains 0.45 mg of Premarin<sup>®</sup> brand of conjugated estrogens<br/>and 1.5 mg of medroxyprogesterone acetate.</paragraph>
                  <paragraph>Directions for Use: Take one tablet each day until all tablets<br/>have been taken. See accompanying information.</paragraph>
                  <paragraph>Store at 20° to 25°C (68° to 77°F); excursions permitted <br/>to 15° to 30°C (59° to 86°F).<br/>[See USP Controlled Room Temperature]</paragraph>
                  <paragraph>Note: Package not child resistant. Keep this and all<br/>medications out of the reach of children.</paragraph>
                  <paragraph>PREMPRO 0.45 mg/1.5 mg</paragraph>
                  <paragraph>Distributed by<br/>Wyeth Pharmaceuticals LLC <br/>A subsidiary of Pfizer Inc.<br/>Philadelphia, PA 19101</paragraph>
                  <paragraph>www.PREMPRO.com</paragraph>
                  <paragraph>Rx only</paragraph>
                  <paragraph>PAA224094</paragraph>
                  <paragraph>WEEK 1<br/>WEEK 2<br/>WEEK 3<br/>WEEK 4</paragraph>
                  <paragraph>LOT XXXXXXX<br/>EXP YYYY-MMM</paragraph>
                  <renderMultiMedia ID="id5429" referencedObject="MM11"/>
               </text>
               <effectiveTime value="20240215"/>
               <component>
                  <observationMedia ID="MM11">
                     <text>PRINCIPAL DISPLAY PANEL - 0.45 mg / 1.5 mg Blister Card</text>
                     <value mediaType="image/jpeg" xsi:type="ED">
                        <reference value="prempro-11.jpg"/>
                     </value>
                  </observationMedia>
               </component>
            </section>
         </component>
         <component>
            <section ID="ID_26355c7b-3869-40ea-9485-e7d91fa114d6">
               <id root="c650261d-f0aa-430a-bf39-94cd0c20839b"/>
               <code code="51945-4" codeSystem="2.16.840.1.113883.6.1" displayName="PACKAGE LABEL.PRINCIPAL DISPLAY PANEL"/>
               <title>PRINCIPAL DISPLAY PANEL - 0.45 mg / 1.5 mg Blister Card Carton</title>
               <text>
                  <paragraph>NDC 0046-1106-11</paragraph>
                  <paragraph>Pfizer</paragraph>
                  <paragraph>PREMPRO<sup>®</sup>
                     <br/>(conjugated estrogens/<br/>medroxyprogesterone<br/>acetate tablets)</paragraph>
                  <paragraph>0.45 mg / 1.5 mg</paragraph>
                  <paragraph>Package contains 1 blister card of 28 tablets.</paragraph>
                  <paragraph>www.PREMPRO.com<br/>Rx only</paragraph>
                  <renderMultiMedia ID="id5454" referencedObject="MM12"/>
               </text>
               <effectiveTime value="20240215"/>
               <component>
                  <observationMedia ID="MM12">
                     <text>PRINCIPAL DISPLAY PANEL - 0.45 mg / 1.5 mg Blister Card Carton</text>
                     <value mediaType="image/jpeg" xsi:type="ED">
                        <reference value="prempro-12.jpg"/>
                     </value>
                  </observationMedia>
               </component>
            </section>
         </component>
         <component>
            <section ID="ID_fe998b69-b012-476b-bead-61a9dbe16ed6">
               <id root="276609c3-b766-432e-b556-d3ff591b620b"/>
               <code code="51945-4" codeSystem="2.16.840.1.113883.6.1" displayName="PACKAGE LABEL.PRINCIPAL DISPLAY PANEL"/>
               <title>PRINCIPAL DISPLAY PANEL - 0.625 mg / 2.5 mg Tablet Blister Card</title>
               <text>
                  <paragraph>28 Tablets<br/>NDC 0046-1107-11</paragraph>
                  <paragraph>WEEK 1<br/>WEEK 2<br/>WEEK 3<br/>WEEK 4</paragraph>
                  <paragraph>Pfizer</paragraph>
                  <paragraph>PREMPRO<sup>®</sup>
                     <br/>(conjugated estrogens/medroxyprogesterone acetate tablets)</paragraph>
                  <paragraph>0.625 mg / 2.5 mg</paragraph>
                  <paragraph>Each peach tablet contains 0.625 mg of Premarin<sup>®</sup> brand of<br/>conjugated estrogens and 2.5 mg of medroxyprogesterone acetate.</paragraph>
                  <paragraph>Directions for Use: Take one tablet each day until all tablets<br/>have been taken. See accompanying information.</paragraph>
                  <paragraph>Store at 20° to 25°C (68° to 77°F); excursions permitted<br/>to 15° to 30°C (59° to 86°F).<br/>[See USP Controlled Room Temperature]</paragraph>
                  <paragraph>Note: Package not child resistant. Keep this and all<br/>medications out of the reach of children.</paragraph>
                  <paragraph>MADE IN IRELAND</paragraph>
                  <paragraph>PREMPRO 0.625 mg/2.5 mg</paragraph>
                  <paragraph>Distributed by<br/>Wyeth Pharmaceuticals LLC<br/>A subsidiary of Pfizer Inc.<br/>Philadelphia, PA 19101</paragraph>
                  <paragraph>Rx only</paragraph>
                  <paragraph>www.PREMPRO.com</paragraph>
                  <paragraph>PAA224092</paragraph>
                  <paragraph>WEEK 1<br/>WEEK 2<br/>WEEK 3<br/>WEEK 4</paragraph>
                  <paragraph>LOT XXXXXXX<br/>EXP YYYY-MMM</paragraph>
                  <renderMultiMedia ID="id5504" referencedObject="MM13"/>
               </text>
               <effectiveTime value="20240215"/>
               <component>
                  <observationMedia ID="MM13">
                     <text>PRINCIPAL DISPLAY PANEL - 0.625 mg / 2.5 mg Tablet Blister Card</text>
                     <value mediaType="image/jpeg" xsi:type="ED">
                        <reference value="prempro-13.jpg"/>
                     </value>
                  </observationMedia>
               </component>
            </section>
         </component>
         <component>
            <section ID="PDP12">
               <id root="2cb5171f-800e-46c7-ac64-20129425298f"/>
               <code code="51945-4" codeSystem="2.16.840.1.113883.6.1" displayName="PACKAGE LABEL.PRINCIPAL DISPLAY PANEL"/>
               <title>PRINCIPAL DISPLAY PANEL - 0.625 mg / 2.5 mg Tablet Blister Card Carton</title>
               <text>
                  <paragraph>NDC 0046-1107-11</paragraph>
                  <paragraph>Pfizer<br/>PREMPRO<sup>®</sup>
                     <br/>(conjugated estrogens/<br/>medroxyprogesterone acetate tablets)</paragraph>
                  <paragraph>0.625 mg / 2.5 mg</paragraph>
                  <paragraph>Rx only</paragraph>
                  <paragraph>Package contains 1 blister card of 28 tablets.<br/>www.PREMPRO.com</paragraph>
                  <renderMultiMedia ID="id5528" referencedObject="MM14"/>
               </text>
               <effectiveTime value="20231129"/>
               <component>
                  <observationMedia ID="MM14">
                     <text>PRINCIPAL DISPLAY PANEL - 0.625 mg / 2.5 mg Tablet Blister Card Carton</text>
                     <value mediaType="image/jpeg" xsi:type="ED">
                        <reference value="prempro-14.jpg"/>
                     </value>
                  </observationMedia>
               </component>
            </section>
         </component>
         <component>
            <section ID="ID_60202014-54b1-4141-a3bb-c04ef39df178">
               <id root="5f0b5bfd-c47b-43c8-aca6-3ce469ad62fd"/>
               <code code="51945-4" codeSystem="2.16.840.1.113883.6.1" displayName="PACKAGE LABEL.PRINCIPAL DISPLAY PANEL"/>
               <title>PRINCIPAL DISPLAY PANEL - 0.625 mg / 5 mg Tablet Blister Card</title>
               <text>
                  <paragraph>28 Tablets<br/>NDC 0046-1108-11</paragraph>
                  <paragraph>WEEK 1<br/>WEEK 2<br/>WEEK 3<br/>WEEK 4</paragraph>
                  <paragraph>Pfizer</paragraph>
                  <paragraph>PREMPRO<sup>®</sup>
                     <br/>(conjugated estrogens/medroxyprogesterone acetate tablets)</paragraph>
                  <paragraph>Rx only</paragraph>
                  <paragraph>0.625 mg / 5 mg</paragraph>
                  <paragraph>Each light-blue tablet contains 0.625 mg of Premarin<sup>®</sup> brand of<br/>conjugated estrogens and 5 mg of medroxyprogesterone acetate.</paragraph>
                  <paragraph>Directions for Use: Take one tablet each day until all tablets<br/>have been taken. See accompanying information.</paragraph>
                  <paragraph>Store at 20° to 25°C (68° to 77°F); excursions permitted<br/>to 15° to 30°C (59° to 86°F).<br/>[See USP Controlled Room Temperature]</paragraph>
                  <paragraph>Note: Package not child resistant. Keep this and all<br/>medications out of the reach of children.</paragraph>
                  <paragraph>MADE IN IRELAND</paragraph>
                  <paragraph>PREMPRO 0.625 mg/5 mg</paragraph>
                  <paragraph>Distributed by<br/>Wyeth Pharmaceuticals LLC<br/>A subsidiary of Pfizer Inc.<br/>Philadelphia, PA 19101</paragraph>
                  <paragraph>www.PREMPRO.com</paragraph>
                  <paragraph>PAA224000</paragraph>
                  <paragraph>WEEK 1<br/>WEEK 2<br/>WEEK 3<br/>WEEK 4</paragraph>
                  <paragraph>LOT XXXXXXX<br/>EXP YYYY-MMM</paragraph>
                  <renderMultiMedia ID="id5578" referencedObject="MM15"/>
               </text>
               <effectiveTime value="20240215"/>
               <component>
                  <observationMedia ID="MM15">
                     <text>PRINCIPAL DISPLAY PANEL - 0.625 mg / 5 mg Tablet Blister Card</text>
                     <value mediaType="image/jpeg" xsi:type="ED">
                        <reference value="prempro-15.jpg"/>
                     </value>
                  </observationMedia>
               </component>
            </section>
         </component>
         <component>
            <section ID="PDP16">
               <id root="2adfd1e9-ccd9-4334-b5a9-33b19c43f6c7"/>
               <code code="51945-4" codeSystem="2.16.840.1.113883.6.1" displayName="PACKAGE LABEL.PRINCIPAL DISPLAY PANEL"/>
               <title>PRINCIPAL DISPLAY PANEL - 0.625 mg / 5 mg Tablet Blister Card Carton</title>
               <text>
                  <paragraph>NDC 0046-1108-11</paragraph>
                  <paragraph>Rx only</paragraph>
                  <paragraph>Pfizer<br/>PREMPRO<sup>®</sup>
                     <br/>(conjugated estrogens/<br/>medroxyprogesterone acetate tablets)</paragraph>
                  <paragraph>0.625 mg / 5 mg</paragraph>
                  <paragraph>Package contains 1 blister card of 28 tablets.<br/>www.PREMPRO.com</paragraph>
                  <renderMultiMedia ID="id5602" referencedObject="MM16"/>
               </text>
               <effectiveTime value="20240215"/>
               <component>
                  <observationMedia ID="MM16">
                     <text>PRINCIPAL DISPLAY PANEL - 0.625 mg / 5 mg Tablet Blister Card Carton</text>
                     <value mediaType="image/jpeg" xsi:type="ED">
                        <reference value="prempro-16.jpg"/>
                     </value>
                  </observationMedia>
               </component>
            </section>
         </component>
      </structuredBody>
   </component>
</document>